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Abstract 
Toxic shock syndrome (TSS) is an acute, potentially fatal condition characterized by 
high-grade fever, hypotensive shock and systemic inflammation. It is caused by exposure 
to staphylococcal and streptococcal superantigens (SAgs), which can activate up to 50% 
of T cells resulting in a hyperinflammatory ‘cytokine storm’ within hours. This 
inflammatory cascade progresses to a life-threatening illness with alarming rapidity, and 
SAg-exposed individuals can develop multi-organ failure within hours of onset of 
symptoms. However, there are currently no available treatments that efficiently mitigate 
the cytokine storm, which drives TSS immunopathology. Therefore, identifying and 
understanding the critical components underlying this process should hold the key to 
designing effective therapeutics to reduce TSS severity. In this thesis, I have utilized a 
clinically relevant humanized HLA-DR4 transgenic (DR4tg) mouse model of TSS to 
reveal the previously unrecognized roles of three rapid host responses in the initiation or 
control of the cytokine storm. First, genetic and antibody-mediated depletion of invariant 
natural killer T (iNKT) cells in DR4tg mice show that iNKT cells are pathogenic in TSS 
and contribute to the cytokine storm. Targeting iNKT cell responses with the T helper 
type-2 (Th2)-polarizing glycolipid agonist OCH also reduces TSS morbidity and 
mortality. Second, I found that granulocytic myeloid-derived suppressor cells (MDSCs) 
are rapidly recruited to the liver of DR4tg mice during TSS. These hepatic MDSCs 
potently suppress SAg-induced T cell responses and may therefore mitigate tissue injury 
in TSS. Lastly, I define the rapid production of interleukin-17A (IL-17A) by effector 
memory T cells as a novel mechanism promoting immunopathology in TSS. Blockade of 
IL-17A signaling in human blood mononuclear cells reduces the expression of multiple 
 ii 
 
inflammatory mediators of TSS, suggesting that IL-17A contributes to the cytokine 
storm. Importantly, the treatment of DR4tg mice with an IL-17A-neutralizing antibody 
attenuates TSS-induced tissue damage, morbidity and mortality. Collectively, the results 
presented in this thesis delineate the novel contributions of iNKT cells, MDSCs and IL-
17A to the early phase of TSS pathogenesis. Furthermore, my findings suggest that 
therapeutic approaches targeting iNKT cells or IL-17A responses may be effective in 
reducing TSS mortality.  
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Chapter 1  
 
Introduction 
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1.1 Preamble 
The immune system is an extraordinary protective entity capable of mounting rapid and 
effective responses against virtually every type of pathogenic microorganism that we 
encounter on a daily basis. Through an elaborate network of physical barriers, anti-
microbial molecules, and a myriad of cell types (e.g., neutrophils, natural killer cells, 
monocytes, macrophages, dendritic cells, mast cells, basophils and eosinophils), the 
innate arm of the immune system provides a non-specific front-line defense against 
foreign invaders. Innate immune cells also help shape the nature of the highly specific 
adaptive arm of immunity, where T and B cell responses to antigens from virtually all 
encountered pathogens work together to limit or outright eliminate infection. This process 
then gives rise to immunological memory, which promotes an immune response that is 
both more rapid and greater in magnitude to pathogens that have been encountered 
previously.     
Not to be outdone, pathogenic microbes engage in an evolutionary ‘arms race’ with the 
host immune system, developing sophisticated tactics for immune evasion to survive. 
Through numerous virulence factors, pathogens exploit opportunities to bypass immune 
defenses and colonize host tissues. The most successful of these pathogenic microbes are 
typically known to be common causes of devastating disease in humans. The Gram-
positive coccus, Staphylococcus aureus, is among these pathogens and is currently the 
most common cause of skin and soft-tissue infections worldwide (1). Interestingly, 
around 20% of the human population appears to be persistently colonized by S. aureus 
with another 30% being intermittent carriers (2). Most often, S. aureus carriage is 
asymptomatic and considered ‘harmless’. However, when afforded the opportunity, S. 
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aureus causes severe, invasive and life-threatening infections including osteomyelitis, 
endocarditis, pneumonia, enterocolitis, sepsis and toxic shock syndrome (TSS) (3).  
One family of virulence factors, the staphylococcal superantigens (SAgs), is known to be 
the direct causative agent of TSS (4). These potent exotoxins trigger the hyperactivation 
of the immune system resulting in an avalanche of inflammatory mediators that cause 
intense fever, hypotensive shock and organ damage. In essence, SAgs ‘short-circuit’ the 
immune system, amplifying the immune response to the point of catastrophic collateral 
damage to the host. Alarmingly, this process can progress to life-threatening disease 
extremely rapidly, whereby multi-organ failure can occur in as little as 8-12 hours after 
the onset of symptoms (5) and mortality rates can range as high as one-in-five (6).  
Despite the high levels of morbidity and mortality in TSS, there is currently no treatment 
for the overwhelming inflammation induced by SAgs. Identifying the underlying 
immunological mechanisms that regulate or drive TSS pathogenesis may hold the key to 
developing therapeutics to reduce disease severity. Here, I identify and define the role of 
three previously unrecognized processes mediating TSS immunopathogenesis in its most 
early phases.  
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1.2 Toxic Shock Syndrome 
A syndrome of disorientation, high fever, and scarlatiniform rash with rapid progression 
to hypotensive shock and multi-organ dysfunction was first formally associated with 
Staphyloccoccus aureus infection in 1978 (7). It was then that Todd and colleagues 
coined the term ‘toxic shock syndrome’. In the early 1980s, TSS rose to public 
consciousness following an outbreak in young females that was related to the usage of 
high absorbency tampons (8-10). Several cases in men and non-menstruating women 
were also reported during this time. A bacterial toxin from vaginal isolates of 
Staphyloccoccus in TSS patients was identified as the cause of TSS (11, 12). These toxins 
were later dubbed ‘superantigens’ due their ability to abnormally stimulate a large 
fraction of T cells (13). As a result, SAgs trigger a massive inflammatory response 
leading to the clinical symptoms of TSS (Table 1.1).  
Cases of TSS are typically defined as either menstrual (14) or nonmenstrual (15) in 
origin. Menstrual TSS occurs within the first few days before or after the beginning of a 
woman’s menstrual cycle and is strongly associated with tampon usage due, at least in 
part, to increases in oxygen levels in the normally anaerobic vaginal environment (16, 
17). In the vast majority of menstrual TSS cases, vaginal colonization of S. aureus can be 
readily detected (18). Nearly all cases of this form of TSS are caused by S. aureus strains 
that produce the SAg toxic shock syndrome toxin-1 (TSST-1) (11, 12). Although the 
exact reason for this association is unclear, it has been proposed that it may be a result of 
the greater ability of TSST-1 to infiltrate mucosal surfaces compared to other SAgs (19, 
20). A large proportion of mucosal S. aureus strains also more commonly produce TSST-
1 relative to other SAgs, which may partly explain the association as well (21). 
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Clinical Criteria 
1. Fever: temperature ≥ 38.9°C (102.0°F) 
2. Rash: diffuse macular erythroderma 
3. Desquamation: 1-2 weeks after onset of rash 
4. Hypotension: systolic blood pressure ≥ 90 mm Hg for adults or less than fifth 
percentile by age for children aged less than 16 years 
5. Multisystem involvement (three or more of the following organ systems): 
• Gastrointestinal: vomiting or diarrhea at onset of illness 
• Muscular: severe myalgia or creatine phosphokinase level at least twice the upper 
limit of normal 
• Mucous membrane: vaginal, oropharyngeal, or conjunctival hyperemia 
• Renal: blood urea nitrogen or creatinine at least twice the upper limit of normal 
for laboratory or urinary sediment with pyuria (greater than or equal to 5 
leukocytes per high-power field) in the absence of urinary tract infection 
• Hepatic: total bilirubin, alanine aminotransferase (ALT) enzyme, or aspartate 
aminotransferase (AST) enzyme levels at least twice the upper limit of normal for 
laboratory 
• Hematologic: platelets less than 100,000/mm3 
• Central nervous system: disorientation or alterations in consciousness without 
focal neurologic signs when fever and hypotension are absent 
Microbiological Laboratory Criteria 
Negative results on the following tests, if obtained: 
• Blood or cerebrospinal fluid cultures (blood culture may be positive for 
Staphylococcus aureus) 
• Negative serology for Rocky Mountain spotted fever, leptospirosis, or measles 
Case Classification 
Probable: A case which meets the laboratory criteria and in which four of the five 
clinical criteria described above are present 
Confirmed: A case which meets the laboratory criteria and in which all five of the 
clinical criteria described above are present, including desquamation, unless the patient 
dies before desquamation occurs 
Table 1.1: Clinical criteria for toxic shock syndrome.  
Adapted from (22). 
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In contrast to menstrual TSS, a nonmenstrual form can originate from any infection or 
colonization of SAg-producing strains of S. aureus. Non-menstrual TSS can occur in a 
variety of clinical settings including skin and soft-tissue infections (15, 23), surgical and 
post-partum wound infections (24, 25), after influenza infections (26) and burns (27-29). 
Additional categories also include recalcitrant erythematous desquamating syndrome 
(30), purpura fulminans (31), extreme pyrexia syndrome (32) and TSS-like 
staphylococcal enterocolitis (33), which are all associated with S. aureus SAgs. 
Approximately half of nonmenstrual TSS cases are caused by TSST-1, with the other half 
caused by the staphylococcal enterotoxins (SEs) A, B, and C (23, 34-36). 
1.2.1 Epidemiology 
At its peak in the early 1980s, the incidence of TSS was estimated to be as high as 13.7 
cases per 100,000 (37). With the removal of high-absorbency tampons from the market 
and increased public awareness, these rates dropped to 0.5 per 100,000 by the late 1980s 
(24, 38). More recently, a population-based surveillance program between 2000 and 2006 
indicated that the annual incidence of TSS remained stable at 0.52 per 100,000 and that 
approximately half of the reported cases were non-menstrual in origin (39). Notably, the 
investigators suggested that this might be an underrepresentation of the disease burden, 
likely due to both the strict CDC case definition (Table 1.1) and current advances in 
supportive therapy that prevent severe manifestations of the disease. Despite its relatively 
low incidence, TSS has an overall case fatality rate of 2-4% (23, 24, 39). Alarmingly, 
however, non-menstrual TSS mortality rates can reach as high as 12-22% in some studies 
(6, 23).  
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1.2.2 Streptococcal TSS 
A significant number of Streptococcus pyogenes or invasive group A Streptococcus 
(GAS) infections share clinical similarities to TSS, and were designated as ‘toxic shock-
like syndrome’ or streptococcal TSS (STSS) in the late 1980s (40-42). STSS patients 
have invasive GAS infections that culminate in shock, multi-organ failure and 
progressive soft tissue destruction (42). Unlike staphylococcal TSS, which is typically 
secondary to a localized S. aureus infection, STSS is the result of an invasive GAS 
infection where the majority of patients are bacteremic (42, 43). Streptococcal M types 1 
and 3 have been most associated with invasive GAS infections and the SAgs 
streptococcal pyrogenic exotoxins (Spe) A and C are often detected in streptococcal 
isolates from STSS patients (40, 44, 45). Annual incidence rates of invasive GAS 
infections in Europe are 1.5-5.2 per 100,000 and approximately 5-14.4% of these patients 
developed STSS (46, 47). A study from 11 European countries (Strep-EURO) revealed 
an overall 7-day case fatality rate of 19% for GAS infections and 44% in patients that 
progressed to STSS (47). 
1.2.3 Therapeutic Strategies  
There are currently no specific therapeutics available for the treatment of TSS. The key to 
successful management of the disease is the rapid identification of the source of infection, 
appropriate and effective use of antibiotics, removal of tampon in menstrual TSS, and 
supportive care (48). In the early stages of the disease, similar therapeutic interventions 
as septic shock are applied, including haemodynamic support, vasopressors and/or 
inotropes, and intubation, if required (49).  
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Based on the finding that individuals lacking effective neutralizing antibodies to SAgs 
may be at increased risk of developing TSS (50-52), intravenous immunoglobulin (IVIG) 
has been proposed as an adjunctive therapy (48). IVIG is a combination of pooled human 
antibodies derived from hundreds to thousands of donors, which typically contain 
antibodies against both staphylococcal and streptococcal SAgs (53). The effectiveness of 
IVIG in improving clinical outcomes has been demonstrated in a number of studies 
involving STSS (54-57); however, evidence for its effectiveness in staphylococcal TSS is 
limited (48). It should also be noted that the mechanism of action for IVIG is unclear. 
IVIG preparations are able to neutralize both staphylococcal and streptococcal SAg 
activity in vitro, though SAgs from S. aureus require much higher doses of IVIG to be 
effectively inhibited (58). IVIG can also directly opsonize GAS, promoting bacterial 
clearance by enhancing phagocytosis (59). Lastly, IVIG has a general anti-inflammatory 
effect mediated by immunoglobulin Fc domains binding to Fc receptors on immune cells 
(60). While IVIG has been shown to suppress SEB-induced T cell activation, this effect is 
largely maintained after SEB-specific antibodies are depleted from the IVIG 
preparations, suggesting that a mechanism independent of toxin neutralization is in effect 
(61).  
Several other strategies to attenuate TSS morbidity have been examined including the 
inhibition of SAg-receptor interactions, blockade of SAg signal transduction, and active 
vaccination against staphylococcal/streptococcal cell wall components or the various 
exotoxins themselves (62, 63). Although promising, these approaches are still in their 
infancy and are currently undergoing preclinical investigation. Despite the significant 
advances made towards understanding the immunopathogenesis of TSS, many questions 
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remain unanswered. A more complete understanding of the cellular interactions and 
biological effects of SAgs may aid in the quest for a therapeutic invention to reduce TSS 
severity.  
1.2.4 Superantigens 
SAgs are a unique group of protein exotoxins secreted by the vast majority of S. aureus 
and GAS strains that are pathogenic to humans (64). S. aureus encodes a large number of 
SAgs including TSST-1 and the SEs A, B, C, D, E, G, H, I, R and T (65). SEs were 
originally defined by their emetic properties and ability to cause food poisoning when 
ingested by humans or when administered orally to monkeys (66). A group of SE-like 
(SEl) toxins that are structurally similar to SEs have also been defined, although these 
toxins either do not induce, or have not yet been shown to induce emesis (65). 
Interestingly, almost all staphylococcal SAgs are encoded on mobile genetic elements 
including pathogenicity islands, plasmids or phages, suggesting an exchange of genetic 
elements between different strains or even different bacterial species (4). GAS also 
produces numerous SAgs including SpeA, C, G-M, streptococcal superantigen (SSA) and 
streptococcal mitogenic exotoxin Z (SMEZ) (64). Similar to staphylococcal SAgs, most 
streptococcal SAgs are encoded on mobile genetic elements. 
It is important to note that SAgs are not specifically limited to S. aureus and GAS, nor to 
bacteria in general. SAgs have also been documented in the human pathogens 
Plasmodium falciparum (67), Clostridium perfringens (68), Toxoplasma gondii (69), 
Yesinia pesudotuberculosis (70) and Yesinia enterocolitica (71) among others. 
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1.2.5 Superantigen Structure and Binding Properties 
SAgs are generated as pro-toxins that require cleavage of a secretion signal to be 
exported from the cell in a Sec-dependent manner and range in size from 22-29 kDa (65). 
Crystal structures of SAgs show that they are commonly made of two major protein 
domains, an N-terminal oligosaccharide/oligonucleotide binding fold with a β barrel 
motif and a C-terminal β-grasp motif, which are connected together by a central α-helix 
(72).  
SAgs are capable of bypassing conventional mechanisms of antigen presentation and 
directly cross-link T cell receptors (TCRs) on T cells with major histocompatibility 
complex (MHC) class II molecules on antigen-presenting cells (APCs) in an unprocessed 
form (73, 74).  SAgs interact with MHC class II outside the antigen-binding groove (75) 
and bind specific TCR β-chain variable domains (Vβ), inducing the activation and clonal 
expansion of T cells bearing the appropriate Vβ segments (76). Each SAg has a unique 
pattern of Vβ specificities resulting in a ‘Vβ T cell signature’ that can be used to identify 
the SAg(s) a patient is exposed to (77). Several SAgs including TSST-1, SEA and SEB 
also bind the co-stimulatory molecule CD28 on T cells, which is required for maximal T 
cell activation (78).  
Based on phylogenetic analyses and structural similarities, staphylococcal and 
streptococcal SAgs can be classified into 5 evolutionary groups (65, 79). Group I consists 
of TSST-1 as an evolutionarily distinct SAg, which has a unique primary amino acid 
sequence compared to other SAgs. TSST-1 lacks a cysteine loop associated with emetic 
activity (80), further distinguishing it from SEs. It also utilizes a low-affinity MHC class 
II α-chain binding site and forms a TCR-MHC complex that is highly dependent on the 
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antigenic peptide present within the MHC class II molecule (81, 82). TSST-1 is also 
specific for Vβ2+ T cells in humans, as it recognizes specific amino acids within the 
complementarity-determining region (CDR) 2 and framework region 3 (83). Group II 
SAgs include SEB, SEC and SpeA. This group also uses a single low-affinity binding 
domain to the α-chain of MHC class II; however, this binding appears to be entirely 
peripheral to the antigenic peptide (84, 85). Notably, group II SAgs bind the TCR Vβ in a 
manner that is less dependent on specific amino acid side-chains, allowing for a wider 
range of Vβ specificities (86-88). Group III SAgs include SEA, which, along with group 
II SAgs, are implicated in the majority of food poisoning cases (89). In addition to the 
low-affinity binding site on the MHC class II α-chain used by groups I and II, group III 
SAgs contain a second high-affinity binding site that is zinc-dependent, which engages 
the MHC class II β-chain and extends over the bound peptide (90-94). It has been 
suggested that the additional presence of the high-affinity binding site may increase the 
efficiency of these SAgs to activate T cells and APCs at significantly lower 
concentrations. Group IV SAgs consist exclusively of streptococcal SAgs, including 
SPEC and SMEZ, which also bind MHC class II α-chain and β-chain similar to group III 
SAgs (95, 96). Lastly, group V SAgs include SEI and the SEl toxins, which use similar 
binding targets as group III and group IV SAgs (97).   
1.2.6 Superantigen-mediated T cell activation 
The mode of TCR engagement by SAgs is in stark contrast with that of conventional 
antigens. Typically, T cell activation is initiated by the interaction between the TCR and 
its cognate antigenic peptide that is presented in the context of self-MHC, called the rule 
of MHC restriction (98). Given that T cell antigen specificity is the result of the 
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variability in TCRs generated by the stochastic joining of TCR α- and β-V(D)J segments, 
at most only 0.01% of naïve T cells can be activated by a specific antigen (99). However, 
SAgs ‘hijack’ the immunological synapse, and activate T cells in a TCR Vβ-dependent 
manner, regardless of T cell antigen specificity. Since there are a limited number of TCR 
Vβ regions expressed by T cells, approximately 50 in humans, SAgs can activate up to 
20-50% of T cells (Fig. 1.1) (64, 65). Furthermore, SAgs do this in an exceptionally 
potent manner, where as low as femtogram (10-15 g) quantities can stimulate human T 
cells in vitro (100).  
Downstream of the TCR, T cell signaling by SAgs is relatively similar to that of 
conventional antigens, whereby the three canonical signals required for T cell activation 
are comparable for both SAgs and conventional antigens. Signal one is induced by SAg 
engagement of the TCR-CD3 complex, recruiting the Src family of protein tyrosine 
kinases including Lck (101). Activated Lck phosphorylates the CD3 immunoreceptor 
tyrosine-based activation motifs (ITAMs), recruits a variety of adaptor molecules, and 
facilitates a series of phosphorylation events mediated by phospholipase C (PLC)-γ1 that 
culminate in the activation of protein kinase C and increased intracellular Ca2+ (102). 
Together, these signaling pathways lead to activation and translocation of the nuclear 
factor of activated T cells (NF-AT) and the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) to the nucleus, facilitating the process of T cell activation and 
proliferation. For signal two, T cell co-stimulatory molecules (e.g. CD28) can either 
engage with their receptors (e.g. CD80/86) on APCs or be directly stimulated by SAgs 
(103). Co-stimulation is required for proper T cell activation and ensuing proliferation, 
cytokine production, and survival (104). The third signal is provided by the cytokine  
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Figure 1.1: SAgs bypass conventional modes of antigen processing and presentation 
to activate a larger number of T cells.   
Conventional protein antigens are taken up, processed into peptide fragments, and 
presented to T cells in the peptide-binding groove of MHC class II by APCs. In contrast, 
SAgs bind the lateral surfaces of MHC class II and the Vβ-domain of the TCR in 
unprocessed form. Whereas conventional antigens activate up to ~0.01% of T cells, SAgs 
may activate up to 50% of exposed T cells resulting in the overwhelming cytokine storm 
in TSS. Adapted from (105). 
SAg	ac va on	
of	T	cells	
Conven onal	ac va on	
of	T	cells	
Up	to	~50%	of	T	
cells	are	ac vated.	
Only	~0.01%	of	T	
cells	are	ac vated.	
APC	 APC	
T	cell	 T	cell	
TCR	 TCR	
SAg	
MHC	II	 MHC	II	
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milieu present at the time of T cell activation and is essential for productive T cell 
responses and polarization of T cell differentiation into distinct effector subtypes (106).  
In 2006, Bueno et al. found that SAg-mediated T cell signaling did not strictly require 
Lck activity and that a Gα11/PLC-β-mediated phosphorylation cascade can initiate an 
Lck-independent signaling pathway (107). Interestingly, both Lck-dependent and -
independent pathways can be utilized by SAgs, where either can lead to the activation of 
transcription factors that ultimately facilitate T cell activation (108). These findings shed 
light on how SAgs activate both CD4+ and CD8+ T cells, despite only cross-linking MHC 
class II molecules. Since one function of the CD4/CD8 co-receptors is to recruit and 
activate Lck, an Lck-independent pathway would allow for T cell activation to occur in 
the absence of CD4/CD8 binding to MHC.  
1.2.7 Cytokine Storm 
The overwhelming immune activation caused by SAgs triggers a ‘cytokine storm’ – a 
rapid and uncontrolled production of cytokines and inflammatory mediators from many 
cell types including T cells, APCs, epithelial cells and endothelial cells. A variety of 
inflammatory cytokines are rapidly produced within hours of SAg exposure, including 
tumor necrosis factor α (TNFα), interleukin (IL)-1, IL-6, and interferon γ (IFNγ) (109, 
110).  
TNFα is a potent inducer of systemic inflammation and signals a range of cellular 
responses including apoptosis, differentiation, proliferation, migration and cytokine 
production (111, 112). TNFα signaling occurs through the TNF receptors (TNFR) 1 and 
2, which utilize death domains (i.e. TNFR-associated death domain and Fas-associated 
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death domain) to activate the caspase 8, mitogen-activated protein kinase (MAPK), and 
NF-κB pathways that mediate its pleiotropic effects. In endothelial cells, TNFα elicits 
vasodilation, vascular permeability, and expression of pro-coagulant proteins such as 
tissue factor to promote intravascular coagulation (113). Together with IL-1, TNFα is 
likely the main mediator of inflammation-driven activation of coagulatory cascades in the 
vasculature (114). The administration of TNFα alone causes septic shock-like state in 
animals (115) and induces a systemic inflammatory response syndrome in humans (116-
118). 
IL-1 can be subdivided into IL-1α and IL-1β that both signal through the IL-1 receptor 
(IL-1R)-1 and accessory protein (IL-1RAcP) complex (119). IL-1 has similar and often 
synergistic inflammatory effects with TNFα (120). IL-1β mediates pro-coagulant activity 
and tissue factor expression in human monocytes when stimulated with SAgs (121). IL-1 
and TNFα are often considered the two primary mediators of shock (122), where they act 
synergistically to induce sustained hypotension, pulmonary edema and hemorrhage (123). 
These overlapping functions may be due to the fact that both cytokines activate the NF-
κB signaling pathway, which plays critical role in the initiation and propagation of the 
inflammatory cascade in TSS and septic shock (122, 124). This pathway promotes: i) the 
expression of adhesion molecules and chemokines to recruit and activate neutrophils 
causing endothelial cell injury, vascular permeability, and tissue damage; ii) expression 
of tissue factor and other pro-coagulants initiating disseminated intravascular 
coagulation; iii) induction of cyclooxygenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS) pathways triggering vasodilator prostaglandins and nitric oxide, 
respectively, which cause systemic hypotension and vascular hyporeactivity; and iv) 
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production of inflammatory cytokines (e.g. TNFα, IL-1, IL-6 and IFNγ) thus amplifying 
and propagating the inflammatory response. The extent of NF-κB activation has been 
shown to correlate with mortality risk in several contexts, including septic shock (125).  
IL-6 binds to the IL-6 receptor (IL-6R) and has many different biological effects 
including the activation of T cells, initiation of the coagulation cascade, and neutrophil 
activation and trafficking (126). Along with TNFα and IL-1, IL-6 is an endogenous 
pyrogen, that is, a group of fever-inducing molecules that stimulate prostaglandin E2 
(PGE2) synthesis, which acts on the hypothalamus to increase the thermostatic set point 
(127). IL-6 is also a major mediator of the acute phase response, a systemic reaction to 
inflammation characterized by the rapid production of acute phase reactants, such as C-
reactive protein, from the liver. These proteins trigger complement activation, 
coagulatory cascades or promote leukocyte chemotaxis (128). Notably, serum IL-6 
concentrations are markedly increased in TSS patients (129) and correlate with sepsis 
severity and mortality (130). In spite of these many pro-inflammatory characteristics, IL-
6 can promote anti-inflammatory responses as well. While TNFα and IL-1 synergistically 
induce IL-6 production, IL-6 can inhibit the release of TNFα and IL-1 and promote the 
expression of several anti-inflammatory mediators, like IL-10 (131, 132). IL-6 responses 
also appear to be protective in mouse models of endotoxemia (133) and streptococcal 
infections (134), likely due to a suppressive effect on TNFα. 
IFNγ signals through the interferon gamma receptor (IFNGR), consisting of subunits 
IFNGR1 and IFNG2, and performs a wide variety of immunoregulatory roles including 
innate immune cell activation, leukocyte trafficking, augmenting MHC class I and II 
expression, activation of iNOS, and promoting T helper type 1 (Th1) responses (135). 
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IFNγ induces the expression of the death receptor Fas, which triggers vascular cell 
apoptosis (136, 137). Together with TNFα, IFNγ also disrupts ion transport and barrier 
functions of epithelial cells leading to increased permeability (138). Indeed, IFNγ and 
TNFα often have synergistic effects, where many IFNγ-induced genes are also induced 
by TNFα, likely due to multiple avenues of cross-talk between signaling pathways (135).  
A variety of chemokines are also rapidly produced in response to SAg stimulation (139, 
140). TSST-1 can stimulate the production of chemokines directly from the human 
vaginal epithelium (141). These chemoattractants facilitate the recruitment of neutrophils, 
macrophages and T cells to the areas of inflammation and injury. In addition to 
increasing the accessibility for SAgs to activate T cells, recruited immune cells can also 
have direct tissue damaging effects. For example, cytokine-activated neutrophils produce 
cytotoxic molecules and matrix metalloproteases once in peripheral tissues (142). 
Recruited immune cells can also produce large amounts of inflammatory cytokines upon 
activation, thus amplifying the cytokine storm. SAgs activate many non-immune cells 
including fibroblasts, endothelial cells and epithelial cells (141, 143, 144) that produce 
other inflammatory molecules (e.g. adhesion proteins, tissue proteases and reactive 
oxygen species) in addition to cytokines, resulting in further tissue injury.  
Overexpression of inflammatory cytokines in the cytokine storm results in widespread 
inflammation, fever, disseminated intravascular coagulation, leukocyte migration, 
vasodilation, capillary leak, shock, and tissue destruction. This process culminates in the 
dysfunction of multiple organ systems, which, if severe, can lead to death. Two distinct 
phases of multiple organ dysfunction have been proposed (145). In the early phase, the 
initial activation of immune cells triggers a wave of inflammatory cytokines that causes 
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endothelial cell damage, increased vascular permeability, swelling and extravasation. The 
later phase of organ dysfunction begins as the inflammatory cells reach the interstitial 
compartments of individual organs. Microvascular coagulopathy, dysregulated apoptosis 
and tissue hypoxia cause damage to parenchymal cells, thus impairing organ function 
(146). The reflux of inflammatory cytokines and other mediators back into circulation 
then creates a positive feedback loop, amplifying this process. 
1.2.8 SAg-Induced Immunosuppression 
Following the hyperactivation of T cells, SAgs induce a state of immune dysregulation in 
the body. Almost immediately after activation, surface TCR expression on SAg-reactive 
T cells is reduced by 50% due to receptor endocytosis (147). The activation and 
proliferation of SAg-reactive T cells is transient and the majority undergo apoptosis by 
activation-induced cell death within days (148, 149). This creates a functional ‘hole’ in 
the T cell repertoire and is sustained for a period of at least 4 weeks, when a 50% 
reduction of T cells bearing SAg-reactive Vβ domains can still be observed (150). 
Neonatal exposure to SAgs in mice also deletes virtually all SAg-reactive mature 
thymocytes, in addition to the majority of immature thymocytes (73). Activated T cells 
that escape deletion become anergic, or functionally unresponsive to in vitro re-
stimulation by SAgs (150, 151). However, whether this translates into anergy in vivo is 
unclear. Multiple studies have demonstrated functional cytokine responses upon SAg re-
challenge, though SAg-reactive CD4+ T cells, and CD8+ T cells, to a lesser extent, show 
impairments in their proliferative capacity (152-154). Exposure to SAgs also generates 
immunosuppressive T regulatory cells (Tregs) (155-158), which may contribute to the 
induction of T cell anergy. Whether Tregs play a protective role in TSS is unclear, as 
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systemic inflammatory responses in TSS destabilize the Treg population, and their 
expansion or adoptive transfer in mice exposed to SAg fail to mitigate immunopathology 
(159). 
In addition to causing T cell dysfunction, SAgs impair B cell-mediated humoral 
immunity (160-162). Low or negative antibody titres for TSST-1 are observed in greater 
than 90% of menstrual TSS patients, with the majority of patients failing to seroconvert 
within two months (50). Some patients even remain seronegative even after recurrent 
bouts of the disease. This is in contrast to a healthy population, where 85% of individuals 
show antibody titres to TSST-1 at a level thought to be at least partially protective (52). 
The failure to develop effective antibody-mediated immunity is likely due to impairment 
in the T cell compartment during TSS. T cells anergized by SAgs can no longer provide 
help for B cells to stimulate antibody production, thus impairing T cell-dependent B cell 
responses (161, 162). SAgs also induce T cell-dependent B cell apoptosis (163-165). 
Lastly, SAgs largely promote Th1-type cytokine responses. Therefore, the minimal Th2-
type cytokines present may be insufficient to support optimal B cell proliferation and 
differentiation (124).   
1.2.9 Animal Models of TSS  
Preclinical animal models that simulate SAg-mediated immunopathology in humans have 
greatly aided the characterization of molecular and cellular events in TSS. Despite our 
current understanding, however, there has yet to be an effective therapy translatable to 
the clinic. The careful and appropriate use of animal models of TSS (listed in Table 1.2) 
remains our most essential tool for the development of novel treatment modalities to 
reduce TSS severity and, hopefully, save human lives.  
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Animal Model SAgs  Defining Immunopathology Reference 
Mouse 
Sensitizing 
agents 
(D-gal/act D) 
SEA, 
SEB, 
TSST-1 
TNFα-dependent lethal shock; severe 
hemorrhagic hepatitis 
(166-170) 
 SAg + LPS 
SEA, 
SEB, 
SEC, 
TSST-1 
Rapid cytokine storm; hypothermia; intestinal 
apoptosis; lethal shock 
(169, 171-
175) 
 
HLA-
transgenic 
SEB 
SpeA 
Rapid cytokine storm; multi-organ inflammation; 
impaired gut permeability; lethal shock 
(170, 176-
178) 
 
Aerosol/ 
i.n 
SEB 
Rapid cytokine storm; pulmonary edema, 
hypothermia; liver neutrophil infiltration and 
necrosis; lethal shock 
(179-184) 
Rabbit 
Mini-osmotic 
pump 
SEA, 
SEB, 
TSST-1 
SpeA 
SpeC 
Rapid cytokine storm; fever; conjuctival 
hyperemia; anorexia, cachexia; lethal shock. 
(185-189) 
 SAg + LPS 
TSST-1, 
SEH 
TNFα production; hyperemia; diarrhea; lethal 
shock 
(190, 191) 
(192, 193) 
 i.v. 
SEA, 
TSST1 
IL-2, IFN, TNF production; fever; lethal shock 
(strain and sex dependent) 
(191, 193-
195) 
Primate i.v. SEB 
Hypotension; cardiac output decline; decreased 
blood oxygen content; lethal shock 
(196) 
 Aerosol SEB 
IL-2, IL-6, IFNγ production; hypotension; fever; 
diarrhea; vomiting; pulmonary edema; lethal 
shock 
(197-199) 
D-gal, D-galactosamine; act D, actinomycin D; LPS, lipopolysaccharide; tg, transgenic; 
i.n., intranasal; i.v., intravenous. 
Table 1.2: Common animal models of TSS 
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Mouse models are most often used to examine the underlying mechanisms of SAg-
induced morbidity, largely due to the variety of available immunological tools and 
reagents, well-defined Vβ signatures, and relatively low cost of maintenance compared to 
other animals. Problematically, mice are considerably more resistant to SAgs when 
compared to humans as a result of a much lower binding affinity of SAgs to mouse MHC 
class II in some strains (200). Therefore, sensitizing compounds such as actinomycin D 
(167) or D- galacatosamine (D-gal) (166) must be used to amplify the effects of SAgs 
and induce mortality. The severity of TSS in models using sensitizing agents varies 
considerably and can skew inflammatory responses or disproportionately impact 
individual organs. One of the most widely utilized models involves priming mice with D-
gal (166, 168, 169, 201, 202) followed by intraperitoneal administration of SAg to induce 
a cytokine storm and other hallmark features of TSS. D-gal induces transcriptional arrest 
in hepatocytes leading to extreme sensitivity to TNFα-induced apoptosis (203). When 
used in combination with SAgs, D-gal induces severe TNFα-dependent hepatotoxicity 
(204), a pathology not typically seen in human TSS (205). Although TNFα responsible 
for the lethality in sensitized mice is derived, at least in part, from SAg-mediated T cell 
activation (166, 206), the dominant event leading to sudden death in this model is likely 
severe hepatitis. As expected, TNFα plays a key role in this model and anti-TNFα/β 
neutralizing antibodies confer protection from lethality (166, 207). Conclusions from 
these models must be drawn with full recognition that sensitizing agents cause cytokine 
responses that do not necessarily reflect human disease. This problem is illuminated by 
the notable failure of a TNFR fusion protein to prevent septic shock in humans, including 
those caused by S. aureus (208). Notably, in patients with Gram-positive infections, the 
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group receiving the highest-dose of the drug exhibited an increase in both disease 
severity and mortality. 
Another common mouse model utilizes bacterial lipopolysaccharide (LPS) as a 
potentiating agent following SAg exposure (169, 171-174, 209, 210). SAgs are known to 
substantially enhance LPS lethality due to a synergistic effect on the production of TNFα 
(192). There is some evidence to suggest this synergy occurs in human TSS, as patients 
with menstrual TSS show increased colonization of Gram-negative bacteria in the vaginal 
flora (211) and low levels of LPS can be detected in acute-phase sera of TSS patients 
(212). In mice, the injection of SAg followed by LPS results in rapid production of IL-1α, 
IL-6, TNFα and IFNγ within hours, which is not observed in SAg-only controls (171). 
Lethality in this model can be correlated to increased serum IL-6, TNFα, macrophage 
inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 (MCP-1) by 8 
hours and IFNγ and IL-2 by 21 hours after TSS induction (174). However, cytokine 
responses and TSS mortality are highly influenced by LPS dosage as opposed to SAg. 
Furthermore, exposure to SAg in human peripheral blood mononuclear cells (PBMCs) 
strongly upregulates TLR4 expression and enhances production of inflammatory 
cytokines by LPS independent of T cells (210). Thus, the use of LPS as a potentiating 
agent may cause unnecessary confounding effects that are more reflective of 
endotoxicosis than TSS. As the role of LPS in human TSS is undefined, the utility of this 
mouse model and its relevance to TSS also remains to be determined.  
In order to avoid potential pitfalls associated with sensitizing and potentiating agents in 
mouse models of TSS, mice expressing human MHC class II, known as HLA-transgenic 
mice, have been used (170, 176-178, 213-215). Due to the higher affinity binding of 
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SAgs to human leukocyte antigens (HLAs)-DQ and -DR, these transgenic mice respond 
to much lower doses of SAg (216-219). Accordingly, our lab has previously 
demonstrated robust cytokine responses in HLA-DR4tg mice injected with 50 μg of SEB 
(220). Similarly, a single 50 μg dose of SEB is sufficient to induce a rapid inflammatory 
cytokine response, inflammation in the liver, lungs, kidney, heart and small intestines, 
and lethal shock in HLA-DR3 transgenic mice (170, 177). Importantly, in comparison to 
D-gal sensitization where the disease is restricted to the liver, HLA-DR3 mice treated 
with SAg alone show multi-organ involvement, similar to humans (170). The inhibition 
of IFNγ in this model attenuates the cytokine storm, prevents severe intestinal pathology, 
and protects against mortality (177). HLA transgenic mouse models have also been 
successfully applied to STSS. HLA-DQ8 transgenic mice expressing human CD4 are 
susceptible to SpeA-induced STSS that is characterized by rapid production of TNFα, 
IFNγ and IL-6, elevated liver enzymes and lethal shock within 72 hours (178). A 
potential limitation for using HLA-transgenic mice as disease models is that MHC class 
II genes are among the most polymorphic genes in the genome and these inbred mouse 
strains only mimic the responses of one specific haplotype. Furthermore, SAgs 
preferentially bind some MHC class II molecules over others; SEB and TSST-1 bind 
HLA-DR more efficiently than HLA-DQ for example (221), and thus care must be taken 
to select the most appropriate transgenic strain for a given SAg. Nevertheless, HLA-
transgenic mice recapitulate many aspects of human TSS and therefore are one of the 
most useful mouse models of the syndrome.  
Several other mouse models have been established to investigate different aspects of TSS 
pathogenesis by varying the SAg entry point. A model of SAg-induced airway 
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inflammation was developed involving a single or double dose of SAg introduced 
intranasally (179-184). TSS in this model culminates in severe lung inflammation, 
systemic release of cytokines, hypothermia and death within days. However, this may 
more accurately represent TSS resulting from the inhalation of aerosolized SEB in a 
bioterrorism setting (222) rather than natural S. aureus infection. Intravaginal exposure to 
SEB in HLA-transgenic mice causes a robust systemic inflammatory response and 
leukocyte infiltration in the liver and lungs (223). Although almost all human menstrual 
TSS cases are caused by TSST-1 and not SEB, further investigations in this model can be 
targeted to understand and/or inhibit the mechanisms by which SAgs can cross mucosal 
barriers and cause disease.  
Historically, rabbits have been the ‘gold standard’ model for SAg-induced TSS as they 
mimic almost all symptoms of human TSS after administration of staphylococcal and 
streptococcal SAgs (185, 186, 191, 192, 194, 224, 225). Rabbits can also be implanted 
with mini-osmotic pumps that release SAg continuously over the course of 7 days, more 
accurately mimicking the mode of SAg exposure in a S. aureus infection (185-189). 
Several rabbit models that utilize chambers to localize SAg-producing S. aureus have 
been instrumental in identifying TSST-1 a causative agent of TSS (226-229). The 
susceptibility to SAg-induced TSS varies among rabbit strains and may require LPS 
sensitization to induce morbidity (191). Currently, the use of rabbits to model TSS is rare, 
likely due to the technical and ethical considerations that make larger animals 
unattractive to study. There are several drawbacks of using rabbits rather than mice, such 
as increased housing and animal care costs, less availability of immunological reagents 
and antibodies, and a greater difficulty for genetic manipulation.  
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In addition to mice and rabbits, several models of TSS utilizing larger animals have been 
described. Intradermal exposure to SEB in non-human primates elicits skin reactions, 
cutaneous mast cell degranulation and emesis (230). Non-human primates have also been 
used to investigate immune responses to aerosolized SEB (197-199) and evaluate the 
efficacy of vaccine candidates against lethal SEB challenge (231, 232). In the hopes of 
more closely simulating human TSS, a porcine model was developed where piglets were 
given SEB intravenously. Intoxicated piglets quickly developed vomiting, diarrhea, 
temperature spikes, hypotension and multi-organ dysfunction (233). Lastly, goats have 
been used to study the effects of both SEB and TSST-1-induced TSS, where intravenous 
injection yields tachycardia, fever and various hematological changes (234). Investigating 
TSS pathogenesis in larger animals is rare, due to both the high cost of animal 
maintenance and significant ethical concerns surrounding their use as disease models 
with high morbidity and mortality. 
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1.3 Invariant Natural Killer T Cells 
Natural killer T (NKT) cells are a specialized group of innate-like T lymphocytes with 
remarkable immunomodulatory properties. Named for their co-expression of both NK 
cell markers (e.g. NK1.1 in mice and CD161 in humans) and αβ TCRs, NKT cells 
possess specific reactivity to glycolipid antigens presented by the MHC class I-like 
glycoprotein CD1d (235). CD1d is a member of the CD1 family of antigen-presenting 
molecules that present lipids, rather than peptides, to non-MHC restricted T lymphocytes. 
In humans, there are five members of CD1 molecules, CD1a-e, while mice only express 
CD1d (236). CD1d is widely expressed on cells of hematopoietic origin, including typical 
antigen-presenting cells like DCs, macrophages and B cells (237).  
Two individual subsets of NKT cells can be defined based on the structural 
characteristics of their TCRs in addition to their reactivity to glycolipid antigens. Type I 
NKT cells, known as invariant NKT (iNKT) cells, express a canonical TCR composed of 
a unique α-chain (Vα24-Jα18 in humans; Vα14-Jα18 in mice) paired with a limited 
number of β-chains (Vβ11 in humans; Vβs 2, 7, or 8.2 in mice) (235). These cells exhibit 
highly conserved reactivity to α-galactosylceramide (αGC) (238) and the invention of 
αGC-loaded CD1d tetramers has enabled their unambiguous identification by flow 
cytometry (239, 240). In mice, iNKT cells are either CD4+CD8- or CD4-CD8- (235), and 
an additional CD8+ population exists in humans (241). iNKT cells also constitutively 
express the activation/memory markers CD25, CD44 and CD69 on their cell surface, 
consistent with a ‘memory-like’ phenotype. In contrast, type II NKT cells, known as 
variant NKT (vNKT) cells, express a diverse αβ TCR repertoire and although they are 
‘CD1d-restricted’, they do not respond to αGC (235). A large proportion of vNKT cells 
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can be activated by the self-lipid sulfatide (242). The understanding of vNKT cell 
responses in health and disease remains limited, largely due to a notable lack of robust 
reagents to specifically identify and characterize vNKT cell function.  
iNKT cells are widely distributed throughout the body and can be found in the thymus, 
liver, bone marrow, spleen, lymph nodes and intestinal tract (239). They express a range 
of chemokine receptors that mediate their homing to individual tissues and, unlike 
conventional T cells, show limited recirculation under homeostatic conditions (243). In 
mice, iNKT cells have been most commonly studied in the liver, where they represent up 
to 20-30% of lymphocytes (239, 240). However, they are less frequent in all other tissues, 
where they constitute ≤1% of T cells. In humans, iNKT cells are not highly enriched in 
the liver and are 10-fold less frequent in most locations (244), except the human 
omentum, where approximately 10% of T cells express the invariant Vα24-Jα18 TCR 
(245). On average, iNKT cells represent ~0.1% of T cells in the peripheral blood of 
humans, but this fraction can range from virtually undetectable to as high as 1% across 
individuals (246, 247). The reason for this extreme variation among individuals as well as 
the differences in abundance and tissue distribution between mice and humans is 
unknown.  
1.3.1 Modes of Activation 
iNKT cells are activated in response to exposure to a wide range of pathogens, from 
bacteria to viruses, protozoa and even fungi (248). Many of these microorganisms contain 
lipid antigens, which can directly stimulate the iNKT cell TCR through their presentation 
by CD1d on APCs. These exogenous antigens are usually glycerol-based lipids (e.g. 
common bacterial membrane phospholipids) or ceramide-based glycolipids (e.g. 
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glycolsphingolipids) and can be found in Spingomonas spp., Ehrlichia spp., Borrelia 
burgdorferi, Aspergillus fumigatus, and Streptococcus pneumoniae (249-253). 
Additionally, other iNKT cell ligands include mycobacterial phosphatidylinositol 
mannoside (254), cholesteryl α-glucosides from Helicobacter pylori (255), and 
lipophosphoglycans from the protozoans Leishmania donovani (256) and Entamoeba 
histolytica (257).  
The prototypical exogenous antigen for iNKT cells is the glycosphingolipid αGC. 
Initially isolated from the extracts of the marine sponge Agelas mauritanius (238), αGC 
is believed to have originated from microbes (possibly Sphingomonas spp.) engaged in a 
symbiotic relationship with the sponge. αGC is composed of a lipid tail that is buried 
deep in the hydrophobic region of CD1d and galactose head that projects out of the CD1d 
molecule to be bound by the α-chain of the iNKT cell TCR (258). The length of the 
sphingosine and acyl chains of the lipid tail controls the binding affinity of the TCR-
lipid-CD1d complex, which partially determines the strength of iNKT cell activation 
(259). Based on this observation, αGC derivatives with altered sphingosine and/or acyl 
chains that skew iNKT cell responses have been generated. OCH, a sphingosine-
truncated analog of αGC promotes the production of Th2-type cytokines, exemplified by 
IL-4 (260). C20:2, which possesses a shorter acyl chain that contains two sites of 
unsaturation also potently stimulates the production of Th2-type cytokines (261), perhaps 
more effectively than OCH in human PBMC cultures (262). Conversely, a C-glycoside 
analog of αGC is a Th1-skewing iNKT agonist that effectively induces IL-12 and IFNγ 
production (263). In addition to the structure of the lipid agonist, several other factors 
influence the production of cytokines by iNKT cells including the location and kinetics of 
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glycolipid loading onto CD1d and its association with lipid rafts (264), the type of APC 
involved (265) and the presence of co-stimulatory molecules on APCs (266).  
In the absence of exogenous lipid antigens, iNKT cells can be activated by APCs that 
have been exposed to microbial products or danger signals, which engage pattern 
recognition receptors such as Toll-like receptors (TLRs) to induce cytokine secretion 
(267, 268). Interestingly, this mode of activation is dependent on IL-12 in addition to 
CD1d-lipid signaling, suggesting that the presentation of self-antigens can facilitate 
iNKT cell activation. This is supported by the fact that iNKT cells are activated in a 
variety of settings where exogenous lipids are absent, such as in viral infections, 
autoimmunity and cancer (269). There has been much debate around the nature of 
glycolipids involved in this process, in addition to the putative self-lipid responsible for 
the positive selection of iNKT cells in the thymus. Many candidates for self-lipids that 
mediate these processes have been proposed, including isoglobotrihexosylceramide 
(270), lysophosphatidylcholine (271), β-glucosylceramide (272), and the plasmogen 
lysophosphatidylethanolamine (273). A recent report by Teyton and colleagues 
demonstrates the presence of endogenous α-anomeric glycolipids like αGC in 
mammalian immune cells (274). However, the biological role of endogenous αGC in 
humans remains to be confirmed.   
As innate T lymphocytes, iNKT cells are highly responsive to cytokines for their 
activation and function. iNKT cells constitutively express several cytokine receptors, 
including the receptors for IL-12 (275), IL-18 (276), IL-23 (277) and IL-25 (278). IL-12 
appears to play a critical role in the activation of iNKT cells both in the absence or 
presence of iNKT cell ligands. iNKT cell-mediated responses to Salmonella 
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typhimurium, which lacks cognate iNKT cell antigens, is blocked by IL-12-neutralizing 
antibodies (267). The activation of iNKT cells by the S. typhimurium LPS is also IL-12-
dependent. Even in microorganisms for which iNKT cell lipid antigens have been 
identified, such as S. pneumoniae, effective iNKT cell responses also depend on IL-12, 
suggesting that these cytokine-driven signals may be the dominant pathway for iNKT cell 
activation (279). A recent study using reporter mice that detect TCR signaling showed 
that while some bacteria that produce iNKT cell antigens signaled through the TCR, 
others thought to require presentation of self-lipids (e.g. those derived from S. 
typhimurium) induced robust iNKT cell responses in the absence of antigenic stimulation 
(280). This pathway was likely mediated by IL-12 and IL-18, which are able to induce 
iNKT cell activation entirely independent of TCR stimulation (276). Based on these 
observations, a general model of iNKT cell activation has been proposed where: a) 
microbes that possess high-affinity cognate iNKT cell lipid antigens can activate iNKT 
cells predominantly through the TCR with little or no need for cytokine stimulation; or b) 
microbes possessing iNKT cell antigens or lacking cognate antigens entirely can activate 
T cells through innate cytokine-driven pathways that may or may not include the 
presentation of endogenous iNKT cell antigens by APCs (281).  
Lastly, our group has recently demonstrated that group II bacterial SAgs can activate both 
mouse and human iNKT cells (220). This activation was independent of CD1d but 
required antigen-presenting cells expressing the human MHC class II molecule HLA-DR.   
1.3.2 Effector Functions 
As their name suggests, iNKT cells are armed with a variety of cytotoxic effector 
molecules including Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) that 
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are able to directly kill target cells (282, 283). However, they are best known for their 
ability to swiftly produce both pro- and/or anti-inflammatory cytokines upon activation. 
The rapidity of this response may be due, at least in part, to the constitutive expression of 
cytokine mRNAs (284). The sheer variety of cytokines produced by iNKT cells, 
including IFNγ, TNFα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-21, 
IL-22 and GM-CSF, further underscores their ability to shape ensuring immune responses 
downstream of their activation (285-290).  
Similar to conventional MHC-restricted CD4+ T cells, iNKT cells can be generally 
categorized into separate functional subsets based on their patterns of cytokine 
production. The fates of individual iNKT cells are therefore determined both by ‘master 
regulator’ transcription factors like promyelocytic leukemia zinc finger protein (PLZF) 
and early growth response 2 (EGR2) as well as ‘cytokine-specific’ transcriptional 
regulators like T-bet (Th1-like), GATA3 (Th2-like) and RORγT (Th17-like) (291). Th1-
like iNKT cells predominantly produce IFNγ in response to αGC or IL-12 stimulation 
and constitute the majority of iNKT cells in the mouse liver (292). They can be CD4+/- 
and NK1.1+/- but characteristically express the CD122 (IL-15R β chain) and require IL-15 
for homeostasis. In contrast, Th2-like iNKT cells produce minimal IFNγ and high 
amounts of IL-4, IL-9, IL-10 and IL-13 (292). Most of these cells express CD4 and IL-
25R (IL-17RB), and are enriched in mouse lymph nodes and lungs. Interestingly, Th2-
like iNKT cells are up to 8-fold more abundant in Balb/c compared to C57BL/6 mice, 
which may partly explain the predominance of Th2 responses in Balb/c mice (293). 
Th17-like iNKT cells principally produce IL-17A and IL-22 in response to stimulation 
and are typically CD4- and NK1.1- (292). IL-17A-producing iNKT cells also express IL-
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25R and are enriched in the lungs, skin and peripheral lymph nodes (292, 294). In 
addition to these three main iNKT cell subsets, other functional populations of iNKT 
cells have been defined, most notably NKT10 cells. Characteristically producing the 
immunosuppressive cytokine IL-10, NKT10 cells are CD4+IL-25R+ and enriched in 
adipose tissue (292). These cells are also a naturally occurring population in human 
peripheral blood (61).   
Through the expression of such a wide variety of cytokines and surface molecules, iNKT 
cells transactivate many different downstream effector cells and can modulate their 
function. DCs constitutively express CD1d and are a major APC population responsible 
for mediating iNKT activation in vivo (265, 295). During this process, CD40-CD40L 
interactions trigger the maturation of DCs to secrete IL-12 (275), promote CD8+ T cell 
cross-priming (296) and enhance conventional CD4+ and CD8+ T cell responses to 
protein antigens (297, 298). iNKT-DC interactions trigger NK cell transactivation, 
yielding sustained IFNγ production (299). iNKT cells can also provide cognate (300) and 
non-cognate (301) B cell help to promote antibody responses. Furthermore, iNKT cells 
can modulate myeloid-derived suppressor cell (MDSC) responses, though the nature of 
this interaction is unclear. During influenza infection, the absence of iNKT cells results in 
the expansion of MDSC populations in mice and iNKT cell adoptive transfer abrogates 
the immunosuppressive function of MDSCs (302). In contrast, the activation of iNKT 
cells by αGC induces the expansion and immunosuppressive function of MDSCs in a 
mouse model of multiple sclerosis (303).  
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1.3.3 Experimental Models to Study iNKT Cell Functions 
There are several available mouse models for the studying iNKT cells in health and 
disease. Vα14-Jα18 transgenic mice overexpress the invariant TCRα chain Vα14-Jα18 of 
iNKT cells, significantly biasing T cell populations towards the iNKT cell lineage. 
Numerous mice with this phenotype have been developed to study the role of the 
invariant TCRα chain on the development of iNKT cells or to overcome the paucity of 
iNKT cells in wild-type mice (304, 305). In contrast, CD1d-/- mice are deficient in all 
NKT cells due to the absence of CD1d, preventing positive selection of all NKT cells in 
the thymus (306). As such, CD1d-/- mice are devoid of both iNKT and vNKT cells and 
therefore any phenotype using these mice cannot be ascribed to one cell subset over the 
other. Jα18-/- mice have a targeted deletion of the Jα18-coding region specific for the 
iNKT cell TCR (307). Since these mice lack only iNKT cells many developmental and 
disease studies utilize both Jα18-/- and CD1d-/- mice in combination to decipher the 
functions of iNKT and/or vNKT cells individually from one another. However, a recent 
report revealed that Jα18-/- mice demonstrate a significant reduction in TCRα repertoire 
diversity (308). The authors propose that, as a result of the insertion of a deletion cassette 
in the TRAJ18 region (coding for Jα18), all gene rearrangements upstream of TRAJ18 
have been suppressed. Importantly, novel Jα18-/- mice that do not possess this defect have 
been recently generated (309, 310), but are not yet widely available.  
Currently, no commercially available antibody for the selective depletion of iNKT cells 
exists. A recently generated iNKT cell-specific antibody called NKT14 was reported to 
effectively deplete iNKT cells in vivo for up to 3 weeks (311). Although extensive 
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characterization of NKT14-mediated iNKT cell depletion is lacking, this antibody holds 
significant future promise once commercially available.  
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1.4 Myeloid-Derived Suppressor Cells 
As the immune system has evolved many different effector mechanisms to combat 
invading pathogens, it has also developed regulatory pathways to keep runaway 
inflammatory processes in check. MDSCs have recently emerged as key players in the 
regulation of immune responses in many different inflammatory diseases. Although the 
majority of research has focused on MDSC function and manipulation in cancer (312-
314), further investigations have highlighted their importance in autoimmunity (315), 
transplantation (316), bacterial (317), viral (318) and parasitic infections (319) and more. 
Originally described as ‘bone marrow suppressor cells’ (320), these cells have the 
remarkable capacity to potently suppress T cell responses and secrete pro- and anti-
inflammatory cytokines to module both innate and adaptive immune responses. Due to 
these immunoregulatory qualities, MDSCs appear to resolve acute inflammation in some 
contexts and contribute to immunopathology in others.  
1.4.1 Definition 
MDSCs are a heterogeneous population of myeloid progenitor cells and immature 
myeloid cells (IMCs) (i.e. neutrophils, monocytes/macrophages and dendritic cells) 
defined by their ability to suppress T cell responses (312). Rather than a distinct subset of 
cells, MDSCs are a mix of myeloid populations that have been prevented from 
differentiating into mature cells and express surface markers indicating various stages of 
immaturity (321). MDSCs can be uniformly characterized in mice by their expression of 
the CD11b and Gr-1 surface markers. Gr-1 consists of the antigens Ly-6G, expressed on 
neutrophils, and Ly-6C, expressed on macrophages. Notably, anti-Gr-1 antibodies 
simultaneously bind both epitopes. Based on morphological and phenotypic differences, 
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two major subsets of MDSCs have been defined: granuolocyctic (or polymorphonuclear) 
MDSCs (G-MDSCs) and monocytic MDSCs (M-MDSCs) (322). In mice, G-MDSCs 
express a CD11b+Gr-1hiLy6G+Ly6Clo phenotype and possess ‘band-like' nuclei, more 
typical of neutrophils. M-MDSCs are CD11b+Gr-1midLy6G-Ly6Chi and are mononuclear 
in appearance, more typical of monocytes. G-MDSCs typically outnumber M-MDSCs in 
most cases and G-MDSCs appear to expand to a greater extent as well (323, 324). In 
culture, M-MDSCs largely retain the ability to differentiate in mature myeloid cells, 
whereas the majority of G-MDSCs remain as immature CD11b+Gr-1+ cells (324). 
Furthermore, M-MDSCs have been suggested to be more suppressive on a per cell basis 
(323, 325), although this may also depend on the disease and/or inflammatory context. 
In humans, G-MDSCs are defined as CD11b+CD14-CD15-/CD66b+ and M-MDSCs as 
CD11b+CD14+HLA-DR-/lowCD15- (322). CD33 is often used instead of CD11b as a 
myeloid marker and can be helpful in separating the two subsets, as G-MDSCs stain as 
CD33dim and M-MDSCs are CD33hi (326). A third subset of MDSCs that contain a mixed 
population more indicative of immature progenitors, known as early-stage MDSCs 
(eMDSCs), are defined in humans, and have no mouse equivalent (322). These cells are 
Lin- (including CD3, CD14, CD15, CD19, CD56) HLA-DR-CD33+.  
Although the surface phenotype of MDSCs is necessary for their identification, it does 
not distinguish them from their mature myeloid counterparts. Presently, there are no 
combination of surface markers that can discriminate between G-MDSCs from 
neutrophils and M-MDSCs from monocytes. Therefore, a suppression assay 
demonstrating the ability of putative MDSCs to inhibit T cell responses is also required 
(322). While many different methods to demonstrate T cell suppression by MDSCs have 
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been employed, most take the form of an in vitro T cell co-culture with varying ratios of 
MDSCs in addition to a T cell stimulus, anti-CD3/CD28 for example. The resulting 
suppression of T cell activity in the presence of MDSCs is then determined. Typically, 
3H-thymidine incorporation or fluorescent carboxyfluorescein succinimidyl ester (CFSE) 
dye dilution assays are used to evaluate T cell proliferation, while ELISA/ELISPOT can 
be used to measure T cell-mediated IFNγ responses (322). The presence of surface 
markers indicative of MDSCs in combination with a demonstrated ability to effectively 
suppress T cell function remains the ‘gold standard’ to merit the designation of MDSC 
(322). 
It should be noted that one of the most controversial aspects regarding the definition of 
MDSCs is why cells with a morphology and surface phenotype resembling neutrophils or 
monocytes should require separate designations as G-MDSCs or M-MDSCs. Indeed, 
immunosuppressive neutrophils (327) and monocytes (328) can be found during 
inflammatory conditions. Koenderman and colleagues go so far as to suggest that G-
MDSCs are an alternative functional heterogenic subset of neutrophils (329). During 
sepsis, the re-programming of monocytes into compensatory anti-inflammatory response 
(CARS)-monocytes, which have the same function and phenotype of M-MDSCs, can be 
also thought of as an alternative monocyte differentiation pathway (330). M-MDSCs 
from breast cancer patients display a more similar gene expression profile to CARS-
monocytes from sepsis patients than to monocytes from healthy controls or tuberculosis 
patients (331). To help resolve this dilemma, a summary of recommendations for MDSC 
characterization standards was recently established by Bronte et. al (322). In addition to 
the established requirements to define MDSCs by surface phenotype and 
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immunosuppressive capability by the assays described above, the investigators propose 
four distinct molecular and biochemical parameters to distinguish MDSCs from their 
myeloid counterparts: i) transcription factors and apoptotic regulators (e.g. active STAT3, 
RORC1, and S100A8/A9 proteins); ii) immunosuppressive genes and molecules (e.g. 
arginase, iNOS, ROS and PGE2); iii) immunoregulatory cytokine production (e.g. IL-10 
and TGFβ); and iv) mediators that contribute to MDSC development and function (e.g. 
GM-CSF, G-CSF and IL-1). Although these parameters are not exhaustive and may not 
necessarily define MDSCs in all disease contexts, they constitute an important step 
forward to guide the growing field of MDSC immunobiology.  
1.4.2 Mechanisms of Immunosuppression 
MDSCs employ major immunosuppressive pathways to potently inhibit both CD4+ and 
CD8+ T cell activity. MDSCs produce high levels of arginase-1, which metabolizes L-
arginine into L-ornithine, thus depleting L-arginine in the local environment. As a result, 
T cells lose the expression of the CD3ζ chain, an essential component of the TCR 
complex responsible for intracellular signal transduction (332). Arginine starvation also 
causes T cell cycle arrest due to reduced expression of cell cycle regulators cyclin D3 and 
cyclin-dependent kinases 4 (333). Predictably, T cells activated in the absence of arginine 
show markedly reduced proliferation and cytokine production, but can be rescued by 
arginine supplementation in vitro (332), or by depletion of arginase-producing MDSCs in 
vivo (334). Both subsets of MDSCs demonstrate arginase-1 activity; however, whether 
arginase-1 plays a major role as an immunosuppressive factor for either G-MDSCs or M-
MDSCs is unclear (323, 325).  
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MDSCs produce another enzyme that metabolizes L-arginine, iNOS, which catalyzes the 
synthesis of the potently immunosuppressive molecule, nitric oxide (NO). NO itself 
impairs T cell responses to IL-2 by directly impairing IL-2R signaling, which is critical 
for T cell proliferation (335). In a similar manner, NO reduces IL-2 mRNA expression 
and impairs IL-2 secretion from activated T cells (336). NO also decreases the expression 
of MHC class II on APCs (337), potentially limiting antigen presentation or SAg binding 
to reduce T cell activation. Furthermore, iNOS activity in the presence of low cytosolic 
arginine (depleted by arginase-1) promotes the generation of superoxide (O2
-) and, 
consequently peroxynitrite, which is a product of superoxide and NO (338). 
Peroxynitrites are among the most powerful oxidants in the body and cause nitration or 
nitrosylation of key amino acids regulating T cell function. The production of 
peroxynitrite by MDSCs directly induces nitration of tyrosine residues in the TCR and 
CD8 co-receptor of T cells impairing antigen-specific CD8+ T cell responses (339). 
Peroxynitrite-mediated nitration in human T cells also triggers apoptosis, due to the 
inhibition of protein tyrosine phosphorylation in activated T cells (340). The NO pathway 
is preferentially used by the M-MDSC subset as evidenced by inhibition of iNOS 
function by L-NG-monomethyl arginine citrate (L-NMMA) in suppression assays, which 
blocks the activity of M-MDSCs but not that of G-MDSCs (323, 325). 
In contrast to M-MDSCs, G-MDSCs generate reactive oxygen species (ROS) as a 
primary means of immunosuppression (323). Increased ROS production by G-MDSCs is 
mediated by the up-regulated activity of NADPH oxidase, which generates superoxide 
(341). In addition to forming peroxynitrites, superoxides also react with protons in water 
to generate hydrogen peroxide (H2O2), which is the main ROS to suppress T cells 
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responses (342). ROS directly reduce CD3ζ chain expression in T cells, impairing T cell 
proliferation and cytokine production (343, 344). ROS also promote apoptosis in 
activated T cells through the downregulation of the anti-apoptotic protein B cell 
lymphoma 2 (Bcl2) (345). The inhibition of ROS production by the H2O2 scavenger 
catalase reverses G-MDSC mediated T cell suppression in both mice and humans (342, 
344).  
In addition to the major mechanisms described above, several other pathways of MDSC-
mediated T cell suppression have been identified. MDSCs can indirectly promote 
immunosuppression through the activation of Treg cells by multiple routes. The 
expression of CD40 (346), CD80 (347) and arginase (348) by MDSCs have been 
separately shown to induce Treg differentiation and function. MDSC production of the 
immunoregulatory cytokines IL-10 and tumor growth factor β (TGFβ) also facilitates 
Treg function (349). Additionally, MDSCs express galactin 9 (350), the ligand for T cell 
immunoglobulin and mucin-domain containing-3 (TIM-3) expressed on Th1 cells, which 
triggers apoptosis (351). Lastly, MDSCs can suppress T cells by the local depletion of 
cysteine, an amino acid essential for T cell activation and survival (352). However, as the 
vast majority of MDSC function involves the use of murine cancer models, the extent to 
which these mechanisms are at play in the many different disease contexts that show 
MDSC involvement has yet to be determined.  
1.4.3 Origin, Expansion and Functions 
As a heterogeneous population of IMCs, MDSCs originate in the bone marrow under 
normal conditions of myelopoiesis (330). In this process, hematopoietic stem cells give 
rise to multi-potent progenitors, which then become common myeloid progenitors and in 
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turn generate IMCs. Under steady-state conditions, IMCs proceed to differentiate into 
their respective mature myeloid populations or exit the bone marrow to complete their 
development in the periphery. In naïve mice, IMCs that express CD11b and Gr-1 can be 
found at low levels in multiple tissues, including bone marrow (20-30% of myeloid 
cells), spleen (2-4%), liver (2-5%) and lymph nodes (<1%), and are not 
immunosuppressive (321). However, during pathological conditions, overwhelming 
inflammation or cancer for example, IMC populations expand and acquire 
immunosuppressive qualities to become MDSCs.  
The expansion of MDSCs is rooted in ‘emergency myelopoiesis’, where IMCs are 
rapidly mobilized from the bone marrow to the blood or sites of inflammation to restore 
or renew myeloid populations during infection (330). Several growth factors responsible 
for the regulation and maturation of myeloid cells promote this process, including 
macrophage colony-stimulating factor (M-CSF), granulocyte-CSF (G-CSF), and 
granulocyte/macrophage-CSF (GM-CSF) (353). However, a variety of inflammatory 
mediators also trigger MDSC expansion, including IL-1 (354), hepatic acute phase 
proteins (355), PGE2 (356) and S100A8/9 (357). These factors commonly converge on 
the Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) 
pathway, a major regulator of MDSC function (312). The activation of STAT3 in 
MDSCs stimulates their expansion and survival through increasing myelopoiesis and 
expression of anti-apoptotic proteins. Recently, retinoic-acid-related orphan receptor 1 
(RORC1) was identified as another critical transcription factor regulating the 
accumulation of MDSCs through promoting myelopoiesis and preventing MDSC 
apoptosis (358). Interestingly, many of the same mediators that stimulate the expansion 
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of MDSCs also block IMC maturation and differentiation to terminal myeloid cells. 
S100A9 (359), vascular endothelial growth factor (360) and PGE2 (361) have been 
shown to mediate accumulation of MDSCs through subverting conventional myeloid 
differentiation pathways. Both emergency myelopoiesis and defective myeloid cell 
maturation have been associated with hyperactivation of STAT3, suggesting that these 
processes may be linked in a positive feedback loop.  
In addition to expansion, MDSCs require an ‘activation signal’ to induce their 
suppressive activity, many of which are inflammatory mediators produced in abundance 
during infection. The activation of the NF-κB pathway, through inflammatory signals IL-
1, TNFα and TLR ligands, strongly regulates the suppressive capability of MDSCs (362-
364). MDSCs deficient in MyD88, a universal adaptor protein used by almost all TLRs 
and the IL-1R, lose their suppressive abilities and even acquire immunostimulatory 
functions (365). Notably, the accumulation of MDSCs remains unaffected. TNFα induces 
the suppressive function of MDSCs through regulation of iNOS activity via NK-κB (366) 
or through the activity of S100A8/9 proteins (367).  However, this appears to primarily 
affect only M-MDSCs (368), which makes sense as iNOS is often undetectable in G-
MDSCs. The inflammatory cytokine IFNγ, linked to the activation of STAT1, is also 
associated with upregulation of iNOS and arginase-1 expression in M-MDSCs (369). 
Interestingly, IFNγ signaling in G-MDSCs may actually hinder suppressive ability and 
cell survival indicating that certain inflammatory signals may have opposite effects on the 
different subsets (370). The Th2 cytokines IL-4 and IL-13, typically thought of as anti-
inflammatory in many cases, stimulate the expression of arginase-1 in MDSCs (371, 
372). This signaling pathway mediated by STAT6 is also involved in promoting the 
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accumulation (373) and survival of MDSCs (374). Lastly, PGE2 augments the 
suppressive capabilities of MDSCs in addition to its role in MDSC expansion and 
differentiation blockade. PGE2 upregulates arginase-1 expression in MDSCs (375). It 
also appears to be involved in a positive feedback loop with the upstream enzyme COX2. 
PGE2 increases the expression of COX2 in monocytes, blocking their differentiation into 
DCs converting them to M-MDSCs, and inducing endogenous PGE2 production in 
addition to other immunosuppressive factors (361).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
44 
1.5 Interleukin-17A 
IL-17A is a potent inflammatory cytokine that plays a critical role in the host defence 
against extracellular bacterial, parasitic and fungal infections (376). Impaired IL-17A 
functions in mice are linked to susceptibility to a wide variety of pathogenic microbes, 
including Staphylococcus aureus (377), Streptococcus pneumoniae (378), Listeria 
monocytogenes (379), Trypanosoma cruzi (380), and Candida albicans (381). In humans, 
genetic deficiencies in IL-17A signaling also significantly increase susceptibility to 
chronic mucocutaneous infections caused by C. albicans and S. aureus (382). However, 
excessive IL-17A responses are also associated with a variety of chronic inflammatory 
disorders including psoriasis, rheumatoid arthritis, multiple sclerosis and inflammatory 
bowel disease among others (383). IL-17A exerts its inflammatory effects primarily 
through induction of downstream inflammatory cytokines, chemokines, effector 
molecules and antimicrobial proteins. As the IL-17A receptor complex is widely 
expressed throughout both hematopoietic and non-hematopoietic tissues, IL-17A is a key 
player in shaping the systemic inflammatory environment.  
1.5.1 The IL-17 Family 
There are six members of the IL-17 family: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E 
and IL-17F (384). IL-17A, the eponymous cytokine of the IL-17 family, was first 
identified as a product of T cells that induces NF-κB activation and IL-6 secretion from 
human fibroblasts (385). It is the most completely characterized member of the IL-17 
family and is well known to promote systemic inflammatory responses. IL-17F is most 
similar to IL-17A and shares approximately 50% sequence homology (386). Both 
cytokines are produced individually as covalent homodimers or as IL-17A/F 
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heterodimers that share many similar functions (387, 388). Together, IL-17A, IL-17F and 
IL-17A/F all signal through the same receptor complex composed of IL-17RA and IL-
17RC (389, 390). However, the signaling potency of IL-17A is substantially greater than 
IL-17F, with the IL-17A/F heterodimer exhibiting an intermediate phenotype (388). 
Interestingly, the individual receptor subunits have differential affinities for IL-17A and 
IL-17F. IL-17RA binds with high affinity to IL-17A but extremely low affinity to IL-
17F, whereas IL-17RC binds IL-17F with greater affinity than IL-17A (389). The 
expression patterns of IL-17RA and IL-17RC also appear to be reciprocal. In contrast to 
IL-17RA, which is highly expressed in lymphoid tissues such as the spleen, liver, 
thymus, lymph nodes, IL-17RC is highly expressed in the intestines and glandular tissue 
including the adrenal glands, prostate and thyroid (385, 389, 391). Although IL-17A and 
IL-17F share many overlapping and similar functions, these differences in receptor 
binding affinity and tissue expression may explain why IL-17A and IL-17F do not always 
act in a functionally redundant manner. In general, IL-17A appears to have a more central 
role in promoting autoimmunity and IL-17F contributes to airway hypersensitivity and 
allergy (392), though both are involved in anti-microbial responses (391). 
The other IL-17 family members IL-17B, IL-17C and IL-17D remain poorly 
characterized. They are classified as inflammatory cytokines based on their ability to 
stimulate neutrophil responses or induce expression of pro-inflammatory genes (393-
396), though their functions in many disease states remain unknown. IL-17B signals 
through the IL-17RB receptor but the signal transduction pathway has yet to be defined. 
IL-17C binds to the heterodimeric receptor IL-17RA/IL-17RE and regulates immune 
responses in epithelial cells in an autocrine fashion (395, 397). IL-17D is the least 
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characterized member of the IL-17 family and can be found in the brain, heart, lungs, 
pancreas, muscle and adipose tissue (396). Its receptor has yet to be identified. 
The final member of the IL-17 family, IL-17E, is also known as the Th2-promoting 
cytokine IL-25 (398). IL-25 is expressed in a wide variety of cell types, including both 
immune and non-immune cells, and signals through IL-17RB in complex with IL-17RA 
(399). As a strong inducer of Th2 type immune response (e.g. IL-4, IL-5, and IL-13), IL-
25 is critical in the defense against parasitic infections but also effectively limits 
intestinal inflammation (400). Interestingly, IL-25 has the lowest homology to the IL-17 
family, and unlike other members, actively limits Th17 cell differentiation by promoting 
IL-13 production by activated DCs (401).  
1.5.2 Sources of IL-17A 
IL-17A is the signature cytokine produced by the Th17 subset of CD4+ effector T cells 
(402, 403). Th17 differentiation from naïve CD4+ T cells is driven by the combination of 
TGFβ, IL-6 and IL-21 (376), which induce the expression of the ‘master regulator’ 
transcription factor RORγT (404). RORγT expression is required for IL-17A production 
and for upregulation of the IL-23 receptor (IL-23R), a hallmark surface marker for Th17 
cells. IL-23 signaling through its receptor is crucial to stabilize the lineage commitment 
of developing Th17 cells and for their maintenance in the periphery (376). In humans, 
Th17 cells are long-lived effector memory T (TEM) cells with a high capacity for self-
renewal (405). These cells are a terminally differentiated population of memory cells (i.e. 
antigen-experienced) that are capable of rapid effector function upon re-activation. In 
addition to IL-17A, Th17 cells also secrete copious amounts of IL-17F, IL-21, IL-22, 
GM-CSF, and TNFα (376). Due to their inflammatory nature, Th17 cells not only play an 
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important role in the clearance of extracellular microbes, particularly at mucosal surfaces, 
but also drive inflammatory pathology in autoimmune diseases.  
Importantly, IL-17A is also produced by a host of other immune cells given the right 
inflammatory context. Most prominently, innate-like T lymphocytes like γδ T cells are a 
rapid source of IL-17A due to their constitutive expression of IL-23R and RORγT (406). 
They can be activated solely by innate cytokine-driven signals in the absence of TCR 
engagement and are highly enriched at mucosal surfaces providing first-line defence 
against invading pathogens. Similarly, Th17-like iNKT cells (discussed previously) 
produce IL-17A when stimulated with their lipid agonists (286). The recently discovered 
innate lymphoid cell (ILC) lineage also contains a subset of IL-17A producing cells 
known as group 3 ILCs (407). This group of ILCs is reliant on RORγT for development 
and consists of lymphoid tissue inducer cells, responsible for the formation of secondary 
lymphoid organs, and ILC3s, which are innate immune cells that express the NK cell 
marker NKp46 yet do not have a cytolytic capacity. Lastly, several innate immune 
myeloid cells have also been reported to produce IL-17A, including neutrophils (408), 
monocytes (409) and mast cells (410).  
1.5.3 Signaling Pathway 
Typically, Th1- and Th2-type cytokines signal through JAK-STAT pathways, which 
promote Th cell differentiation in addition to facilitating effector functions. Instead, IL-
17A signaling is more similar to innate immune pathways such as the IL-1 family or TLR 
ligands. IL-17 family receptors encode conserved cytoplasmic motifs with distinct 
homology to Toll/IL-1R (TIR) domains, known as SEF/IL-17R (SEFIR) domains (411). 
Just as TIR domains are essential for the binding of intracellular adaptor MYD88 for IL-
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1/TLR signaling, the binding of IL-17A to its receptor complex recruits the signaling 
adaptor molecule ACT1 via SEFIR domain interactions (412). ACT1 serves both as an 
adaptor molecule and an E3 ubiquitin ligase, recruiting and ubiqutinating TNFR-
associated factors (TRAFs), including TRAF6 (413). TRAF6 is a critical signaling 
molecule facilitating the activation of NF-κB pathway and several MAPK pathways such 
as extracellular signal regulated kinase (ERK), p38 and JNK (414). IL-17A signaling also 
activates the CCAAT/enhancer binding proteins (C/EBPs) C/EBPβ and C/EBPδ, which 
act in concert with NF-κB to induce IL-17A target genes (415, 416). Furthermore, ACT1 
recruits TRAFs 2 and 5 that promote the activation of the RNA-binding protein Hur, 
which stabilizes the mRNA of both IL-17A and other downstream effector genes (417, 
418).  
1.5.4 Inflammation   
As the direct targets of IL-17A signaling include a host of cytokines, chemokines and 
inflammatory effector molecules, IL-17A is clearly a potent inducer of systemic 
inflammatory responses. In fact, the inflammatory cytokine IL-6 is one of the earliest 
known gene targets of IL-17A (419) and its production still remains the standard bioassay 
for measuring IL-17A activity. IL-17A signaling triggers a positive feedback loop of IL-6 
expression (420) thus amplifying both Th17 cell differentiation and activation of the 
acute phase response. IL-17A directly stimulates the production of a variety of 
inflammatory cytokines including TNFα, IFNγ, IL-1β, IL-6, IL-8 and IL-12 from 
macrophages and DCs (421, 422). Further, IL-17A induces COX-2 and microsomal 
prostaglandin E-synthase expression that catalyze the production of the inflammatory 
mediator PGE2 (423, 424).  
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Many non-hematopoietic cell types such epithelial cells, endothelial cells and fibroblasts 
express the IL-17RA/C complex and thus are among the main targets of IL-17A. 
Stimulation of these cells by IL-17A induces the secretion of IL-6, IL-8, G-CSF and 
PGE2 (419). Endothelial cells also respond to IL-17A by increasing the expression of 
tissue factor, which promotes coagulopathy (425). Epithelial, endothelial and 
mesenchymal cells are important sources of chemokines induced by IL-17A, such as the 
neutrophil chemoattractants CXCL1, CXCL2, CXCL5 and CXCL8/IL-8 (426). 
Neutrophil responses are also further bolstered by IL-17A through the production of G-
CSF, which promotes granulopoiesis and neutrophil accumulation (427). Importantly, IL-
17A plays a critical role in triggering granulopoiesis and neutrophil recruitment that is 
required for host defence against microbial pathogens, such as Klebsiella pneumoniae 
(428). Other chemokine targets of IL-17A include CCL2 and CCL20, which mediate 
monocyte and dendritic cell migration to inflamed tissue (429, 430), and CXCL9-12, 
which are potent T cell chemoattractants (431, 432).  
A major factor potentiating the inflammatory effects of IL-17A is a strong synergism 
with other cytokines in regulating its downstream targets. IL-17A induces IL-6 
production synergistically with IFNγ, IL-1β, IL-22, and in particular, TNFα (426). The 
underlying molecular mechanisms for this synergy are not completely understood and 
likely involve multiple factors. First, IL-17A enhances the mRNA stability of cytokines 
and chemokines that contain AU-rich elements in their 3’ untranslated region (433, 434). 
Similarly, IL-17A markedly enhances TNFα-induced IL-6 mRNA expression resulting in 
significantly augmented protein production (435). IL-17A-mediated stabilization of 
mRNA has also been demonstrated for G-CSF, GM-CSF, CXCL1, CXCL2, CXCL5, IL-
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8 and COX-2 (426). A second potential mechanism of synergy is the convergence of IL-
17A and other cytokine signaling pathways at the level of target gene transcription. Both 
IL-17A and TNFα upregulate the IL-6 promoter through the cooperative activation of the 
transcription factors C/EBPδ and NF-κB (416). Many IL-17A-target genes have 
promoters that contain binding sites for C/EBPδ and NF-κB suggesting this may be the 
case for a variety of IL-17A-induced products (415). Lastly, IL-17A can regulate the 
expression of cytokine receptors, including TNFR II, to enhance the signaling capacity of 
inflammatory cytokines (436). In a similar fashion, the synergy between IL-17A and IL-
22 in the production of IL-20 subfamily cytokines is due to the upregulation of the IL22R 
(437). IL17A and IL-22 also synergize in the production of S100A8/9 proteins, though 
the exact mechanism facilitating this process is unknown (438). It should be noted that 
although IL-17A itself is a relatively modest inducer of NF-κB in vitro (384), due to its 
synergistic functions with other cytokines it can play a critical role in mediating 
inflammation or anti-microbial immunity in vivo.  
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Chapter 2  
 
Rationale and Specific Aims 
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2.1 Rationale  
Toxic shock syndrome (TSS) is a potentially fatal illness characterized by a systemic 
inflammatory response triggered by exposure to superantigens (Sags) (1). These bacterial 
toxins directly cross-link T cell receptors (TCRs) on T cells with major histocompatibility 
complex (MHC) molecules on antigen-presenting cells (APCs) to activate an 
extraordinary number of T cells. This overwhelming activation of T cells causes rapid 
and massive production of inflammatory mediators known as a ‘cytokine storm’, 
beginning hours after SAg exposure. The cytokine storm initiates a cascade of drastic 
tissue-damaging effects including disseminated intravascular coagulation, vascular leak 
and tissue hypoxia. If unchecked, this inflammatory process culminates in the 
dysfunction of multiple organ systems and possibly death. Alarmingly, there currently are 
no available therapeutic options to attenuate the cytokine storm. Successful treatment of 
TSS relies almost entirely on supportive therapy and critical care (2). Given the rapidity 
with which TSS progresses to life-threatening disease, identifying early mediators of the 
cytokine storm may hold the key to designing effective therapies that mitigate the 
severity of TSS. Furthermore, much of our understanding regarding TSS 
immunopathology relies on imperfect animal models that are limited in their ability to 
reflect human disease. Mouse models of TSS have been hampered by the fact that SAgs 
bind to certain mouse MHC molecules with very poor affinity resulting in minimal T cell 
activation and little cytokine production (3). Transgenic mice expressing humanized 
MHC (e.g. HLA-DR) that are exposed to SAgs have been shown to faithfully recapitulate 
many aspects of human TSS (4-6). Therefore, my objective is to utilize an HLA-DR4 
transgenic (DR4tg) mouse model to identify and characterize regulatory and effector 
  
94 
immune responses in the early phase TSS. I hypothesize that rapid effector and 
suppressor cell responses are critical to TSS pathogenesis and may be targeted to reduce 
disease severity.  
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2.2 Specific Aims 
2.2.1 Aim 1: To delineate the role of invariant natural killer T cells 
in TSS immunopathogenesis 
Invariant natural killer T (iNKT) cells are a subset of T lymphocytes possessing innate-
like characteristics and are able to rapidly produce copious amounts of 
immunomodulatory cytokines upon activation. As a result, they can effectively modulate 
the function of many downstream regulatory and effector cells types, thus shaping the 
nature of the ensuing immune response. iNKT cells can also be therapeutically targeted 
by glycolipid agonists to polarize them towards a pro- or anti-inflammatory phenotype. 
Previous work in our lab utilizing DR4tg mice demonstrated that SAgs activate iNKT 
cells to produce inflammatory cytokines in vivo (7). However, whether iNKT cells play a 
regulatory or effector role during TSS was unknown. In light of our previous findings, I 
hypothesized that iNKT cells are pathogenic in TSS and contributed to the cytokine 
storm. In Chapter 3, I compared TSS morbidity and mortality in DR4tg mice to a newly 
generated strain of ‘iNKT-deficient’ DR4tg mice, dubbed ‘DJ’ mice. These findings were 
confirmed using the recently described iNKT cell-depleting monoclonal antibody NKT14 
(8). To determine whether iNKT cells participate in the cytokine storm, I quantified the 
levels of serum cytokines in DR4tg and DJ mice within the first 24 hours of TSS onset. 
Finally, I ascertained whether the polarization of iNKT cells towards an anti-
inflammatory phenotype by the glycolipid agonist OCH (9) could reduce TSS severity. 
Here, I provided the first report addressing the role of iNKT cells in TSS pathogenesis. 
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 2.2.2 Aim 2: To determine the identity and function of a suddenly 
prominent population of hepatic myeloid cells in a 
humanized mouse model of TSS 
While investigating TSS in a DR4tg mouse model, I detected a suddenly prominent 
population of cells in the liver within hours of SAg exposure. These cells exhibited a high 
forward- and side-scatter phenotype by cytofluorimetric analysis, consistent with cells of 
the myeloid lineage. Given that severe and/or chronic inflammation drives the 
accumulation of myeloid-derived suppressor cells (MDSCs) in peripheral tissues, such as 
in sepsis (10) or cancer (11), I hypothesized that these hepatic myeloid cells were 
MDSCs. Importantly, the presence of MDSCs in TSS was yet to be defined and therefore 
their role in TSS was unknown. In Chapter 4, I characterized the surface phenotype of 
putative MDSCs using a panel of fluorochrome-labeled mAbs. I also determined the 
capacity of these cells to prevent SAg-activated T cell responses via a suppression assay. 
Using chemical inhibitors of MDSC pathways, I established the major effector molecule 
responsible for MDSC-mediated T cell suppression. Lastly, I generated human MDSCs 
in vitro to address whether they were able to similarly able to prevent autologous T cells 
responses to SAg. Taken together, I demonstrated for the first time the accumulation and 
function of hepatic MDSCs in TSS.  
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2.2.3 Aim 3: To define the contribution of interleukin-17 to TSS 
immunopathology 
Interleukin-17A (IL-17A) is a potent inducer of systemic inflammation, stimulating the 
production of a variety of inflammatory mediators including cytokines, chemokines, and 
transcription factors from many cell types. Importantly, IL-17A both directly triggers and 
acts synergistically with inflammatory cytokines involved in the TSS cytokine storm, 
namely tumor necrosis factor α (TNFα), interferon γ (IFNγ), IL-1 and IL-6 (12). It can 
also be rapidly produced upon activation of conventional CD4+ T helper type 17 (Th17) 
cells in addition to innate-like T lymphocytes such as γδ T cells and iNKT cells (13). 
However, whether SAgs elicit IL-17A responses that contribute to the cytokine storm and 
potentiate TSS immunopathogenesis was unexplored. A previous investigation in our lab 
identified the presence of IL-17A in serum within hours of exposure to SAg in DR4tg 
mice (7). Thus, I hypothesized that SAgs trigger a rapid IL-17A response that promotes 
TSS immunopathology. In Chapter 5, I characterized the magnitude, timing and source of 
IL-17A production in both DR4tg mice and human peripheral blood mononuclear cells 
(PBMCs) in response to SAgs. Utilizing a mAb to the IL-17A receptor in human PBMCs, 
I identified the effects of IL-17A signaling on the expression of key downstream 
inflammatory mediators implicated in TSS-associated cytokine storm. Finally, I 
investigated the in vivo significance of IL-17A function in the DR4tg mouse model of 
TSS and assessed its impact on disease morbidity, mortality and tissue damage. 
Collectively, this study reveals for the first time the role of IL-17A in the cytokine storm 
and TSS-mediated immunopathology. 
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Chapter 3  
 
Invariant NKT Cells are Pathogenic in the HLA-DR4-
Transgenic Humanized Mouse Model of Toxic Shock 
Syndrome and Can Be Targeted to Reduce Morbidity 
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3.1 Introduction 
Staphylococcal enterotoxin B (SEB) and other superantigens (SAgs) secreted by 
Staphylococcus aureus cause human illnesses ranging from mild food poisoning to 
potentially fatal toxic shock syndrome (TSS) (1). Systemic exposure to SAgs results in 
polyclonal stimulation of T cells irrespective of their cognate specificity. SAgs are 
inherently capable of binding to select Vβ regions of the T cell receptor (TCR) and lateral 
surfaces of MHC class II harbored by antigen-presenting cells. Consequently, rapid and 
massive release of inflammatory mediators is triggered, which can be followed by fever, 
shock and organ failure. 
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes with profound 
immunoregulatory properties (2). Mouse iNKT cells express a canonical TCRα chain 
with a characteristic Vα14-Jα18 rearrangement, which is paired with one of a limited 
number of Vβ chains. iNKT cells uniquely recognize glycolipid antigens presented by 
CD1d.   
We previously established that mouse and human iNKT cells can directly respond to 
group II bacterial SAgs, including SEB, in a CD1d-independent manner (3). However, 
whether these cells play a pathogenic or regulatory role during TSS is unknown. This is 
an important question in light of the facts that: i) iNKT cells are strategically located at 
the host-pathogen interface; ii) they exhibit a ‘pre-activated’ or ‘memory-like’ phenotype 
(2) and can, as such, be quickly activated; iii) iNKT cells possess pre-formed mRNA for 
certain inflammatory cytokines (4), which enables them to secrete such cytokines amply 
and speedily; iv) iNKT cells exert pleiotropic effects on numerous downstream 
effector/regulatory cell types including NK, T, B and dendritic cells, macrophages and 
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myeloid-derived suppressor cells. Therefore, they shape the nature of ensuing immune 
responses; v) iNKT cells are easily ‘polarizable’ towards a pro- or anti-inflammatory 
phenotype. Therefore, they can be manipulated by synthetic glycolipids in a disease-
tailored fashion (5). 
In this work, we have used a humanized mouse model mimicking several aspects of TSS 
and two distinct experimental strategies, namely genetic deficiency and antibody-
mediated depletion of iNKT cells, to determine if: i) iNKT cells are pathogenic effectors 
of TSS; ii) deviating iNKT cell responses towards a TH2 phenotype ameliorates the 
severity of TSS.  
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3.2 Materials and Methods 
3.2.1 Ethics 
This study was conducted using a protocol approved by the Western University Animal 
Use Subcommittee and in full adherence to the Canadian Council on Animal Care 
guidelines.  
3.2.2 Mice   
Age- and sex-matched adult mice were used in all experiments. Wild-type C57BL/6 mice 
were purchased from Charles River Canada. HLA-DR4-transgenic (DR4tg) mice on a 
C57BL/6 background were bred in our barrier facility. These animals are endogenous 
MHC class II (IA)-deficient but express a chimeric HLA molecule encoded by HLA-
DRA-IEα and HLA-DRB1*0401-IEβ transgenes (6).  
To develop an iNKT cell-deficient mouse strain that is humanized to express HLA II, 
DR4tg mice were crossed with Jα18-/- mice, on a C57BL/6 background, which lack iNKT 
cells (7). The resultant HLA-DR4tg.Jα18-/- mice, hereafter referred to as DJ mice, were 
bred to homozygosity and examined for the presence of HLA-DR transgenes, Jα18 and 
IAβ, or lack thereof, by PCR. Briefly, ear clip genomic DNA was prepared using 
HotSHOT, and PCR was performed using Platinum Taq DNA polymerase (Thermo 
Fisher). PCR products were visualized by agarose gel electrophoresis. Primers used for 
genotyping are listed in Table 3.1.  
Wild-type C57BL/6, J18-/-, DR4tg and DJ mice were all housed in the same facility.   
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Probe/Primer  Sequence (5’-3’)/Assay ID  Dye Source 
Vα14-Jα18 Primer  
(Forward) 
TGGGAGATACTCAGCAACTCTGG N/A Sigma-
Aldrich 
Vα14-Jα18 Primer 
(Reverse) 
CAGGTATGACAATCAGCTGAGTCC N/A Sigma-
Aldrich 
Vα14-Jα18 
TaqMan Probe 
CACCCTGCTGGATGACACTGCCAC FAM-
MGB 
Thermo 
Fisher 
Scientific 
TBP TaqMan 
Assay 
Mm00446973_m1 FAM-
MGB 
Thermo 
Fisher 
Scientific 
HLA-DRA-IEα 
Primer (Forward) 
GGGAAGCAGGGGGACTATGAC 
from Ref (6) 
N/A Sigma-
Aldrich 
HLA-DRA-IEα 
Primer (Reverse) 
TTAGGGCAATGACTTCGTAGG 
from Ref (6) 
N/A Sigma-
Aldrich 
HLA-DRB1*0401-
IEβ Primer 
(Reverse) 
TGAAAGCGGTGCGTGCTGTTTAA 
from Ref (6) 
N/A Sigma-
Aldrich 
HLA-DRB1*0401-
IEβ Primer 
(Reverse) 
CACCCGCTCCGTCCCGTTGAA 
from Ref (6) 
N/A Sigma-
Aldrich 
HLA-DRtg 
Insertion Primer 
(Forward) 
CCATGGACAAGGCAGGGACAAA N/A Sigma-
Aldrich 
HLA-DRtg 
Insertion Primer 
(Reverse) 
CCGTGACCAAAATGCACATTGAA 
 
N/A Sigma-
Aldrich 
IAβ-neor Primer 
(Forward) 
GGGAGGAGTACGTGCGCTACGACAG 
 
N/A Sigma-
Aldrich 
IAβ-neor Primer 
(Reverse) 
GAGAACCTGCGTGCAATCCATCTTG 
 
N/A Sigma-
Aldrich 
Jα18 TCR Primer 
(Forward) 
CCCTCTTTCCTCCCTTCCCACCTT 
 
N/A Sigma-
Aldrich 
Jα18 TCR Primer 
(Reverse) 
ACAATGCCCTCCACCTTAGTCCTGA 
 
N/A Sigma-
Aldrich 
Jα18-neor Primer 
 (Forward)  
CCCTCTTTCCTCCCTTCCCACCTT 
[same as Jα18 TCR Primer (Forward)] 
N/A Sigma-
Aldrich 
Jα18-neor Primer 
(Reverse)  
ATCGCCTTCTATCGCCTTCTTGACG 
 
N/A Sigma-
Aldrich 
Table 3.1: PCR probes/primers used for genotyping and gene expression 
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3.2.3 Immunophenotyping 
Splenic single cell suspensions were prepared in cold, sterile PBS using a Wheaton 
Dounce tissue grinder. Non-parenchymal hepatic mononuclear cells were isolated by 
density gradient centrifugation in 33.75% Percoll PLUS (GE Healthcare). For 
cytofluorimetric analyses, cells were pre-incubated with 5 μg/mL anti-mouse 
CD16/CD32 (clone 2.4G2) before they were stained with fluorochrome-conjugated 
monoclonal antibodies (mAbs) and tetramers listed in Table 3.2. A FACSCanto II 
cytometer and FlowJo software were used to acquire and analyze data, respectively.  
3.2.4 iNKT cell depletion 
DR4tg mice were injected i.p. with 200 μg of an iNKT cell-depleting mAb, NKT14 (8), 
which was supplied by NKT Therapeutics Inc. (Waltham, MA). A mouse IgG2a (clone 
C1.18.4 from BioXCell) was utilized as isotype control. To confirm iNKT cell depletion 
in NKT14-treated mice, splenic and hepatic mononuclear cells were stained with PBS-
57-loaded mouse CD1d tetramer or with empty tetramer (staining control), which were 
both provided by the NIH Tetramer Core Facility. An aliquot of the same cell 
suspensions were subjected, in parallel, to real-time quantitative PCR (qPCR) assaying 
for the V14-J18 TCR gene rearrangement. In brief, RNA was extracted using a 
PureLink RNA Mini Kit and converted to cDNA by SuperScript VILO Master Mix 
(Thermo Fisher). Contaminating genomic DNA was eliminated using on-column 
PureLink DNase. PCR was performed using a StepOnePlus System, TaqMan Probes 
listed in Table 3.1 and TaqMan Fast Advanced Master mix (Thermo Fisher). Gene  
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Target Species 
Reactivity 
Host 
Species 
Clone 
 
Isotype Fluoro-
chrome 
Source 
TCRβ Mouse Armenian 
Hamster 
H57-
597 
IgG FITC eBioscience 
HLA-DR Human Mouse G46-6 IgG2a, κ PE BD 
Pharmingen 
iNKT TCR  
(PBS-57-
loaded CD1d 
tetramer) 
Mouse N/A N/A N/A APC NIH 
Tetramer 
Core 
Facility 
CD4 Mouse Rat GK1.5 IgG2b, κ FITC eBioscience 
CD8 Mouse Rat 53-6.7 IgG2a, κ PE eBioscience 
CD11c Mouse Armenian 
Hamster 
N418 IgG APC eBioscience 
CD19 Mouse Rat eBio-
1D3 
IgG2a, κ FITC eBioscience 
CD45R 
(B220) 
Mouse/ 
Human 
Rat RA3-
6B2 
IgG2a, κ PE eBioscience 
F4/80 Mouse Rat BM8 IgG2a, κ APC eBioscience 
NK1.1 Mouse Mouse PK136 IgG2a, κ PE-Cy 7 eBioscience 
Table 3.2: Fluorochrome-conjugated antibodies/tetramers used for iNKT cell 
studies 
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expression fold-changes were calculated by ΔΔCT using TATA-binding protein (TBP) as 
the reference gene. 
3.2.5 TSS induction and treatment  
Recombinant SEB was cloned from the Staphylococcus aureus strain COL, expressed in 
E. coli BL21 (DE3), and purified via nickel column chromatography. Mice were injected 
i.p. with 100 g SEB and monitored for up to 7 days, the maximum duration allowed 
under our protocol. Animals were euthanized when moribund or when 20% weight loss 
was reached.   
Separate cohorts of mice were bled 2, 12 and/or 24 hours after they were injected with 
SEB or with 4 µg of -galactosylceramide (GC) (Funakoshi). Serum cytokine analyses 
were performed by bead-based multiplexing (Eve Technologies), and the matrix2png 
utility was employed to generate heat maps. 
In several experiments, DR4tg mice were treated i.p. with the T helper 2 (TH2)-polarizing 
iNKT cell agonist OCH (NIH Tetramer Facility) at 4 µg/dose every day beginning one 
day before or 2 hours after SEB injection. Control DR4tg mice received vehicle 
containing 0.5% Tween-20, 56 mg/mL sucrose and 7.5 mg/mL histidine. Animals were 
monitored for weight loss and signs of morbidity.         
3.2.6 Statistical analysis 
Statistical comparisons were made using Student’s t-test, ANOVA or log-rank test as 
appropriate. *, **, ***and **** denote p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001, 
respectively. 
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3.3 Results and Discussion 
We previously demonstrated that bacterial SAgs directly activate iNKT cells (3). Rieder 
et al. reported that intranasal administration of SEB causes acute lung injury in wild-type 
mice, but to a lesser degree in Jα18-/- or CD1d-/- mice (9). However, intranasal inoculation 
of SEB does not provoke a cytokine storm (9) among other features of TSS, and the 
overall in vivo significance of iNKT cells in TSS pathogenesis remains unknown – hence 
the current investigation.    
SAgs display poor affinity for MHC II molecules expressed in certain conventional 
mouse strains including C57BL/6 mice (10), which partially explains why such animals 
do not provide bona fide models in which to study host responses to SAgs. Therefore, we 
used DR4tg mice that express a humanized MHC II molecule that can establish 
interactions of sufficient affinity with SEB (11). Using this model also eliminates the 
need for pre-sensitization of mice with commonly used but notoriously toxic agents such 
as D-galactosamine (12).  
We took two logistically distinct approaches to investigate the role of iNKT cells during 
TSS in the DR4tg model. First, we crossed DR4tg mice with germ-line iNKT cell 
knockout mice (Jα18-/-) to generate an iNKT cell-deficient, SEB-responsive strain. We 
confirmed that the resulting “DJ” mice express HLA-DR but are devoid of iNKT cells 
(Fig. 3.1A). The frequencies of CD4+ and CD8+ T cells, B cells, dendritic cells, 
macrophages and NK cells were comparable in DR4tg and DJ mice (Fig. 3.2). When 
systemically exposed to SEB, DJ mice lost significantly less weight than did iNKT-
sufficient DR4tg mice (Fig. 3.1B). Strikingly, by day 7, 75% of DJ mice had survived, 
whereas all DR4tg mice succumbed to the SAg challenge (Fig. 3.1B).  
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Figure 3.1: Genetic or antibody-mediated depletion of iNKT cells reduces morbidity 
and mortality in SEB-injected DR4tg mice. 
(A) Splenic and non-parenchymal hepatic mononuclear cells from wild-type C57BL/6, 
J18-/-, DR4tg and DJ mice were stained with a FITC-conjugated anti-TCR mAb, a PE-
conjugated anti-HLA-DR mAb and/or allophycocyanin-conjugated, PBS-57-loaded 
CD1d tetramer. Dot plots representing samples from 3 mice per group are depicted. (B) 
C57BL/6 (n=6), J18-/- (n=6), DR4tg (n=8) and DJ (n=8) mice were injected with 100 μg 
SEB and monitored for weight loss and survival for up to 7 days. Error bars represent 
SEM, and * and *** denote p ≤ 0.05 and p ≤ 0.001, respectively, for statistical 
differences (two-way ANOVA; Tukey) between DR4tg and DJ mice at indicated time 
points. For survival analyses, mice were euthanized when they reached a weight loss of 
20% and the log-rank test was used for statistical comparisons. (C) DR4tg mice were 
treated with 200 μg of the iNKT cell-depleting mAb NKT14 (n=12) or an isotype control 
(n=15) 24 hours before they were injected with 100 μg SEB. Mice were monitored for up 
to 7 days and euthanized when moribund as above. The noted p value was calculated 
using the log-rank test. (D) At the end point, hepatic and splenic mononuclear cells were 
isolated and stained with PBS-57-loaded or empty (control) CD1d tetramers and a FITC-
conjugated anti-TCR mAb. Representative dot plots are illustrated (n=6/group). In 
addition, V14-J18 mRNA levels were quantified by qPCR. Gene expression fold-
changes relative to isotype control-treated mice (dotted line) are shown (n=6/group). * 
denotes a statistical difference with p ≤ 0.05 (Student’s t-test; two tailed) between ΔCT 
values of NKT14- and isotype control-treated DR4tg mice.   
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Figure 3.2: DJ mice lack iNKT cells but harbor other major immune cell subsets.  
Splenic cells from naïve C57BL/6, Jα18-/-, DR4tg, and DJ mice were stained with a panel 
of fluorochrome-conjugated mAbs (or CD1d tetramer) and immunophenotyped by flow 
cytometry. Mean values (± SEM) for 3 mice per group are shown. **** denotes p ≤ 
0.0001 (ANOVA). n.s. = not significant 
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Furthermore, 5 of the 6 surviving DJ mice had either returned to their initial weight or 
gained weight. SEB-exposed, wild-type C57BL/6 and Jα18-/- mice showed no signs of 
morbidity, as expected, due to their lack of humanized MHC II (Fig. 3.1B).  
The observed differences in morbidity and mortality between DR4tg and DJ mice 
strongly suggested that iNKT cells are pathogenic in SEB-induced illness. We are 
cognizant of the recent report that the cellular deficiency found in the original Jα18-/- 
mice, which we used to generate DJ mice, is not exclusive to iNKT cells (13). Therefore, 
to unequivocally address the role of iNKT cells in TSS, we took advantage of a mAb, 
clone NKT14, which has become available only recently and which depletes iNKT cells 
selectively (8). Pre-treatment of DR4tg mice with NKT14 before SEB injection 
effectively reduced TSS mortality in comparison with DR4tg mice receiving an isotype 
control reagent (Fig. 3.1C), thus recapitulating the DJ phenotype. On day 7 post-SEB 
insult, 3 out of 4 surviving NKT14-treated mice exhibited moderate weight loss, which 
was not the basis for their euthanization at the experimental endpoint. To verify iNKT 
cell depletion by NKT14, livers and spleens were harvested from NKT14-treated and 
control mice and examined for the absence or presence of iNKT cells. CD1d tetramer 
staining revealed a near complete absence of splenic and hepatic iNKT cell detection in 
NKT14-treated mice (Fig. 3.1D). To rule out the possibility that this was due to iNKT 
cell TCR internalization, as opposed to their depletion, we isolated splenic and hepatic 
mononuclear cell mRNA from NKT14-treated and control mice and assessed the 
expression levels of the Vα14-Jα18 TCR gene segment by qPCR. We found the mRNA 
level corresponding to the Vα14-Jα18 TCR chain to be dramatically diminished (by 
~90%) in the liver of NKT14-treated mice. Interestingly, the mRNA levels in the spleen  
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showed approximately 50% reduction (Fig. 3.1D), suggesting that the efficacy of iNKT 
cell depletion by NKT14 is tissue-specific. This may explain the observed difference in 
the survival patterns of DJ mice and NKT14-treated DR4tg mice although we find it 
reassuring that this difference was not statistically significant (Fig. 3.3). 
TSS is characterized by a rapid and overwhelming cytokine storm. As iNKT cells are 
directly activated by SEB (3) and since they can secrete inflammatory cytokines within 
hours of activation, we hypothesized that they should participate in the cytokine storm, 
especially in its early wave. Therefore, DR4tg and DJ mice were injected with SEB or 
with the prototypic iNKT cell superagonist αGC (positive control), and serum cytokine 
levels were measured 2, 12 and 24 hours later. Consistent with our hypothesis, the 
majority of cytokines and chemokines induced by SEB in DR4tg mice reached their peak 
at the earliest time point examined (i.e., at 2 hours) (Fig. 3.4A). In fact, several pro-
inflammatory cytokines including IL-1, IL-6, IL-17A and TNF were only present at 
the 2-hour time point (Fig. 3.4A and Fig. 3.5), suggesting that this early wave of 
cytokines may initiate or at least contribute to the TSS inflammatory cascade. 
Importantly, when compared to DR4tg mice, SEB-exposed DJ mice showed reduced 
levels of several cytokines known to play a direct role in TSS immunopathology, namely 
IL-1, IL-2, IL-6, and TNF (Fig. 3.4B). Multiple chemokines (CCL1, CCL4, CCL5, 
CXCL1 and CXCL10) and growth factors (G-CSF and GM-CSF) were also decreased in 
DJ mice (Fig. 3.4B). Together, these results implicate iNKT cells in production of 
inflammatory mediators early in the course of TSS and suggest that the observed 
reduction in morbidity and mortality of DJ mice may be owed to an attenuated cytokine 
storm.  
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Figure 3.3: TSS mortality is reduced in two separate models of iNKT cell deficiency.  
DJ mice (n=8), NKT14-treated DR4tg (n=12) and naïve or isotype control-treated DR4tg 
mice (n=23 combined) were injected with 100 μg SEB and monitored for 
mortality/survival. **, *** denote p ≤ 0.01 and p ≤ 0.001, respectively, by the log-rank 
test. n.s. = not significant 
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Figure 3.4: iNKT cells are required for rapid inflammatory mediator production 
during TSS and their TH2-polarization reduces TSS severity. 
(A and B) DR4tg and DJ mice were injected with 100 μg SEB or 4 μg GC (control), 
and bled 2, 12 and 24 hours later. Serum cytokine concentrations were quantified by 
bead-based multiplexing for DR4tg mice injected with SEB or GC (n=6 for each 
cohort) and for DJ mice injected with SEB (n=6) or GC (n=3). Mean values for each 
time point were used to generate a heat map (A). In addition, mean  SEM values 
(pg/mL) are depicted for the 2-hour time point with *, **, ***, **** denoting p ≤ 0.05, p 
≤ 0.01, p ≤ 0.001 and p ≤ 0.0001, respectively (Student’s t-test; two tailed) (B). (C) 
DR4tg mice (n=6 per group) were treated daily with OCH (4 g/dose) or vehicle 
beginning one day before SEB injection. The weight loss percentage (± SEM) is shown 
for up to 132 hours, after which time high mortality was observed in the vehicle-treated 
group. * denotes p ≤ 0.05 at indicated individual time points (Student’s t-test; two-tailed). 
For survival analysis, mice were sacrificed when moribund (20% weight loss) and the p 
value was calculated by the log-rank test. 
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Figure 3.5: SEB-injected DJ mice exhibit a mild cytokine storm. 
DR4tg and DJ mice were injected with 100 μg SEB or 4 μg GC, and serum cytokines 
levels at 2, 12 and 24 hours were quantified. Mean values (pg/mL) ± SEM are shown. 
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Since the role of iNKT cells in TSS was generally pro-inflammatory, we attempted to 
skew their responses towards an anti-inflammatory phenotype using a TH2-polarizing 
GC analog called OCH (14). DR4tg mice were administered OCH or vehicle daily 
before and after receiving SEB. OCH pre-treatment markedly reduced weight loss and 
rescued ~85% of the animals (Fig. 3.4C). Mechanistically, this finding indicates that it is 
indeed the pro-inflammatory capacity of iNKT cells that promotes TSS pathogenesis. To 
simulate clinical scenarios in which treatments are given after the TSS onset, we started 
OCH treatment in a separate cohort of DR4tg mice 2 hours after the SEB insult, which 
coincides with the peak of several inflammatory cytokines (Fig. 3.4A). Therapeutic 
administration of OCH inhibited SEB-induced weight loss and mortality (Fig. 3.6). 
Our findings are likely translatable to clinical settings because: i) iNKT cells’ mode of 
glycolipid antigen surveillance is evolutionarily conserved (15); ii) glycolipid agonists of 
iNKT cells have shown promise in clinical trials for conditions other than TSS (5). 
Unlike conventional T cells that are restricted by highly polymorphic MHC molecules, 
iNKT cells respond to glycolipid antigens presented by the monomorphic CD1d. 
Therefore, CD1d-restricted glycolipids can be used in diverse human populations. iNKT 
cells likely represent only one of several early mediators of TSS. Nevertheless, tangible 
clinical benefits may arise from iNKT cell-based therapies, alone or in combination with 
other modalities, for TSS. 
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Figure 3.6: Therapeutic administration of OCH ameliorates SEB-inflicted 
morbidity and mortality in DR4tg mice.  
Male DR4tg mice (n=9 per group) were treated daily with OCH (4 mg/dose) or vehicle 
beginning at 2 hours post-SEB injection. The weight loss percentage (± SEM) is shown 
for up to 84 hours, after which time high mortality was observed in vehicle-treated mice 
and to a lesser degree in OCH-treated animals. * denotes p ≤ 0.05 at indicated time points 
(Student’s t-test; two-tailed). For survival analysis, mice were euthanized when they lost 
20% of their initial weight and the log-rank test was used to calculate the indicated p 
value. 
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4.1 Introduction 
Superantigens (SAgs) are exotoxins secreted by select bacterial pathogens including 
Staphylococcus aureus and Streptococcus pyogenes. SAgs cause various illnesses ranging 
from typically self-limiting food poisoning to potentially life-threatening TSS (1). 
Moreover, if fallen into the wrong hands, SAgs can be weaponized and used against 
human populations. In fact, staphylococcal enterotoxin B (SEB), a prototype bacterial 
SAg and a cause of non-menstrual TSS, is considered a “category B priority” 
bioterrorism agent (2). 
SAgs activate a sizeable fraction of the T cell repertoire, up to 50% of exposed T cells, 
irrespective of their T cell receptor (TCR) specificity for cognate peptide:MHC 
complexes. This occurs through unconventional contacts SAgs establish, in unprocessed 
form, with lateral surfaces of MHC class II molecules on antigen-presenting cells and 
select TCR -chain variable (V) domains expressed by many T cells (3, 4). The 
consequent polyclonal T cell activation can lead to a ‘cytokine storm’, systemic toxicity 
and hyperinflammation, which is often accompanied or followed by a state of profound 
immunosuppression. T cells targeted by SAgs in mouse models undergo activation-
induced death or become anergic (4, 5). This generates physical or functional ‘holes’ in 
the T cell repertoire, thus potentially compromising the host’s ability to combat the very 
bacteria that produce SAgs as well as concomitant or secondary infections. 
Regulatory/suppressor cells have also been implicated in SAg-mediated 
immunosuppression. For instance, in vitro exposure to SAgs reportedly converts 
conventional CD25- T cells to IL-10-producing CD25+FoxP3+ regulatory T (Treg) cells 
(6). However, the in vivo significance of SAg-induced Treg cells is unclear. The potential 
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contribution of other suppressor cell types including myeloid-derived suppressor cells 
(MDSCs) to TSS-associated immunosuppression is ill-defined. Equally important, 
whether suppressor cell functions may benefit the host by mitigating tissue damage 
inflicted by unleashed, massive T cell responses remains a matter of debate. We have 
serendipitously discovered a dramatic, early-onset and tissue-selective influx of MDSCs 
into the liver of HLA-DR4 transgenic (DR4tg) mice shortly after systemic exposure to 
SEB. Here, we describe phenotypic and immunosuppressive characteristics of liver-
infiltrating MDSCs in a humanized mouse model of TSS. We also extend our findings to 
an in vitro culture system in which human MDSCs modulate the T cell response to SEB. 
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4.2 Materials and Methods 
4.2.1 Ethics 
Peripheral blood was drawn from consenting healthy volunteers following a protocol 
approved by the Western University Research Ethics Board for Health Sciences Research 
Involving Human Subjects. Animal experiments were conducted in accordance with 
Canadian Council on Animal Care guidelines.  
4.2.2 Animals 
DR4tg mice on a B6 background were bred in our barrier facility. These mice lack 
endogenous MHC class II molecules but express a chimeric HLA encoded by HLA-
DRA-IE and HLA-DRB1*0401-IE transgenes (7). Adult wild-type (WT) B6 mice 
were purchased from Charles River, housed and cared for in the same facility.  
4.2.3 Mouse model of TSS 
Using an approved biosafety protocol and following the Public Health Agency of Canada 
regulations, recombinant SEB was cloned from Staphylococcus aureus COL, expressed 
in Escherichia coli BL21 (DE3) and purified by nickel column chromatography (8). As a 
negative control, we generated and used an inactive form of SEB that carries an NA 
point mutation at position 23 (9). This mutant, hereafter referred to as SEBN23A, is 
impaired in binding to mouse TCR V8.2, which is a known target of intact SEB. 
Mouse MHC II molecules exhibit poor affinity for SEB (10). Therefore, to simulate 
staphylococcal TSS, we injected DR4tg mice intraperitoneally (i.p.) with 50 g SEB (8, 
9). This model may not mimic all clinical features of TSS (e.g., capillary leakage due to 
SAgs’ toxicity for human endothelial cells), but provides a powerful system in which to 
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study many inflammatory and immunological aspects of TSS. Control DR4tg animals 
received PBS or 50 g SEBN23A. As an additional control, SEB was administered i.p. to 
WT B6 mice. 
4.2.3 Cytofluorimetric analyses  
Mice were sacrificed by cervical dislocation. Splenic, lymph node and thymic single-cell 
suspensions were prepared in cold, sterile PBS. Bone marrow cells were flushed, under 
aseptic conditions, out of femurs and tibias. To obtain non-parenchymal hepatic 
mononuclear cells, livers were perfused through the central or portal vein with PBS. The 
tissue was then pressed through a wire mesh, and the resultant homogenate was 
resuspended in 33.75% Percoll PLUS (GE Healthcare) and spun at room temperature. 
Erythrocytes among pelleted cells were lysed, and a nylon mesh strainer was used to 
remove clumps and debris. Cells were incubated on ice with 5 µg/mL anti-mouse 
CD16/CD32 monoclonal antibody (mAb) (clone 2.4G2) to prevent Fc receptor-mediated 
false positive staining with fluorochrome-labeled mAbs that were subsequently added. 
These included mAbs to cell surface CD11b, CD11c, CD31, CD244, CCR2, CCR5, Gr-1, 
Ly-6C, Ly-6G, F4/80 and c-kit. mAbs used in this study are listed in Table 4.1. For 
detection of intracellular Ki-67 after surface staining for indicated markers, cells were 
fixed and permeabilized using a BD Cytofix/CytopermTM kit followed by incubation with 
an anti-Ki-67 mAb. The ‘Fluorescence Minus One’ (FMO) control was used to precisely 
set the gate for Ki-67+ events. A FACSCanto II cytometer and FlowJo software were 
employed for data collection and analysis, respectively.  
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Marker Species 
Reactivity 
Clone Isotype Source 
CD11b Mouse M1/70 Rat IgG2b, κ eBioscience 
CD11c Mouse N418 Armenian Hamster 
IgG 
eBioscience 
CD31 Mouse 390 Rat IgG2a, κ eBioscience 
CD244 Mouse 244F4 Rat IgG2a eBioscience 
CCR2 Mouse 475301 Rat IgG2b R&D Systems 
CCR5 Mouse HM-CCR5 
(7A4) 
Armenian Hamster 
IgG 
eBioscience 
Ly6G (Gr-1) Mouse RB6-8C5 Rat IgG2b, κ eBioscience 
Ly6G Mouse 1A8 Rat IgG2a, κ BD Pharmingen 
Ly6C Mouse HK1.4 Rat IgG2c, κ BioLegend 
F4/80 Mouse BM8 Rat IgG2a, κ eBioscience 
c-Kit Mouse 2B8 Rat IgG2b, κ eBioscience 
Ki-67 Mouse SolA15 Rat IgG2a, κ eBioscience 
CD3ε Mouse 145-2C11 Armenian Hamster 
IgG 
eBioscience 
CD33 Human WM-53 Mouse IgG1, κ eBioscience 
Table 4.1: Fluorochrome-conjugated antibodies used for MDSC studies 
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4.2.4 In vitro generation of mouse BMDCs  
Bone marrow cells were obtained from femurs and tibias of DR4tg mice, depleted of 
erythrocytes, filtered and seeded at a density of 1×106 cells/mL in RPMI 1640 medium 
containing 10% heat-inactivated fetal bovine serum, GlutaMAXTM, nonessential amino 
acids, sodium pyruvate, penicillin and streptomycin, which is referred to as complete 
medium in this report. Cells were cultured for 6 days in complete medium containing 10 
ng/mL recombinant mouse GM-CSF and IL-4 (PeproTech). Every other day, non-
adherent cells were discarded and cultures were replenished with fresh medium and 
cytokines. On day 6, CD11c+ cells were magnetically purified using an EasySepTM 
Mouse CD11c Positive Selection Kit (STEMCELL Technologies).        
4.2.5 In vitro generation of human MDSCs 
We used the method of Lechner et al. (11). Briefly, peripheral blood mononuclear cells 
(PBMCs) were isolated from heparinized whole blood by density gradient centrifugation 
in Ficoll-Paque PLUS medium (GE Healthcare) and cultured for 7 days at 5×105 cells/mL 
complete medium supplemented with 10 ng/mL recombinant human IL-6 and GM-CSF 
(PeproTech). Adherent cells were then gently harvested using DetachinTM (Genlantis) and 
stained with an anti-human CD33 mAb before a FACSAria III cytometer was used to sort 
CD33+ cells.   
4.2.6 T cell suppression assays 
Hepatic CD11b+Gr-1high cells from SEB-treated DR4tg mice were sorted. A small aliquot 
was stained with Wright-Giemsa for morphological assessments. Splenic T cells from 
WT B6 mice were passed through nylon wool and magnetically purified using CD90.2 
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MicroBeads (Miltenyi Biotec). T cells were co-incubated with -irradiated BMDCs at a 
4:1 (T cell:DC) ratio and stimulated with 100 ng/mL SEB in complete medium for 3 
days. CD11b+Gr-1high cells were absent or present at indicated ratios. Cells were pulsed 
with tritiated thymidine ([3H]TdR) during the final 18 hours, and [3H]TdR uptake was 
determined by liquid scintillation counting. T cell proliferation was also judged by 
carboxyfluorescein succinimidyl ester (CFSE) dye dilution within the CD3ε+ population. 
In several experiments, NG-monomethy-L-arginine (L-NMMA, Calbiochem), N-
hydoxy-nor-arginine (nor-NOHA, Calbiochem) or catalase (Sigma-Aldrich) were added 
to the cultures to inhibit nitric oxide synthase (NOS), arginase or reactive oxygen species 
(ROS), respectively (12).     
For human T cell suppression assays, PBMCs were subjected to two successive rounds of 
purification using nylon wool columns (Polysciences).  T cells were seeded at 8×104 
cells/well in a 96-well plate along with 2×104 -irradiated, nylon wool-adherent accessory 
cells, which consist mainly of B cells and monocytes. Autologous CD33+ MDSCs were 
added to the cultures before SEB treatment, and [3H]TdR uptake was quantified.         
4.2.7 Statistical analysis 
Statistical comparisons were performed using Student’s t-test, and differences with 
p0.05 were deemed significant.    
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4.3 Results and Discussion 
While investigating TSS in the DR4tg mouse model (8, 9), we found a rapid and sizable 
rise in a high forward- and side-scatter population among non-parenchymal hepatic 
mononuclear cells (Fig. 4.1A), but not within the spleen, thymus or lymph nodes (Fig. 
4.2). Two hours after SEB injection, there was more than a three-fold increase in this 
population compared with untreated or PBS-treated DR4tg mice (Fig. 4.1A). This 
phenotype was much less pronounced in SEB-injected WT mice, indicating a 
requirement for higher-affinity human MHC interactions with SEB, which is in 
agreement with our previous reports (8, 9, 13).  
To definitively demonstrate that T cell activation by SEB is a prerequisite for this 
phenotype, we used SEBN23A, a mutated version of SEB with a partially defective TCR 
binding capacity (9). As anticipated, injection of DR4tg mice with SEBN23A failed to 
induce a robust enlargement in the high forward- and side-scatter population within the 
liver (Fig. 4.1A). SEBN23A retains the ability to bind to DR4, and the modest response it 
elicits is likely contributed by TCR Vs other than V8.2.   
Next, we used a wide panel of mAbs specific for various surface markers, including but 
not limited to those listed in Fig. 4.1B, to characterize the population under our scrutiny. 
This revealed a CD11b+Gr-1highLy-6C+ phenotype for the vast majority of the cells, 
which fits the granulocytic MDSC (G-MDSC) definition (14). The anti-Gr-1 mAb we 
used (clone RB6-8C5) may bind to both Ly-6G and Ly-6C. Therefore, in separate 
experiments, we employed a different mAb (clone 1A8) and confirmed that CD11b+Gr-
1high cells were indeed Ly-6G+ and Ly-6C+ (Fig. 4.3). Furthermore, sorted cells stained 
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Figure 4.1: CD11b+Gr-1highLy-6C+ cells amass in the liver of DR4tg mice shortly 
after SEB injection.  
WT or DR4tg mice were injected with SEB, SEBN23A or PBS, and the frequencies of high 
forward- and side-scatter cells among non-parenchymal hepatic mononuclear cells was 
determined 2 hours post-SEB exposure. Representative dot plots are illustrated and mean 
± SEM values for indicated number of mice per group are shown (A). The gated 
population from SEB-injected DR4tg mice was characterized cytofluorimetrically using 
mAbs specific for indicated markers (open histograms) and isotype controls (filled 
histograms) (B). The frequencies of CD11b+Gr-1highLy-6C+ and CD11b+Gr-1low/negLy-
6C+ cells among hepatic mononuclear cells of PBS- and SEB-injected DR4tg mice were 
determined (C). * and *** denote p˂0.05 and p˂0.001, respectively.   
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Figure 4.2: G-MDSCs accumulate selectively in the liver following systemic exposure to 
SEB.  
Indicated numbers of DR4tg mice were injected with SEB. Two hours later, non-
parenchymal hepatic mononuclear cells as well as splenic, thymic and pooled lymph 
node cells were isolated and analyzed by a flow cytometer. Representative forward- and 
side-scatter dot plots are shown, and the mean frequency [± standard error of the means 
(SEM)] of the gated population is stated for each group (A). The percentages of 
CD11b+Gr-1high cells were determined in the same cohorts and compared with values 
corresponding to PBS-injected DR4tg mice (B). Error bars represent SEM, and * denotes 
p<0.05. 
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Figure 4.3: Systemic exposure to SEB results in intrahepatic accumulation of CD11b+ 
cells that concomitantly express Gr-1, Ly-6G and Ly-6C.  
A DR4tg mouse was injected i.p. with SEB. Two hours later, non-parenchymal hepatic 
mononuclear cells were isolated and co-stained with fluorochrome-labeled mAbs to 
CD11b (clone M1/70), Gr-1 (clone RB6-8C5), Ly-6G (clone 1A8) and Ly-6C (clone 
HK1.4) before they were analyzed by a flow cytometer. 
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with Wright-Giemsa mostly exhibited a ring-shaped nucleus (Fig. 4.4), which is again 
consistent with the G-MDSC morphology in mice (14). It is noteworthy that a minority 
fraction of the high forward- and side- scatter cells were CD11b+Gr-1low/negLy-6C+, 
stained positive for F4/80, and had a monocytic morphology. However, their frequencies 
in SEB- and PBS-treated DR4tg mice were similar (Fig. 4.1C). 
Some of the markers expressed by MDSCs can be found on other cell types (e.g., 
neutrophils). It was therefore crucial to verify the immunosuppressive nature of 
CD11b+Gr-1high cells before we could define them as MDSCs. To this end, we 
demonstrated that CD11b+Gr-1high cells sorted from the livers of SEB-treated DR4tg mice 
significantly attenuated ex vivo T cell proliferation in response to SEB (Fig. 4.5A) or 
anti-CD3ε mAb (data not shown). We next investigated the mechanism by which MDSCs 
suppressed T cell proliferation using the pharmacological inhibitors L-NMMA, nor-
NOHA or catalase, which inhibit NOS, arginase and ROS, respectively. MDSC-mediated 
suppression was abrogated in the presence of catalase, but not L-NMMA or nor-NOH, 
indicating that the suppressive effect of MDSCs was mediated by ROS (Fig. 4.5B).  
MDSCs are known to amass in certain inflamed or tumor-bearing tissues, albeit at much 
later time points. The rapidity with which G-MDSCs accumulate in the liver of TSS-
afflicted mice suggests their recruitment to the liver as opposed to their in situ 
proliferation. This notion is supported by two lines of evidence. First, the expression of 
the proliferation marker Ki-67 by CD11b+Gr-1high cells was lower in SEB-treated mice in 
comparison with controls (Fig. 4.6A). Second, CD11b+Gr-1high cell accumulation in the 
liver was accompanied by a simultaneous decrease in the bone marrow (Fig. 4.6B), 
suggesting a bone marrow-to-liver trafficking route. The exact cellular and/or soluble  
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Figure 4.4: Hepatic CD11b+Gr-1high cells from SEB-treated DR4tg mice exhibit a ring-
shaped nucleus.  
DR4tg mice were injected i.p. with SEB. Two hours later, non-parenchymal hepatic 
mononuclear cells were isolated and stained for CD11b and Gr-1. CD11b+Gr-1high cells 
were sorted cytofluorimetrically, stained with Wright-Giemsa, and evaluated 
morphologically under a light microscope. 
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Figure 4.5: Mouse and human MDSCs suppress SEB-induced T cell proliferation. 
CD11b+Gr-1high cells were sorted from the livers of DR4tg mice 2 hours after injection 
with SEB. They were then co-cultured with naïve mouse T cells and in vitro-generated 
DR4tg BMDCs in the presence or absence of SEB for 3 days. T cell proliferation was 
assayed by [3H] TdR incorporation or by CFSE dye dilution. Representative data from 
two independent experiments are illustrated. Error bars correspond to standard deviation 
(SD), and ** denotes p˂0.01 (A). In separate experiments, L-NMMA (0.5 mM), nor-
NOHA (0.5 mM) or catalase (1000 U/mL) were added to the cultures and T cell 
proliferation was measured by [3H] TdR incorporation. Three independent experiments 
yielded similar results, which were pooled. Error bars represent SEM, and * denotes 
p˂0.05 (B). Human MDSCs were generated in a 7-day culture system in the presence of 
recombinant human GM-CSF and IL-6 (10 ng/mL each). This method led to a dramatic 
expansion of CD33+ cells among PBMCS isolated from all the 3 donors recruited to this 
study (C). Sorted CD33+ cells were co-incubated for 3 days with autologous T cells and 
accessory cells and tested for their ability to suppress SEB-triggered T cell proliferation 
as described in Methods. Similar results were obtained in 3 independent experiments, 
each of which utilized PBMCs from one of the 3 donors recruited to this study (D). Error 
bars represent SD, and ** and *** denote p˂0.01, p˂ 0.001, respectively. 
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Figure 4.6: SEB administration does not elevate Ki-67 expression by CD11b+Gr-1high 
cells in the liver but lowers their frequency in the bone marrow. 
DR4tg mice (n=3/group) were given SEB or PBS i.p. Two hours later, the mean 
fluorescence intensity (MFI) of Ki-67 on hepatic CD11b+Gr-1high cells was determined 
and normalized to PBS controls (A). The frequencies of CD11b+Gr-1high cells were 
determined by flow cytometry in the bone marrow of indicated numbers of DR4tg mice 2 
hours after they were injected with SEB, SEBN23A or PBS (B). Representative dot plots 
and mean ± SEM values are demonstrated. *** denotes p<0.001. 
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factors that mediate CD11b+Gr-1high cells’ recruitment to the liver during TSS remain 
unknown. Invariant natural killer T (iNKT) cells, which we demonstrated are directly 
responsive to SEB (9), comprise up to 40% of lymphocytes in the mouse liver. However, 
genetic deficiency or Ab-mediated depletion of iNKT cells did not affect the G-MDSC 
buildup in the liver nor did systemic depletion of CD4+ or CD8+ cells (unpublished data). 
Regardless, once present in the liver, G-MDSCs appear to be retained in this organ as 
evidenced by their elevated frequencies even at 24 hours post-SEB exposure (data not 
shown).  
The liver is uniquely tolerogenic among immunological sites. This is dictated in part by 
anti-inflammatory properties of liver-resident cells and by expression of co-inhibitory 
receptors that dampen T cell responses to self and foreign antigens (15). We have now 
defined a novel mode of immunosuppression during TSS, which may benefit the host by 
diminishing hepatic tissue damage. A substantial proportion of SAg-mediated illnesses 
are non-menstrual. Staphylococcal enterotoxins released in the gastrointestinal tract, due 
for instance to food poisoning, may cross the perturbed epithelium and access the liver 
through the portal vein. Therefore, it is fitting that MDSCs can swiftly and selectively 
home to the liver (Fig. 4.2A-B) to help protect this vital organ from SAgs’ deleterious 
effects with inflammatory and metabolic repercussions. 
Finally, ex vivo-generated human MDSCs were able to inhibit autologous T cell 
responses to SEB (Fig. 4.5C-D), which recapitulates our findings on immunosuppressive 
function of sorted mouse MDSCs. Whether human liver attracts MDSCs in the early 
phase of TSS and/or other SAg-mediated illnesses warrants further investigation.      
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5.1 Introduction 
Toxic shock syndrome (TSS) is a life-threatening illness characterized by high-grade 
fever, diffuse erythematous rash formation, desquamation, severe hypotension and multi-
organ dysfunction (1). It is caused by systemic exposure to bacterial toxins known as 
superantigens (SAgs), which are secreted by Staphylococcus aureus and Streptococcus 
pyogenes. TSS can be of menstrual (2) or non-menstrual (3) origin. The vast majority of 
menstrual TSS cases, which are linked to high-absorbency tampon usage (4), are caused 
by S. aureus strains expressing the powerful SAg toxic shock syndrome toxin-1 (TSST-1) 
(5). In contrast, non-menstrual TSS can occur with virtually any S. aureus infection and 
is primarily associated with TSST-1 and staphylococcal enterotoxin B (SEB) (6). The 
expression of streptococcal pyrogenic exotoxin A (SpeA) is also strongly correlated with 
streptococcal TSS (7).  
SAgs are a unique family of exotoxins that activate a large proportion of T cells 
irrespective of their TCR specificity. Cognate peptide antigens presented in the context of 
self MHC by APCs typically activate 1 in every 10,000 T cells. In contrast, SAgs 
simultaneously bind MHC class II molecules on APCs outside their antigen-binding 
groove (8) and select TCR Vβ domains on T cells (9). By doing so, SAgs circumvent 
conventional modes of antigen processing and presentation to induce the activation and 
proliferation of up to 50% of all exposed T cells (10). The overwhelming activation of T 
cells by SAgs results in excessive production of inflammatory mediators, which is 
commonly referred to as ‘cytokine storm’. SAgs directly stimulate the secretion of IL-2, 
IFNγ and lymphotoxin-α from T cells, as well as TNFα, IL-1β and IL-6 from APCs (10, 
11). Additionally, SAgs initiate secondary inflammatory cytokine and chemokine 
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responses from various non-hematopoietic cell types such as epithelial cells, endothelial 
cells and fibroblasts (12). The massive and uncontrolled release of these inflammatory 
mediators has drastic tissue damaging effects through the activation of the coagulatory 
cascade, vasodilation, edema, and vascular leakage (13-16). SAgs also promote the 
production of chemokines CXCL8, CCL2, CCL3, and CCL4 (17, 18), resulting in further 
recruitment of leukocytes to areas of tissue injury. The net effect of the cytokine storm is 
a systemic inflammatory response syndrome that may culminate in fatal multi-organ 
failure.  
IL-17A is a potent inducer of systemic inflammation, potentiating the production or 
activation of inflammatory cytokines (e.g., TNFα, IL-1β, IL-6), chemokines, matrix 
metalloproteases and transcription factors in both hematopoietic and non-hematopoietic 
cell types (19). IL-17A also acts synergistically with other inflammatory cytokines, 
including TNFα, IL-1β and IFNγ, to stabilize mRNA transcripts or activate promoter 
regions of other inflammatory mediators (20). Although IL-17A is the archetypal 
cytokine of the CD4+ Th17 cell lineage (19), it can also be quickly produced by innate-
like T lymphocytes such as γδ T cells, invariant natural killer T (iNKT) cells and mucosa-
associated invariant T (MAIT) cells (21, 22). IL-17A is often associated with early and 
protective host responses to bacteria, and little is known about its pathogenic potentials 
during infection. For example, whether exposure to SAgs elicits an early IL-17A 
response that may contribute to the cytokine storm is essentially unexplored.  
Identification of early inflammatory mediators of the cytokine storm and their cellular 
sources is of utmost importance due to the rapidity with which TSS may progress to life-
threatening disease. The clinical status of a SAg-exposed individual can deteriorate to 
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multi-organ failure as early as 8-12 hours after the onset of the symptoms (23), and 
estimates of TSS mortality range from 4% to 22% (24-26). Also alarmingly, there are 
currently no available therapeutics to attenuate the cytokine storm, which drives the 
immunopathology of TSS. Therefore, understanding the critical components of this 
process may hold the key to designing effective therapies that reduce TSS-associated 
morbidity and mortality.  
In this investigation, using humanized mice and human PBMCs, we found and 
characterized a vigorous IL-17A response that was detectable within the first few hours 
of SAg exposure. The kinetics of this response initially suggested the involvement of 
innate-like T cells (21), which we we were able to rule out. Instead, we identified effector 
memory T (TEM) cells as the major source of mouse and human IL-17A, which were 
surprisingly unable to co-produce IFN. IL-17A receptor blockade diminished the 
expression of several pro-inflammatory mediators by SAg-stimulated human PBMCs and 
also prevented the secondary upregulation of the transcription factor C/EBP delta 
(CEBPD) in human dermal fibroblasts. These findings suggested a pathogenic role for 
IL-17A in TSS, which we confirmed using a humanized mouse model of the syndrome. 
Therefore, this work defines a previously unrecognized mechanism of TSS 
immunopathology that is dependent upon rapid IL-17A production by a distinct 
subpopulation of TEM cells.  
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5.2 Materials and Methods 
5.2.1 Mice 
Adult 6-to-12-week-old mice closely matched for age and sex were used in all 
experiments. Wild-type C57BL/6 mice were purchased from Charles River Canada Inc. 
(St. Constant, Quebec). IL-17A-GFP mice that express enhanced GFP as a marker of IL-
17A expression were obtained from The Jackson Laboratory (Bar Harbor, Maine) and 
bred in a barrier facility at Western University. HLA-DR4tg (DR4tg) mice, which are 
devoid of endogenous MHC class II and instead express HLA-DRA-IEα and HLA-
DRB1*0401-IEβ on a C57BL/6 background (27), were bred in the same facility. 
To develop a SAg-sensitive IL-17A reporter mouse strain, DR4tg and IL-17A-GFP mice 
were crossed. The resultant “D17 mice” were bred to homozygosity and confirmed to 
express HLA-DR transgenes and the IL-17A-GFP reporter construct but not IAβ. In brief, 
genomic DNA was extracted from mouse ear clips using Hot Sodium Hydroxide and Tris 
(HotSHOT). PCR-amplified products were generated using Platinum Taq DNA 
polymerase (Thermo Fisher Scientific, Ottawa, Ontario) and primer sets that are listed in 
Table 5.1. Agarose gel electrophoresis was performed to visualize PCR products.  
Wild-type C57BL/6, IL-17A-GFP, DR4tg and D17 mice were cared for in the same 
facility. All animal experiments were conducted in accordance with an approved 
institutional animal use protocol (AUP# 2010-241) and in compliance with the Canadian 
Council on Animal Care (CCAC) guidelines. 
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Target (reference if applicable) Species Sequence (5’-3’) or Accession #  Source 
HLA-DRA-IEα Forward (27) Human GGGAAGCAGGGGGACTATGAC Sigma-Aldrich 
HLA-DRA-IEα Reverse (27) Human TTAGGGCAATGACTTCGTAGG Sigma-Aldrich 
HLA-DRB1*0401-IEβ Forward (27) Human TGAAAGCGGTGCGTGCTGTTTAA Sigma-Aldrich 
HLA-DRB1*0401-IEβ Reverse (27) Human CACCCGCTCCGTCCCGTTGAA Sigma-Aldrich 
HLA-DR Transgene Insertion Site Forward* Mouse CCATGGACAAGGCAGGGACAAA Sigma-Aldrich 
HLA-DR Transgene Insertion Site Reverse* Mouse CCGTGACCAAAATGCACATTGAA Sigma-Aldrich 
IL-17A-GFP Common Forward (Jackson Primer #15240) Mouse AAGCTGGACCACCACATGA Sigma-Aldrich 
IL-17A-GFP Wildtype Reverse (Jackson Primer #15241) Mouse TGAATCCACATTCCTTGCTG Sigma-Aldrich 
IL-17A-GFP Mutant Reverse (Jackson Primer #11188) Mouse GACATTCAACAGACCTTGCATTC Sigma-Aldrich 
IAβ-neor Forward Mouse GGGAGGAGTACGTGCGCTACGACAG Sigma-Aldrich 
IAβ-neor Reverse Mouse GAGAACCTGCGTGCAATCCATCTTG Sigma-Aldrich 
IAβ Forward Mouse GGCATTTCGTGTACCAGTTCATGG Sigma-Aldrich 
IAβ Reverse Mouse GTCTCCGGCCCCTCGTAGTTGTGT Sigma-Aldrich 
CCL11 Human Hs00237013_m1 Thermo Fisher 
CCL2 Human Hs00234140_m1 Thermo Fisher 
CCL20 Human Hs00355476_m1 Thermo Fisher 
CCL5 Human Hs00982282_m1 Thermo Fisher 
CCL7 Human Hs00171147_m1 Thermo Fisher 
CEBPB Human Hs00270923_s1 Thermo Fisher 
CEBPD Human Hs00270931_s1 Thermo Fisher 
CSF2 Human Hs00929873_m1 Thermo Fisher 
CSF3 Human Hs00738432_g1 Thermo Fisher 
CXCL1 Human Hs00605382_gH Thermo Fisher 
CXCL10 Human Hs01124252_g1 Thermo Fisher 
CXCL11 Human Hs04187682_g1 Thermo Fisher 
CXCL12 Human Hs03676656_mH Thermo Fisher 
CXCL2 Human Hs00601975_m1 Thermo Fisher 
CXCL5 Human Hs01099660_g1 Thermo Fisher 
CXCL6 Human Hs00605742_g1 Thermo Fisher 
CXCL9 Human Hs00171065_m1 Thermo Fisher 
GATA3 Human Hs00231122_m1 Thermo Fisher 
IFNG Human Hs00989291_m1 Thermo Fisher 
IL10 Human Hs00961622_m1 Thermo Fisher 
IL12A Human Hs01073447_m1 Thermo Fisher 
IL12B Human Hs01011518_m1 Thermo Fisher 
IL13 Human Hs00174379_m1 Thermo Fisher 
IL17A Human Hs00174383_m1 Thermo Fisher 
IL17F Human Hs00369400_m1 Thermo Fisher 
IL18 Human Hs01038788_m1 Thermo Fisher 
IL19 Human Hs00604657_m1 Thermo Fisher 
IL1B Human Hs00174097_m1 Thermo Fisher 
IL2 Human Hs00174114_m1 Thermo Fisher 
IL22 Human Hs01574154_m1 Thermo Fisher 
IL23A Human Hs00900828_g1 Thermo Fisher 
IL4 Human Hs00174122_m1 Thermo Fisher 
IL6 Human Hs00985639_m1 Thermo Fisher 
IL8 Human Hs00174103_m1 Thermo Fisher 
LTA Human Hs04188773_g1 Thermo Fisher 
MYD88 Human Hs01573837_g1 Thermo Fisher 
NFKB1 Human Hs00765730_m1 Thermo Fisher 
NFKBIZ Human Hs00230071_m1 Thermo Fisher 
NOS2 Human Hs01075529_m1 Thermo Fisher 
PTGS2 Human Hs00153133_m1 Thermo Fisher 
RORC Human Hs01076112_m1 Thermo Fisher 
RPL13A Human Hs04194366_g1 Thermo Fisher 
TBP Human Hs00427620_m1 Thermo Fisher 
TBX21 Human Hs00203436_m1 Thermo Fisher 
TGFB1 Human Hs00998133_m1 Thermo Fisher 
TNFA Human Hs01113624_g1 Thermo Fisher 
ZBTB16 Human Hs00957433_m1 Thermo Fisher 
Table 5.1: PCR primers/probes used in IL-17A studies. *Primer was designed to span 
the insertion site of the HLA-DR4 transgenes in the mouse genome, thus enabling 
discrimination between homozygous and heterozygous transgenic mice. 
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5.2.2 Generation of bone marrow chimeras  
To obtain donor cells, IL-17A-GFP mice were euthanized by cervical dislocation, and 
bone marrow was flushed out of femurs and tibias with ice-cold PBS. Erythrocytes were 
lysed by addition of ACK lysis buffer for 2 minutes, and resulting cells were filtered 
through a 70-μm nylon mesh strainer. Twenty million donor cells were injected i.v. into 
recipient DR4tg mice, which were lethally irradiated at 900 cGy using a 137Cs γ-irradiator 
before adoptive transfer. Recipient mice were maintained on drinking water 
supplemented with 2 mg/mL neomycin sulfate (Teknova Inc., Hollister, California) for 2 
weeks after irradiation to prevent infection. 
5.2.3 Bacterial toxins 
Recombinant staphylococcal and streptococcal SAgs were generated using an approved 
institutional biosafety protocol that follows established Public Health Agency of Canada 
regulations as described previously (28). Briefly, SAgs were expressed in BL21 (DE3) E. 
coli and purified by nickel column chromatography. As an additional control, an 
attenuated mutant of SEB that is impaired in binding to mouse TCR Vβ8.2 (29) was 
generated by site-directed mutagenesis (30). The mutant SEB carries an NA point 
mutation at position 23 and is referred to as SEBN23A. LPS was purchased from Sigma-
Aldrich (Oakville, Ontario).  
5.2.4 TSS mouse model and in vivo IL-17A neutralization 
Animals were injected i.p. with indicated amounts of SEB or the equivalent volume of 
PBS as a control. They were bled via the saphenous vein, and serum samples were 
obtained following centrifugation of blood at 17,000  g for 40 minutes and analyzed for 
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their cytokine content using ELISA kits from eBioscience (San Diego, California). For in 
vivo IL-17A neutralization, DR4tg mice were treated with 200-μg i.p. doses of an anti-IL-
17A mAb (clone 17F3, BioXCell, West Lebanon, New Hampshire) or a mouse IgG1 
isotype control (clone MOPC-21) 3 hours before and 1 hour after they were injected with 
100 μg of SEB. Mice were monitored every 3 hours for the initial 12 hours and every 8 
hours thereafter for up to 7 days. Weight loss was assessed at indicated time points, and 
mice were sacrificed when 20% weight loss was reached following institutional protocols 
and CCAC guidelines. For histological analyses, mice were sacrificed at 48 hours post-
SEB stimulation. Liver and small intestine were extracted, fixed in 10% neutral-buffered 
formalin, embedded in paraffin, sectioned and stained with H&E. Sections were scored 
by a board-certified veterinary pathologist who was blinded to the experimental 
conditions.  
5.2.5 Human PBMC isolation and stimulation with SAgs 
Peripheral blood was collected in heparinized vacutainers from healthy volunteers after 
their written consent was secured and following a protocol approved by the Western 
University Research Ethics Board for Health Sciences Research Involving Human 
Subjects (HSREB #5545). PBMCs were isolated by density centrifugation using 50-mL 
SepMate tubes from Stemcell Technologies Inc. (Vancouver, British Columbia) and low-
endotoxin (<0.12 EU/mL) Ficoll-Paque Plus (GE Healthcare Life Sciences) according to 
manufacturer’s instructions. PBMCs were suspended in RPMI 1640 medium 
supplemented with 10% heat-inactivated FCS, 0.1 mM MEM non-essential amino acids, 
2 mM GlutaMAX-I™, 1 mM sodium pyruvate, 10 mM HEPES, 100 U/ml penicillin and 
100 μg/mL streptomycin. PBMCs were stimulated with 100 ng/mL of indicated SAgs for 
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up to 24 hours at 37°C in polystyrene U-bottom plates at a density of 2  106 per well. To 
block IL-17 receptor A (IL-17RA) prior to SEB stimulation, PBMCs were incubated with 
10 μg/mL of an anti-IL-17RA mAb (clone #133617) or mouse IgG1 isotype control 
(clone #11711) from R&D Systems (Minneapolis, Minnesota) for 30 minutes.  
For cytokine assays, culture supernatants were harvested at indicated time points and 
analyzed by a bead-based multiplex assay (Eve Technologies, Calgary, Alberta). Heat 
maps were generated using the matrix2png utility (31). For RNA studies, PBMCs were 
isolated in RNAlater (Thermo Fisher Scientific) and RNA was extracted using the 
Purelink RNA Mini Kit (Thermo Fisher Scientific). To eliminate contaminating genomic 
DNA, on-column Purelink DNase (Invitrogen Canada, Burlington, Ontario) was used as 
per manufacturer’s instructions. RNA quantity and purity was measured by a NanoDrop 
ND-1000 spectrophotometer. RNA was converted to cDNA via SuperScript VILO 
Master Mix (Invitrogen Canada). Quantitative real-time PCR (qPCR) was performed on a 
StepOnePlus Real-Time PCR System using TaqMan Gene Expression Assays (Table 
5.1) and TaqMan Fast Advanced Master Mix, all from Thermo Fisher Scientific. qPCR 
reactions and cycling conditions were set up according to manufacturer’s instructions. 
Fold changes between conditions were calculated by the ΔΔCT method. For low-
expressing gene targets that consistently amplified with CT values >37, CT values were set 
to 37 for analysis. 
As reliable comparisons of gene expression by qPCR require normalization to stably 
expressed reference genes, we first tested several commonly used reference genes for 
changes in SEB-stimulated PBMCs when compared to unstimulated controls. The mean 
fold changes of TATA-binding protein (TBP) and ribosomal protein L13a (RPL13A) 
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were no more or less than 20% (data not shown). TBP and/or RPL13A were thus used as 
reference genes in our qPCR assays.  
To analyze RNA stability/degradation, PBMCs were stimulated with SEB for 4 hours 
followed by treatment with 5 μg/mL of the transcriptional inhibitor actinomycin D (act-
D). Cells were harvested at indicated time points, RNA was extracted and converted to 
cDNA, and qPCR for target genes was performed as described above using 18S RNA as 
the reference gene.  
5.2.6 Human PBMC-dermal fibroblast co-culture 
Using an approved ethics protocol (HSREB #104888), primary human fibroblasts were 
derived from surgically resected normal skin samples as previously described (32). 
Fibroblast cultures were maintained for a maximum of six passages in DMEM medium 
containing 10% heat-inactivated FCS, 2 mM GlutaMAX-I™ and 1X Antibiotic-
Antimycotic (Thermo Fisher Scientific). Fibroblasts were seeded at a density of 5  
105/well in a tissue culture-treated polystyrene flat-bottom plate. Four million freshly 
isolated PBMCs were plated into a NuncTM Polycarbonate Membrane Insert (pore size: 
0.4 m), which was placed inside the fibroblast culture well. Co-cultures were then 
stimulated with 100 ng/mL of SEB. Eight hours later, the insert was removed and 
fibroblasts were harvested and examined by qPCR for their CEBPD expression. In 
several experiments, anti-IL-17RA mAb or isotype control was added to co-cultures at 10 
g/mL 30 minutes before SEB stimulation.   
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5.2.7 Isolation and cytofluorimetric analyses of mouse cells 
PBS- and SAg-primed mice were sacrificed at indicated time points to harvest spleen, 
pooled lymph nodes (cervical, axillary, brachial, mesenteric, inguinal and popliteal 
nodes), liver, lungs and small intestine. Spleen and lymph nodes were homogenized using 
a Wheaton Dounce tissue grinder. To obtain hepatic and lung non-parenchymal 
mononuclear cells (MNCs), tissue specimens were pressed through a wire mesh, and the 
extracted cells were washed, resuspended in 33.75% low-endotoxin Percoll Plus (GE 
Healthcare Life Sciences, Mississauga, Ontario) and centrifuged at 700  g for 12 
minutes at room temperature. Pelleted cells were treated with ACK lysis buffer, washed, 
filtered and resuspended in cold sterile PBS.   
Intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) were isolated 
from the small intestine as described by Sheridan and Lefrançois (33). Briefly, the small 
intestine was  aseptically removed, flushed with HBSS containing 5% FCS and 10 mM 
HEPES, digested at 37C with 1 mM dithioerythritol and filtered through a cell strainer 
(pore size: 70 μm) to generate an IEL-containing homogenate. To prepare LPLs, the 
remaining intestinal pieces were additionally digested, first in 1.3 mM EDTA and then in 
a solution containing 100 U/mL collagenase, and subsequently filtered. IEL- and LPL-
containing homogenates were washed, resuspended in 44% Percoll Plus (GE Healthcare 
Life Sciences), underlaid with 67% Percoll Plus and spun at 600  g for 20 minutes. IELs 
and LPLs were harvested by a Pasteur pipette from the buffy coat formed at the gradient 
interface, washed and resuspended in cold PBS.  
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Freshly isolated mouse cells were incubated with 5 μg/mL of an anti-mouse CD16/CD32 
mAb (clone 2.4G2) to block Fcγ receptors and stained at 4C with fluorochrome-
conjugated mAbs to cell surface molecules listed in Table 5.2. Corresponding isotype 
controls were used in parallel for appropriate gating. A FACSCanto II cytometer (BD 
Biosciences, Mississauga, Ontario) was used for data collection. Data were analyzed by 
FlowJo software (Tree Star, Ashland, Oregon).  
5.2.8 Surface and intracellular staining of human cells and RNA 
flow cytometry 
Freshly isolated human PBMCs were stimulated with SAgs for 4 hours, unless otherwise 
stated, in the presence of 1 μM brefeldin A (Sigma-Aldrich). Cells were thoroughly 
washed and stained at 4C with fluorochrome-conjugated mAbs to cell surface molecules 
(Table 5.2). For intracellular detection of cytokines, the Intracellular Fixation and 
Permeabilization Buffer Set from eBioscience was used. We also employed a Mouse IL-
17A Secretion Assay kit from Miltenyi Biotec (Auburn, California) to confirm the 
secretion of this cytokine. For detection of transcription factors, the FoxP3 Staining 
Buffer Set (eBioscience) was used. For RNA staining, the Prime FlowRNA Assay 
(eBioscience) was used with probes designed for the detection of IL-17A, IFNγ and 
RPL13A signals. Cells were treated and stained for surface and intracellular molecules 
(Table 5.2) following the manufacturer’s instructions. Isotype and/or fluorescence-
minus-one (FMO) controls were used in parallel for proper gating. Samples were run on a 
BD FACSCanto II or a BD LSR II (when using violet fluorochrome-conjugated mAbs) 
and analyzed by FlowJo software (Tree Star). 
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Target React. Host Species Clone/ 
Accession #  
Isotype Fluorochrome Source 
Surface Molecules       
TCRβ Mouse Arm. Hamster H57-597 IgG PE-Cyanine7 eBioscience 
CD4 Mouse Rat GK1.5 IgG2b, κ Alexa Fluor® 700 eBioscience 
CD44 Human/ 
Mouse 
Rat IM7 IgG2b, κ PerCP-Cyanine5.5 eBioscience 
CD62L Mouse Rat MEL-14 IgG2a, κ APC-eFluor® 780 eBioscience 
CCR7 Mouse Rat 4B12 IgG2a, κ APC eBioscience 
CD127 Mouse Rat A7R34 IgG2a, κ PE eBioscience 
iNKT TCR  
(detected by CD1d 
loaded tetramer) 
Mouse Mouse N/A N/A APC NIH Tetramer 
Core Facility 
CD3ε Human 
 
Mouse 
 
OKT3 
UCHT1 
IgG2a, κ 
IgG1, κ 
FITC 
eFluor® 450 
eBioscience 
eBioscience 
CD4 Human Mouse 
 
RPA-T4 
SK3 
IgG1, κ 
IgG1, κ 
Alexa Fluor® 700 
Brilliant Violet™ 510 
eBioscience 
BD Biosciences 
CD8 Human Mouse RPA-T8 IgG1, κ Alexa Fluor® 700 eBioscience 
CD45RA Human Mouse 
 
HI100 
 
IgG2b, κ 
 
PE 
PE-Cyanine7 
eBioscience 
eBioscience 
CD45RO Human Mouse UCHL1 IgG2a, κ APC 
Brilliant Violet™ 785 
eBioscience 
BD Biosciences 
CCR6 Human Mouse G034E3 IgG2b, κ PE BioLegend 
CCR7 Human Rat 3D12 IgG2a, κ PerCP-eFluor® 710 
PE-eFluor® 610 
eBioscience 
eBioscience 
CD161 Human Mouse HP-3G10 IgG1 APC 
PerCP-Cyanine5.5 
eBioscience 
eBioscience 
Vα7.2 TCR Human Mouse 3C10 IgG1, κ PE 
PerCP-Cyanine5.5 
BioLegend 
BioLegend 
iNKT TCR  
(detected by CD1d 
loaded tetramer) 
Human Human N/A N/A APC NIH Tetramer 
Core Facility 
γδ TCR Human Mouse B1 
B1.1 
IgG1, κ 
IgG1, κ 
PE 
PerCP-eFluor® 710 
BD Biosciences 
eBioscience 
Cytokines       
IL-17A Human Mouse eBio64-
DEC17 
IgG1, κ PE 
PE-Cyanine7 
eBioscience 
eBioscience 
IFNγ Human Mouse 4S.B3 IgG1, κ PE 
PE-Cyanine7 
eBioscience 
eBioscience 
Transcription 
Factors 
      
RORγT Human Mouse Q21-559 IgG2a, κ Alexa Fluor® 647 BD Biosciences 
FoxP3 Human Mouse 236A/E7 IgG1, κ APC eBioscience 
Prime-Flow RNA       
IL-17A Human  NM_002190  Type 1 Alexa Fluor® 647 Affymetrix 
IFNγ Human  NM_000619  Type 4 Alexa Fluor® 488 Affymetrix 
RPL13A Human  NM_012423  Type 6 Alexa Fluor® 750 Affymetrix 
Table 5.2: Antibodies/tetramers used in IL-17A studies 
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5.2.9 Statistical analyses 
Analyses were carried out using GraphPad Prism 7 software (La Jolla, California). The 
Shapiro-Wilk test was performed to verify the normal distribution of our data sets. 
Statistical comparisons were made using parametric Student’s t-tests, ANOVA with 
Holm-Sidak post-hoc analysis, or log-rank test, as appropriate and as indicated in figure 
legends. Differences with p ≤ 0.05 were deemed statistically significant. 
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5.3 Results 
5.3.1 IL-17A is rapidly produced by CD4+ TEM cells in a 
humanized mouse model of TSS 
SAgs have notoriously poor binding affinity for MHC class II molecules expressed in 
certain conventional mouse strains such as C57BL/6 mice (34). Thus, we investigated the 
pathogenesis of TSS in humanized DR4tg mice that allow for high-affinity interactions 
with SAgs and consequently recapitulate many aspects of TSS-mediated 
immunopathology (28, 29, 35-39). Using this model, we serendipitously found a dramatic 
serum IL-17A spike at 2 hours post-SEB exposure (Fig. 5.1A). Given that the role of IL-
17A in TSS is unknown and that IL-17A induces and synergizes with many inflammatory 
mediators implicated in the cytokine storm, we sought to fully characterize this 
phenomenon. IL-17A was present in the serum at 2 hours but not detectable at 12 or 24 
hours after i.p. injection of SEB (Fig. 5.1A). In contrast, IL-17A was not detectable in 
SEB-injected wild-type C57BL/6 mice (Fig. 5.1A) neither were several other cytokines 
tested (e.g., IFN and IL-4). This highlights the requirement for human MHC class II 
molecules in the optimal activation of T cells by SAgs. The injection of SEBN23A, a 
mutant version of SEB with impaired binding to Vβ8.2 TCR (29), into DR4tg mice also 
resulted in no detectable IL-17A in the serum (Fig. 5.1A), indicating that SEB-induced 
IL-17A production is highly T cell-dependent.  
We next tested a panel of bacterial SAgs other than SEB for their ability to induce IL-
17A production in DR4tg mice. These included TSST-1, staphylococcal enterotoxin A 
(SEA), SpeA, streptococcal pyrogenic exotoxin I (SpeI) and streptococcal mitogenic 
exotoxin Z (SmeZ). TSST-1 administration did not result in IL-17A appearance in the  
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Figure 5.1: Rapid IL-17A production by CD4+ TEM cells in a humanized mouse 
model of TSS.  
(A) DR4tg mice were injected i.p. with 50 μg SEB, SEBN23A or PBS, and bled at 
indicated time points for serum cytokine measurements. Mean ± SEM values from 2 
independent experiments are shown (n = 4). (B-D) IL-17A-GFP/DR4tg chimeric mice 
were injected i.p. with PBS or 50 μg SEB and sacrificed after 2 hours. (B) Serum IL-17A 
levels in SEB- and PBS-treated IL-17A-GFP/DR4tg bone marrow chimeric mice were 
determined by ELISA. N.D.= not detectable. Mean values ± SEM from 3 independent 
experiments are shown (n = 4-5 mice per group). (C) The frequencies of IL-17A-GFP+ 
cells and the geometric MFI of IL-17 were determined by flow cytometry among non-
parenchymal mononuclear cells obtained from indicated organs of SEB- and PBS-treated 
mice. Mean values ± SEM from 3 independent experiments are shown (n = 6-7 per 
group). * denotes p ≤ 0.05 (Student’s t-test; two-tailed). (D) The phenotype of IL-17A-
GFP+ cells among IELs from SEB-treated mice was determined using fluorochrome-
conjugated antibodies and tetramers for indicated markers (open black histograms) and 
isotype controls (filled, grey histograms). Representative dot plot and histograms from 3 
independent experiments are shown (n = 4-6). 
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serum neither did SpeI or SmeZ (data not shown). As such, DR4tg mice do not appear to 
provide a suitable model in which to study the role of IL-17A in the context of TSST-1-
mediated TSS or SpeI/SmeZ-triggered host responses. In contrast, animals injected with 
SEA and SpeA had detectable IL-17A levels in their serum (55 pg/mL and 286 pg/mL, 
respectively). Therefore, the early IL-17A production may not be limited to 
staphylococcal TSS, and may also play a role in streptococcal infections. Of note, LPS, a 
potent stimulus that activates immune cells through a different mechanism than SAgs, 
failed to trigger an IL-17A response in DR4tg mice (data not shown).  
To identify the cellular source of IL-17A, we generated IL-17A-GFP/DR4tg bone 
marrow chimeric mice. This system allows for quantification of IL-17A responses as 
measured by GFP fluorescence in SAg-sensitive, human MHC II-expressing mice. Three 
weeks after the adoptive transfer of bone marrow cells, chimeric mice were injected with 
50 μg SEB and sacrificed 2 hours later to obtain blood, spleen, lymph nodes (cervical, 
axillary, brachial, mesenteric, inguinal and popliteal), liver, lungs and small intestine. 
When compared to PBS controls, which showed no detectable IL-17A in serum, SEB-
injected chimeric mice produced substantial amounts of IL-17A after 2 hours (Fig. 5.1B). 
The greatest frequency of IL-17A-expressing cells was found among IELs of the small 
intestine (Fig. 5.1C). Notably, the frequencies of IL-17A-expressing cells did not 
significantly differ between SEB and PBS treatment groups (Fig. 5.1C). However, the 
mean fluorescence intensity (MFI) of GFP, an indicator of IL-17A production on a per 
cell basis, increased upon in vivo SEB exposure in IELs and to a lesser degree among 
lung and splenic non-parenchymal MNCs (Fig. 5.1C).  
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Having determined that IL-17A expression was highly upregulated and most abundant in 
the IEL compartment after SEB exposure, we next sought to immunophenotype these 
rapidly IL-17A-producing cells. The majority of IL-17A+ cells were defined as CD4+ TEM 
cells due to their TCRβ+CD4+CD44+CCR7-CD62L-CD127+ surface phenotype (Fig. 
5.1D) (40). Similarly, CD4+ TEM cells constituted the majority of IL-17A
+ cells among 
IELs of PBS-treated mice (data not shown).  
We previously reported that iNKT cells can be activated by group II bacterial SAgs, 
including SEB, leading to a swift cytokine response (29). In addition, a subset of iNKT 
cells is capable of producing IL-17A in response to glycolipid antigens (41). Therefore, it 
was important to rule in or rule out the participation of iNKT-17 cells in our model. We 
found that in vivo stimulation with SEB gives rise to IL-17A-expressing cells that do not 
possess the canonical TCR of iNKT cells as judged by their lack of staining with -
galactosylceramide-loaded CD1d tetramer (Fig. 5.1D). 
As a confirmatory approach, we generated D17 mice by crossing DR4tg mice with IL-
17A-GFP reporter animals. We found a pattern similar to that observed in the bone 
marrow chimeras, namely increased IL-17A MFI among IELs of SEB-primed D17 mice 
(Fig. 5.2A-C). IL-17-producing cells in D17 mice also similarly exhibited a TEM 
phenotype. Having an adequate supply of D17 animals enabled us to additionally 
investigate the lamina propria, a site in which IL-17-secreting T cells are known to be 
abundant (42). These experiments revealed that systemic exposure to SEB raises both the 
frequency IL-17+CD4+ TEM cells in the lamina propria and the intensity of IL-17A 
production by these cells. In fact, the IL-17A response was stronger in the LPL 
compartment in comparison with IELs (Fig. 5.2B-C).  
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Figure 5.2: SEB-primed D17 mice launch a rapid IL-17A response and harbor an 
enriched population of IL-17A-producing CD4+ TEM cells in their small intestine. 
D17 mice, generated by crossing DR4tg and IL-17A-GFP reporter mice, were injected 
i.p. with 50 μg SEB or with PBS. (A) Two hours later, mice were euthanized and the IL-
17A content of serum samples was measured. N.D.: not detectable. Error bars represent 
SEM (n=3/group). (B) The frequencies of GFP+
 
cells and the MFI of GFP were 
determined in non-parenchymal mononuclear cells (MNCs) from indicated tissues and 
among intestinal intraepithelial lymphocytes (IELs) and lamina propria lymphocytes 
(LPLs). * denotes p 0.05 by two-tailed Student’s t-test. (C) GFP+
 
IELs and LPLs from 
SEB-injected mice were immunophenotyped using fluorochrome-labeled mAbs to 
indicated markers (open histograms) and isotype controls (filled histograms). Depicted 
data represent findings from 3 mice used in independent experiments. 
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Together, the above findings show that select SAgs induce rapid IL-17A production by 
CD4+ TEM cells in a clinically relevant mouse model of TSS. The IL-17A response by 
mouse CD4+ TEM cells requires high-affinity interactions between SAgs and human 
MHC, and is most pronounced among intestinal IELs and LPLs.  
5.3.2 SAgs induce a rapid IL-17A response by human PBMCs in 
vitro 
After we established that SAgs were able to stimulate early IL-17A production in DR4tg 
mice, we assessed whether SAgs also elicit IL-17A responses in human PBMCs. First, 
PBMCs from healthy donors were stimulated with SEB or TSST-1 and analyzed for 
changes in cytokine mRNA levels by qPCR. Samples from all donors showed massive 
IL-17A mRNA upregulation after stimulation by SEB and, to a slightly lesser extent, by 
TSST-1 (Fig. 5.3A). IL-17A mRNA was highly upregulated at 2 hours, reached a 
maximum at 4 hours, and gradually decreased until 24 hours post-stimulation (Fig. 5.3A). 
Interestingly, the magnitude and the kinetics of the IL-17A mRNA response differed 
considerably when compared with IFNγ (Fig. 5.3A-B), a prototypic pro-inflammatory 
cytokine that is induced by SAgs in humans (43) and that is considered pathogenic in 
mouse models of TSS (44). IL-17A mRNA upregulation was far greater in magnitude at 
early time points and began to decline after 4 hours whereas IFNγ mRNA levels steadily 
increased until 24 hours (Fig. 5.3A-B).  
To ascertain whether human IL-17A was actively secreted among other rapidly produced 
inflammatory mediators (43), culture supernatants from SAg-stimulated PBMCs were 
assayed for cytokines by bead-based multiplexing. Both SEB and TSST-1 provoked rapid 
IL-17A and IFNγ responses, which were detectable as early as 2 hours and continued to  
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Figure 5.3: SAgs induce rapid IL-17A synthesis by human PBMCs. 
Human PBMCs were left untreated or stimulated with 100 ng/mL of SEB or TSST-1 for 
indicated durations. (A) IL-17A or (B) IFNγ mRNA upregulation in SAg-stimulated 
PBMCs was determined by qPCR. Data are shown as fold change relative to 
unstimulated medium control at each time point. (C and D) Cytokine concentrations in 
the supernatant of SAg-stimulated PBMCs at indicated time points were determined by 
bead-based cytokine multiplexing. Mean values ± SEM from 4 individual donors are 
shown. Statistical comparisons were made by two-way ANOVA (p ≤ 0.0001) with Holm-
Sidak post-hoc analysis (* and **** denote p ≤ 0.05 and p ≤ 0.0001, respectively). (E) 
Human PBMCs were stimulated with SEB for 4 hours prior to act-D treatment. IL-17A 
and IFNγ mRNA fold changes normalized to time zero (i.e., addition of act-D) were 
determined by qPCR. Data pooled from 3 individual donors are shown. Statistical 
comparisons were made by two-way ANOVA (p = 0.0072) with Holm-Sidak post-hoc 
analysis (*, ** and *** denote p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, respectively). 
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accumulate by 24 hours (Fig. 5.3C). The inflammatory cytokines TNFα and IL-6 as well 
as the growth-promoting cytokine IL-2 were also produced within hours of SAg 
stimulation (Fig. 5.3D). While the kinetics of cytokine expression was consistent for both 
SEB and TSST-1 stimulation, SEB elicited a more robust response for most cytokines 
tested when compared to TSST-1 (Fig. 5.3C-D).  
Thus far, our findings revealed an unexpected discordance vis-à-vis the kinetics of IL-
17A expression at mRNA and protein levels – that is while IL-17A mRNA was rapidly 
upregulated and gradually declined after 4 hours, IL-17A protein continued to accumulate 
in the supernatant up to 24 hours (Fig. 5.3A-C). This discordance was especially apparent 
when compared to the IFNγ expression kinetics that followed a similar pattern for both 
cytokine mRNA and protein (Fig. 5.3B-C). We hypothesized that disparities in mRNA 
stability between IL-17A and IFNγ may account for the noted differences as more stable 
mRNA may not require consistent upregulation for translation into increasing amounts of 
protein. Since the degree of IL-17A mRNA stability in primary human T cells was 
unknown, we tested our hypothesis by comparing the half-lives of IL-17A and IFNγ 
mRNA in SEB-stimulated PBMC cultures using the transcriptional inhibitor act-D (45). 
PBMCs were challenged with SEB for 4 hours consistent with the IL-17A mRNA 
response peak (Fig. 5.3A), treated with act-D, and analyzed for cytokine mRNA 
expression in the subsequent 8 hours after transcriptional arrest. Intriguingly, while IFNγ 
mRNA was quickly degraded within the first few hours, IL-17A mRNA expression 
remained remarkably stable after the addition of act-D (Fig. 5.3E). 
These results indicate that SAgs potently activate human PBMCs to rapidly upregulate 
IL-17A mRNA and secrete IL-17A protein within hours. Interestingly, the initial IL-17A 
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mRNA upregulation is greater in magnitude and yields more stable mRNA in comparison 
with the canonical inflammatory cytokine IFNγ although both cytokines are quickly 
secreted in culture. 
5.3.3 SAg-exposed human CD4+ TEM cells are rapid and potent 
producers of IL-17A. 
As this work provides the initial report of IL-17A secretion in human PBMCs within the 
first few hours of SAg exposure, we next aimed to identify its cellular source. Exposure 
to either SEB or TSST-1 resulted in substantial intracellular IL-17A production by CD3+ 
T cells within 4 hours (Fig. 5.4A). SEB was significantly more potent than TSST-1 and 
caused IL-17A production by 0.182% of all PBMCs (Fig. 5.4A). The MFI of IL-17A 
staining was equivalent though, indicating that SEB- and TSST-1-stimulated cells 
synthesized similar amounts of IL-17A on a per cell basis (Fig. 5.4A). We also observed 
that IL-17A+ cells among TSST-1-stimulated PBMCs showed reduced CD3 expression 
suggesting partial TCR downregulation. Lastly, we confirmed that only CD3+ T cells 
were actively secreting IL-17A using a cytokine secretion assay in which IL-17A that is 
about to be secreted binds to the cell surface via a bivalent antibody molecule specific for 
both CD45 and IL-17A (data not shown). 
To immunophenotype IL-17A-producing cells, PBMCs were challenged with SEB for 4 
hours and analyzed for a variety of surface markers and transcription factors by flow 
cytometry. The vast majority of IL-17A+ cells expressed high levels of CD4 and 
CD45RO, and were CCR7- (Fig. 5.4B), indicating a surface phenotype characteristic of 
CD4+ TEM cells (46). In line with previous studies (47-49), IL-17A
+ cells also expressed 
CCR6 and the transcription factor RORγT (Fig. 5.4B), which are hallmarks of the Th17 
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Figure 5.4: CD4+ TEM cells are the major source of IL-17A in SAg-stimulated 
human PBMCs.   
Human PBMCs were left untreated in medium or stimulated with 100 ng/mL of SEB or 
TSST-1 for 4 hours. (A) IL-17A-producing cells were identified by intracellular cytokine 
staining and further analyzed by flow cytometry. Representative dot plots of SAg-
stimulated PBMCs are depicted. The percentage of IL-17A-expressing cells and 
geometric MFI of IL-17A are shown as mean values ± SEM for 6 individual donors. 
One-way ANOVA (p = 0.0007) with Holm-Sidak post-hoc analysis was used (* and ** 
denote p ≤ 0.05 and p ≤ 0.01, respectively); n.s. = not significant by two-tailed Student’s 
t-test. (B) IL-17A+ cells were immunophenotyped based on their expression of indicated 
cell surface and intracellular markers (open red histograms) relative to isotype control 
(filled, gray histograms). Illustrated data represent 4 individual donors displaying similar 
results. (C) Values represent mean percentages ± SEM of 4 individual donors. Subtypes 
were defined as: CD4+ TEM (CD4
+CD3+CD45RO+CCR7-), CD4+ TCM 
(CD4+CD3+CD45RO+CCR7+), γδ T (γδ TCR+), iNKT (CD3+CD1d tetramer+), MAIT 
(CD3+Vα7.2 TCR+CD161+), CD8+ T (CD3+ CD4- CD8+). (D) IL-17A protein and mRNA 
co-expressing cells were identified using the PrimeFlow RNA technology and analyzed 
by flow cytometry. Dot plots are representative of 4 individual donors. 
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lineage. Notably, the majority of IL-17A+ cells expressed the lectin receptor CD161 (Fig. 
5.4B). CD161 is highly expressed on innate-like T cells including γδ T, MAIT and iNKT 
cells but only moderately expressed on Th17 cells (50). Thus, we investigated γδ TCR, 
Vα7.2 TCR and iNKT TCR expression to rule in/out γδ T, MAIT and iNKT cells, 
respectively (Fig. 5.4B). These innate-like T cell subsets, in addition to a small 
population of CD8+ T cells, constituted only minor fractions of the overall IL-17A+ cell 
population (Fig. 5.4C). In contrast, CD4+ TEM cells were the dominant IL-17A-expressing 
population, which comprised greater than 75% of IL-17A+ cells (Fig. 5.4C).  
Strikingly, our results revealed thus far that only a small fraction of PBMCs produced IL-
17A protein in response to SAgs (Fig. 5.4A) despite the massive upregulation of IL-17A 
mRNA observed in bulk PBMCs (Fig. 5.3A). We initially postulated that other cells 
types in addition to CD4+ TEM cells contributed to the substantial IL-17A mRNA 
response, but were not detectable by intracellular IL-17A staining. To address this, we 
utilized the PrimeFlow RNA assay, a new technology that utilizes fluorescent in situ 
hybridization to enable simultaneous detection of cells expressing IL-17A mRNA and 
intracellular IL-17A protein by flow cytometry. As expected, SEB stimulation enhanced 
the expression of IL-17A mRNA (Fig. 5.4D). Moreover, CD4+ TEM cells 
(CD3+CD45RO+CCR7-) comprised the majority of IL-17A mRNA+ cells (Fig. 5.4D), 
consistent with our intracellular IL-17A protein findings (Fig. 5.4C). Notably, a small 
proportion of IL-17A mRNA-producing CD4+ T cells stained positively for CCR7 (Fig. 
5.4D), indicating that CD4+ central memory (TCM) cells may be a source of IL-17A 
protein at later time points. These results indicate that CD4+ TEM cells are primarily 
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responsible for rapid IL-17A secretion among SAg-stimulated PBMCs despite their 
relative rarity. 
As multi-cytokine-producing T cells are reportedly induced by SEB stimulation at 
relatively late time points (51), we explored whether early IL-17A-producers would also 
co-express IFNγ. Surprisingly, only a minute subset of IL-17A/IFNγ co-expressors was 
detectable following SAg stimulation over a 4-hour period, and the overwhelming 
majority of cytokine-producing cells exclusively expressed either IL-17A or IFNγ (Fig. 
5.5A). A similar trend for IL-17A and IFNγ expression was also evident at 24 hours post-
SAg stimulation (Fig. 5.5B). Interestingly, at 4 hours post-SEB, CD4+ TEM cells 
constituted a large proportion of IFNγ+ cells (Fig. 5.5C), similar to IL-17A+ cells 
observed above. This finding prompted us to examine whether IL-17A-producing CD4+ 
TEM cells had the potential to produce IFNγ mRNA, but were not synthesizing 
appreciable amounts of IFNγ protein. We found that only a small fraction of IL-17A+ 
cells showed detectable IFNγ mRNA transcripts (Fig. 5.5D).  
Collectively, the above results indicate that SAg-based stimulation of human PBMCs 
induces a rapid and potent IL-17A response that is chiefly mediated by CD4+ TEM cells. 
Although CD4+ TEM cells are responsible for substantial early IFNγ production as well, 
the IL-17A- and IFNγ-producing subsets were two independent populations. 
5.3.4 IL-17RA blockade reduces inflammatory gene expression in 
SEB-exposed human PBMCs and secondarily activated 
dermal fibroblasts. 
Many downstream targets of IL-17A signaling are inflammatory cytokines and 
chemokines (52), which likely augment or perpetuate the overwhelming inflammatory  
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Figure 5.5: SAg-stimulated IL-17A- and IFNγ-producing cells are two distinct 
populations. 
Human PBMCs from healthy volunteers were left untreated or stimulated with 100 
ng/mL of SEB or TSST-1 for 4 hours (A) or 24 hours (B). IL-17A- and IFNγ-producing 
cells were identified by intracellular cytokine staining and quantified by flow cytometry. 
Representative dot plots of SAg-stimulated PBMCs and mean percentages ± SEM from 
2-4 individual donors are shown. Statistical comparisons were made by one-way 
ANOVA (p = 0.0255 and p = 0.0224 for SEB and TSST-1 treatment conditions, 
respectively) with Holm-Sidak post-hoc analysis (* denotes p ≤ 0.05). (C) Gated IFNγ-
producing cells were immunophenotyped by their expression of surface markers (open 
black histograms) relative to isotype control (filled, gray histograms). Data are 
representative of 4 individual donors. (D) IL-17A and IFNγ mRNA co-expressing cells 
were identified using the PrimeFlow RNA technology and analyzed by flow cytometry. 
Dot plots are representative of 4 individual donors. 
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cascade encountered in TSS. Accordingly, stimulation of human PBMCs with SEB for 8 
hours resulted in upregulation of many different pro- and anti-inflammatory genes known 
to be modulated by IL-17A (Table 5.3). Also highly upregulated was the related 
inflammatory cytokine IL-17F, which signals through the same IL-17RA/IL-17RC 
complex (53). Thus, we sought to evaluate the contribution of IL-17RA signaling to 
induction of inflammatory genes in the initiation of the cytokine storm. 
PBMCs were pre-incubated with a blocking IL-17RA mAb or isotype control, stimulated 
with SEB for 8 hours and evaluated for changes in gene expression by qPCR. IL-17RA 
blockade resulted in diminished expression of several key inflammatory cytokines 
involved in TSS, including TNFα, IFNγ and IL-6 (Fig. 5.6A). Additionally, the 
expression of many chemokines such as CCL5, CCL7, CXCL1 and CXCL6 were highly 
downregulated. Interestingly, the blockade of IL-17RA signaling also resulted in 
upregulation of notable anti-inflammatory cytokines IL-4, TGFβ1 and IL-10 (Fig. 5.6A). 
It is noteworthy that in these experiments, we chose to work with a mAb dose (i.e., 10 
µg/mL) that was previously reported to efficiently block IL-17RA (54, 55). In a limited 
number of experiments, we reconfirmed that this dose could significantly inhibit the 
upregulation of CEBPD, a transcription factor linked to acute inflammatory conditions 
(56), in SEB-exposed PBMCs. In contrast, a 0.1 µg/mL-dose of anti-IL-17RA was 
completely ineffective, and a 1 µg/mL-dose inhibited CEBPD upregulation only 
marginally (data not shown). 
In the next series of experiments, we utilized a human PBMC-dermal fibroblast co-
culture system to mimic the secondary effect of IL-17A signaling in non-hematopoietic 
cells. To this end, PBMCs and fibroblasts were cultured in physically separate  
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Target 
Fold Change (SEB relative to 
medium control) 
Donor 1    Donor 2   Donor 3 
IL22 1059.25 355.71 2198.29 
IL17F 737.24 137.67 780.40 
IFNG 304.81 661.94 445.69 
IL17A 253.73 96.47 651.44 
CSF3 583.76 20.88 296.10 
IL6 111.03 6.77 140.41 
IL19 70.28 50.68 115.96 
IL13 45.96 24.00 84.64 
IL2 32.45 58.60 19.38 
IL12B 32.24 2.08 71.23 
CCL20 40.69 2.49 45.23 
CSF2 17.49 26.89 21.14 
IL10 28.65 5.74 29.33 
CXCL9 2.59 37.62 4.11 
CXCL1 10.29 0.74 31.46 
PTGS2 14.72 1.86 12.92 
LTA 5.37 13.70 10.01 
CXCL11 0.51 14.43 1.33 
IL1B 6.39 1.20 5.01 
TNFA 2.26 3.47 6.43 
CXCL5 3.93 0.19 7.15 
CXCL2 4.29 0.56 5.42 
TBX21 3.48 3.80 0.95 
IL8 3.98 0.82 3.03 
IL12A 2.12 3.13 1.63 
IL4 3.13 1.22 2.53 
IL23A 2.13 2.12 2.20 
NFKB1 2.43 1.53 2.02 
CXCL6 2.75 0.08 3.14 
NFKBIZ 2.11 1.29 1.74 
CCL2 1.86 0.39 2.68 
RORC 1.87 2.01 1.00 
CXCL10 0.33 3.50 0.61 
C/EBPB 1.11 0.89 0.90 
ZBTB16 0.93 1.05 0.73 
TGFB1 0.70 1.06 0.66 
GATA3 0.50 0.66 0.82 
CCL7 0.55 0.26 1.00 
CCL5 0.68 0.60 0.34 
MYD88 0.58 0.63 0.32 
NOS2 0.58 0.12 0.36 
C/EBPD 0.23 0.33 0.32 
CXCL12 0.14 0.27 0.15 
IL18 0.12 0.16 0.06 
Table 5.3: Fold changes in gene expression of SEB-stimulated human PBMCs 
relative to medium control. 
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Figure 5.6: Blockade of IL-17RA signaling attenuates SEB-induced inflammatory 
gene expression in human PBMCs and in downstream non-hematopoietic cells.  
(A) Human PBMCs were pre-incubated with 10 μg/mL of an anti-IL-17RA blocking 
antibody or isotype control and subsequently stimulated with 100 ng/mL of SEB for 8 
hours. Changes in gene expression were determined by qPCR and represented as log2 
(fold-change) of the anti-IL-17RA group normalized to isotype control. Differentially 
regulated genes were defined as >10% fold-change difference between treatment groups. 
Fold-changes in gene expression were pooled from 3 individual donors and are 
represented as mean values. (B) Human dermal fibroblasts were grown in a flat-bottom 
plate and co-cultured with human PBMCs that were seeded into a cell culture insert with 
a permeable membrane. Fibroblasts and PBMCs were in two physically separate 
compartments. Co-cultures were left untreated or stimulated with 100 ng/mL of SEB. 
Eight hours later, the insert was removed and fibroblasts were harvested and examined by 
qPCR for their CEBPD expression. Anti-IL-17RA or isotype control (10 g/mL each) 
was added 30 minutes before SEB stimulation as indicated. Fold changes in CEBPD gene 
expression relative to the ‘fibroblast-only’ condition was calculated for 3 PBMC samples 
prepared from 3 individual donors. Data are shown as mean  SEM, and * denotes p ≤ 
0.05 (Student’s t-test; two-tailed). 
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compartments prior to SEB stimulation. We found a ~3-fold increase in the expression 
level of CEBPD by dermal fibroblasts that were co-cultured with SEB-primed PBMCs 
(Fig. 5.6B). Importantly, this response was abrogated in the presence of 10 µg/mL of 
anti-IL-17RA mAb. Also as expected, SEB did not change the expression of CEBPD in 
fibroblasts alone, a condition that was used as a control (Fig. 5.6B). 
Taken together, the above findings strongly suggest that IL-17RA signaling plays an 
important pro-inflammatory role in TSS by increasing the expression of inflammatory 
mediators that are expected to contribute to TSS pathogenesis. 
5.3.5 IL-17A is pathogenic in an in vivo model of TSS 
Since the cytokine storm drives many symptoms of TSS, attenuation of rapidly produced 
cytokines that further perpetuate the inflammatory cascade, such as IL-17A, may be of 
prime importance to reduce TSS severity. Furthermore, IL-17A functions through 
induction of inflammatory mediators in both hematopoietic and non-hematopoietic 
compartments (19). Thus, we utilized the DR4tg mouse model, which provides a 
powerful in vivo system in which to delineate the role of early IL-17A responses in TSS. 
We treated DR4tg mice with an anti-IL-17A mAb 3 hours prior to and 1 hour after the 
administration of SEB and monitored disease progression. Neutralizing IL-17A at the 
TSS onset resulted in significantly attenuated weight loss as early as 20 hours after SEB 
injection (Fig. 5.7A). Importantly, by 7 days after SEB injection, 67% of mice that were 
treated with anti-IL-17A, compared to only 27% of mice receiving isotype control, had 
survived (Fig. 5.7B).  
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Figure 5.7: IL-17A neutralization in a humanized mouse model of TSS reduces 
morbidity, mortality and tissue damage. 
DR4tg mice were injected i.p. with 200 μg of an anti-IL-17A neutralizing antibody or an 
isotype control 3 hours before and 1 hour after receiving 100 μg of SEB. (A) Weight loss 
was monitored every 3 hours for the first 12 hours and every 8 hours thereafter (n = 15 
per group). Statistical comparisons were made using two-way ANOVA (p = 0.0012) with 
Holm-Sidak post-hoc analysis (* and ** denote p ≤ 0.05 and p ≤ 0.01, respectively). (B) 
Survival was monitored up to 7 days after SEB (n = 15 per group). Mice were sacrificed 
when moribund (20% weight loss). p = 0.0101 (log-rank test). (C and D) At 48 hours 
after SEB injection, mice were sacrificed for their organs and H&E staining was 
performed as per standard protocols. Sections were scored by a veterinary pathologist 
blinded to the experimental conditions. Histopathology scores represent sum of changes 
in the liver (periportal inflammation + microvesicular steatosis) and small intestine 
[inflammatory cell infiltration + mucosal score (epithelial cell damage + villi blunting)] 
observed in each section. Parameters received scores from 0-3, with 0 = normal, 1 = mild, 
2 = moderate and 3 = severe. * denotes p ≤ 0.05 (Student’s t-test; two-tailed). Stained 
sections are representative of sham (n = 2), SEB + isotype control (n = 3) and SEB + anti-
IL-17A (n = 4) groups. (E) Two hours after SEB injection, anti-IL-17A- and isotype 
control-treated mice (n=4/group) were bled and the IL-6 content of serum samples was 
quantified by ELISA. Mean  SEM values are shown. Two-way ANOVA was used (p = 
0.05) with Holm-Sidak post-hoc analysis (** denotes p ≤ 0.01). 
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Since TSS is characterized by multi-organ dysfunction, we investigated whether IL-17A 
neutralization affects SAg-induced liver and intestinal damage. DR4tg mice receiving 
SEB and either an anti-IL17A mAb or an isotype control were sacrificed at 48 hours 
post-SEB, and liver and the small intestine were collected for histopathological analyses. 
SEB induced moderate periportal inflammation in the livers of both anti-IL-17A- and 
isotype control-treated mice (Fig. 5.7C). However, hepatic steatosis, an early indication 
of hepatotoxicity (57), was greatly reduced in anti-IL-17A-treated mice compared to 
those receiving the isotype control (Fig. 5.7C). Furthermore, the small intestines of mice 
receiving anti-IL-17A showed less inflammation, epithelial cell damage and villar 
blunting compared to the control cohort (Fig. 5.7C). As scored by a veterinary 
pathologist blinded to the cohorts, the overall TSS pathology for mice receiving anti-IL-
17A was significantly reduced (Fig. 5.7D). Finally, we found a statistically significant 
decrease in the serum concentration of IL-6, a downstream target of IL-17A signaling, in 
anti-IL-17A-treated mice 2 hours after SEB administration (Fig. 5.7E).  
Collectively, these results provide the first report that IL-17A is pathogenic in TSS and 
that neutralizing IL-17A ameliorates morbidity, mortality and tissue damage in a 
humanized mouse model of TSS. 
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5.4 Discussion 
The inflammatory response mediated by IL-17A is the result of the induction and 
activation of a large network of immune effector molecules including cytokines, 
chemokines, acute phase reactants, tissue remodeling enzymes, antimicrobial peptides 
and transcription factors (19). In this way, IL-17A plays a critical role in the immune 
response against many different pathogens including S. aureus (58) and S. pyogenes (59). 
However, unbalanced or dysregulated IL-17A responses may also lead to excessive 
inflammation and can therefore be detrimental in several diseased states (52). In this 
study, we report a pathogenic role for IL-17A during infection.  
Much of the existing knowledge of TSS pathogenesis has relied on conventional mouse 
models (12). However, SAgs exhibit poor affinity for certain mouse MHC class II 
molecules (34), and as a result, many strains of laboratory mice are resistant to TSS. 
Sensitizing agents such as D-galactosamine (D-galN) (60) or LPS (61) have been 
employed to amplify the effects of SAgs and induce lethality, but the extent to which 
these models accurately reflect human TSS is questionable. For example, D-galN 
pretreatment leads to extreme sensitivity to TNFα-induced apoptosis in hepatocytes (62), 
which causes rapid mortality solely due to fulminant hepatitis, which does not represent 
human TSS (63). Here, we investigated SAg-induced cytokine responses utilizing DR4tg 
mice that transgenically express the human MHC class II molecule HLA-DR4. This 
allows for high-affinity SAgs-MHC class II interactions resulting in robust activation of 
T cells and a cytokine storm that, if left untreated, simulates the potentially catastrophic 
human TSS (35-37). 
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We found that exposure of DR4tg mice to SEB resulted in swift production of several 
cytokines in serum, including the inflammatory cytokine IL-17A. Cytokines secreted in 
the early phase of the cytokine storm are especially important as they trigger endothelial 
cell damage that compromises vascular homeostasis and precipitates multi-organ 
dysfunction (64). Furthermore, rapid secretion of IL-17A not only has inflammatory 
effects on a wide variety of cell types throughout the body, it can directly induce and also 
synergize with other cytokines that are produced in the same timeframe. Other studies 
have found mouse IL-17A secretion in response to SAgs (36, 44, 65). IL-17 is also 
reportedly detectable in SEB-stimulated human PBMC cultures, albeit at relatively late 
time points (66, 67). Here, we demonstrate that very early IL-17A is of CD4+ TEM cell 
origin in mice and in human PBMC cultures. Furthermore, we show that the rapid 
induction of IL-17A, in addition to other cytokines, is dependent on T cell stimulation 
since the injection of DR4tg mice with a TCR-binding mutant form of SEB (SEBN23A) 
resulted in minimal cytokine secretion. We believe the observed presence of IFNγ, at 
moderate levels, after SEBN23A exposure is likely the consequence of SEB engaging T 
cells that bear Vβ domains other than Vβ8.2 (29). Lastly, we extended our investigation 
to other SAgs and found that SpeA and SEA could also induce early IL-17A secretion. 
Therefore, we propose that rapid IL-17A secretion plays a pathogenic role in both 
staphylococcal and streptococcal TSS. 
To identify the location of IL-17A production in DR4tg mice, we generated IL-17A-
GFP/DR4tg bone marrow chimeric mice as well as D17 mice in which IL-17A 
expression can be quantified by GFP fluorescence. Using these models, we found an 
increase in the frequency of IL-17A+ cells and/or the signal intensity of IL-17A in several 
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tissues, but chiefly among IELs and LPLs from the small intestine, upon exposure to 
SEB. Interestingly, although IL-17A was consistently absent from the serum of PBS-
injected mice, IL-17A-producing cells were readily detectable in these animals, 
suggesting that IL-17A is expressed at basal levels in multiple organs. This observation is 
in agreement with those of previous investigations utilizing alternatively generated IL-
17A-GFP mice (68) or IL-17A fate-mapping reporter mice (69) that showed resting 
levels of IL-17A among cells of the small intestine. We expand on these findings to 
implicate CD4+ TEM cells as the main source of constitutively expressed IL-17A in naive 
mice. Nevertheless, it stands to reason that additional sources/locations of IL-17A may 
also exist.  
Memory T cells are highly enriched in the intestinal mucosa and their propensity for 
immediate effector function upon re-activation (70) puts them in a unique position to be 
rapidly activated by SAgs. It has also been suggested that SAgs produced in the intestinal 
tract by food-borne pathogens may cross the gut mucosa directly (71), placing memory T 
cells among the first responders to SAgs. In support of this hypothesis, IL-17A was 
preferentially induced in the intestinal epithelial layer by CD4+ TEM cells when mice were 
exposed to SEB. Furthermore, a study by Tilahun et al. demonstrated that most NF-κB 
expression in SEB-injected HLA-DR3 mice was induced in the intestines (36).  
The IL-17A response to SEB in mice appears to be translatable to humans, as PBMCs 
from healthy human volunteers stimulated with SAgs in vitro also exhibited rapid IL-17A 
production. IL-17A was secreted within hours of SAg exposure along with other 
inflammatory cytokines such as IFNγ, TNFα and IL-6. This inflammatory profile was 
most pronounced within the first few hours of SAg stimulation, with anti-inflammatory 
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cytokines IL-10 and IL-13 only reaching appreciable levels towards later time points. 
This pattern of expression provides additional evidence suggesting that potential 
therapies aimed at curbing the overwhelming cytokine storm in TSS may be most 
effective early after exposure to SAgs. A study by Krakauer et al. supports this line of 
reasoning, where mice surviving TSS showed reduced inflammatory cytokine and 
chemokine levels, though not including IL-17A, at 8 hours post-SEB administration (72). 
Furthermore, in a TSS model utilizing HLA-DR1 mice, lethality was prevented by anti-
TNFα treatment, which dampened the early but not later phase of cytokine release (73). 
Therefore, it is likely that the early phase of the cytokine storm is responsible for TSS 
lethality and that attenuating this response may be a fruitful strategy to prevent mortality. 
Unexpectedly, we observed apparently paradoxical differences between the kinetics of 
mRNA upregulation and resulting protein expression between IL-17A and IFNγ 
responses in SAg-stimulated PBMCs. We propose that the variation of kinetics between 
the two cytokines may be due, at least in part, to differences in mRNA stability. 
However, the mechanisms of post-transcriptional regulation of IL-17A remain ill-
defined. In mice, the RNA-binding protein Hu antigen R positively regulates IL-17A 
expression and mRNA stability (74). Conversely, another RNA-binding protein, 
tristetraprolin, binds directly to the 3’ untranslated region of IL-17A mRNA to mediate 
its decay (75). Lastly, the positive correlation between microRNAs and IL-17A 
expression in many diseases other than TSS also suggest that microRNAs may play a 
critical role in regulating IL-17A responses (76). Whether RNA-binding proteins or 
microRNAs post-transcriptionally regulate human IL-17A in TSS remains to be 
elucidated. 
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 Our findings indicate that CD4+ TEM cells predominate in the early production of both 
IL-17A and IFNγ in SAg-stimulated human PBMCs. We also observed that IL-17A and 
IFNγ responses by CD4+ TEM cells were mutually exclusive, with only a small number of 
cells capable of producing both cytokines simultaneously. Thus, we propose that SAgs 
stimulate pre-existing and independent lineage-committed CD4+ TEM cell subsets to 
rapidly produce IL-17A (TEM-17 cells) and IFNγ (TEM-γ cells) in the initial phases of the 
cytokine storm. Our results may extend the traditional paradigm of Th1-, Th2- and Th17-
lineages of activated effector CD4+ T cells, which proceed to generate the body’s long-
lived pool of TEM cells (77). This notion is supported by recent reports that human Th17 
cells are a terminally differentiated TEM cell population with a high capacity of self-
renewal (78, 79). 
The timing and the intensity of SAg stimulation in human PBMCs also apparently affect 
the phenotype and cytokine profiles of activated cells. We found that at 4 hours post-SEB 
stimulation, IL-17A-producing CD4+ TEM cells exclusively expressed the Th17-lineage 
transcription factor RORγT but did not co-produce IFNγ. In contrast, a recent study by 
Björkander et al. demonstrated that 24-hour stimulation of human PBMCs with SAgs 
induces IL-17A in CD4+ T cells that express the regulatory T cell transcription factor 
FoxP3 (80). As FoxP3 has been previously shown to be upregulated in SAg-stimulated 
CD4+ T cells over days of SAg exposure (81), it remains to be seen whether early IL-
17A-producing CD4+ TEM cells may acquire FoxP3 expression after longer periods of 
SAg stimulation. In a separate study, overnight stimulation of human PBMCs with 10 
μg/mL of SEB (a 100-fold greater concentration of SAg than the dose used in this study) 
induced multi-functional CD4+ TEM cells that often co-expressed IL-17A and IFNγ (51). 
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Both at 4 and 24 hours after SAg stimulation, we detected only a minute subpopulation of 
co-producing CD4+ TEM cells. It is possible that the high concentration of SAg used by 
McArthur et al. may have been responsible for the co-producer phenotype. Circulating 
levels of SAgs in patients’ serum samples range from ~40 pg/mL in intensive care units 
(82) to 50-100 ng/mL in adult burn patients (83), and as high as 1,000 ng/mL in 
streptococcal TSS patients (84). As such, our findings utilizing a more conservative 
concentration of SAg may represent a more physiologically relevant outcome for SAg 
stimulation of human PBMCs. 
We found that the blockade of IL-17RA signaling in SEB-stimulated PBMCs attenuated 
the expression of multiple inflammatory genes including IL-6, TNFα, and IFNγ, which 
mediate many toxic effects of TSS (12). Concomitantly, the expression of anti-
inflammatory cytokine genes (IL-10, TGFβ1 and IL-4) was upregulated by IL-17RA 
blockade. To our surprise, CCL20, a chemokine that binds CCR6 to mobilize 
lymphocytes and dendritic cells, was also upregulated. Nevertheless, the overall picture 
emerging from our IL-17RA blockade experiments strongly suggests a pro-inflammatory 
role for IL-17RA signaling in the context of human PBMC responses to SAgs. Equally 
important, IL-17RA blockade in dermal fibroblasts prevented their secondary response to 
SEB-exposed PBMCs. Therefore, this approach may work at multiple levels and may 
have therapeutic potentials for TSS. When patients with severe plaque psoriasis were 
treated with brodalumab, a mAb against IL-17RA, reduced expression of inflammatory 
cytokine transcripts was noted (85). Our results are also supported by the findings of 
Crowe et al. that IL-17RA knockout mice show greatly attenuated cytokine storm when 
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infected with influenza virus (86). In this model, the absence of IL-17RA signaling 
decreased lung inflammation, weight loss and morbidity.  
Remarkably, in vivo neutralization of IL-17A in DR4tg mice at the onset of TSS led to a 
significant reduction in weight loss and a striking increase in survival. We also observed 
drastic pathological changes in both the liver and the epithelium of the small intestine in 
DR4tg mice exposed to SEB. These mice developed hepatic microvesicular steatosis, an 
early toxic change in hepatocytes that signals serious disease. Characterized by the 
accumulation of small lipid vesicles in hepatocytes, microvesicular steatosis is indicative 
of impaired mitochondrial β-oxidation of fatty acids and can lead to multi-organ 
dysfunction (57). Importantly, microvesicular steatosis occurs in both human TSS (87, 
88) and sepsis (89). To our knowledge, our work is the first description of its reversal in 
an animal model of TSS. We also observed considerable epithelial damage and villi 
blunting in the small intestine of mice injected with SEB. These pathological changes 
likely impair intestinal function and contribute to the weight loss observed in SAg-
exposed mice. Importantly, in vivo neutralization of IL-17A in this model markedly 
attenuated both hepatic steatosis and damage to the intestinal epithelium. As almost all 
human TSS patients show multi-organ dysfunction (90), our results suggest that IL-17A 
may be an attractive clinical target to reduce TSS severity.    
The key to successful treatment of TSS remains the rapid identification of the source of 
infection, appropriate and effective use of antibiotics, drainage of wounds (or removal of 
tampon in menstrual TSS) and supportive care (91). Intravenous immunoglobulin has 
also been shown to improve clinical outcomes in TSS caused by group A Streptococcus 
(92). However, there is currently no cure for the cytokine storm induced by SAgs. Here, 
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we define the rapid production of IL-17A by CD4+ TEM cells as a novel mechanism 
underlying TSS immunopathology. Our findings suggest that neutralizing IL-17A 
function may serve to lessen systemic inflammatory cytokine levels and decrease tissue 
damage in TSS. Thus, a therapeutic approach targeting the early induction of multiple 
inflammatory mediators that are involved in the cytokine storm, including IL-17A, may 
be effective in averting TSS mortality.  
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6.1 Discussion 
Over the last few decades of intensive research, much has been learned about the 
biological and molecular determinants of TSS pathogenesis. It is clear that bacterial SAgs 
cause TSS through the abnormal activation of large numbers of T cells, resulting in a 
massive release of systemic inflammatory mediators in a matter of hours (1, 2). This 
‘cytokine storm’ defines many, if not most, signs and symptoms of clinical TSS, which 
can progress to multi-organ failure as early as 8-12 hours after the onset of symptoms (3). 
Despite our current understanding of the factors that trigger TSS pathology, there 
currently are no available therapeutic options that decrease the severity of the cytokine 
storm. Successful clinical management of TSS still relies almost wholly on supportive 
care (4). Together, these issues highlight the need to identify the key players of the early 
stages of the cytokine storm, where clinical intervention is most likely to be effective. 
Towards this goal, this thesis aimed to utilize clinically relevant humanized mouse 
models and human cells to characterize rapid immune responses in TSS.  
6.1.1 iNKT cells are pathogenic in TSS 
In Chapter 3, I defined the role of iNKT cells in TSS pathogenesis using a humanized 
DR4tg mouse model. These mice express the human MHC class II molecule HLA-DR4, 
which, unlike some mouse MHC class II, allows for potent T cell activation by SAgs 
similar to human TSS. To generate a mouse strain that is iNKT cell-deficient yet retains 
is ability to potently respond to SAgs, I crossed DR4tg mice with germ-line iNKT cell 
knockout mice (Jα18-/-). When challenged with SAg, these novel iNKT cell-deficient 
‘DJ’ mice showed significantly attenuated weight loss and mortality compared to the 
iNKT cell-sufficient DR4tg mice (Fig. 3.1B), strongly suggesting that iNKT cells were 
  
202 
acting in a pathogenic manner. However, a relatively recent report highlights that Jα18-/- 
mice may have additional cellular deficiencies (5). Therefore, I confirmed my findings 
utilizing an iNKT cell-depleting antibody (6) that selectively eliminated iNKT cells from 
the liver and, to a somewhat lesser extent, from the spleen (Fig. 3.1C-D). Both 
experimental approaches demonstrated that iNKT cells are pathogenic in TSS.  
iNKT cells are known for their rapid and copious production of both pro- and anti-
inflammatory cytokines, due to the constitutive expression of cytokine mRNAs (7). To 
evaluate the contribution of iNKT cells to the TSS cytokine storm, I quantified the levels 
of serum cytokines of DR4tg and DJ mice after exposure to SEB. Strikingly, when 
compared to DR4tg mice, DJ mice showed reduced quantities of many inflammatory 
cytokines and chemokines consistent with an attenuated cytokine storm (Fig. 3.4A). 
Importantly, several inflammatory cytokines known to play a direct role in TSS 
immunopathology were present only at the 2-hour time point after SEB injection and 
were markedly decreased in DJ mice (Fig. 3.4B). These results indicate that iNKT cells 
are major contributors to the early cytokine storm in TSS. The finding that TSS 
morbidity/mortality was reduced when iNKT cells were polarized towards Th2-type, 
anti-inflammatory cytokine responses by OCH (Fig. 3.4C and 3.6) further strengthens 
this notion.  
In light of the results presented in this chapter, further investigations dissecting the 
mechanistic contribution of iNKT cells to TSS immunopathology are clearly warranted. 
However, this study, like the vast majority of iNKT cell research utilizing germ-line 
knockout mouse models, is hindered by the lack of ‘clean’ iNKT cell-deficient mice. 
CD1d-/- mice lack NKT cells in general (8) and therefore the contribution of either iNKT 
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and vNKT cells cannot be disentangled. As noted previously, Jα18-/- mice show reduced 
TCR α-chain diversity, which does not seem to impact the frequency of major immune 
cell subsets (Fig. 3.2) yet may have unknown ramifications to immune responses in these 
mice. Additional studies with Jα18-/- mice should use newly generated strains that do not 
possess TCRα repertoire defects, once they become available. 
The iNKT cell-specific mAb NKT14 shows considerable promise in the depletion of 
iNKT cells in mouse models. Scheuplein et. al. demonstrated the efficient and selective 
depletion of iNKT cells in NKT14-injected mice by flow cytometry (6). However, the 
authors did not rule out whether the absence of iNKT cells is due to TCR 
downregulation, a common characteristic of activated iNKT cells (9). To address this 
issue, I evaluated gene expression levels of the iNKT cell TCR α-chain (Vα14-Jα18) in 
NKT14- and isotype control-treated mice. Although Vα14-Jα18 expression in mice 
injected with NKT14 was greatly reduced in the liver (by ~90%), the mRNA levels in the 
spleen showed only a 50% reduction compared to controls (Fig. 3.1D). This finding 
suggests that the efficacy of iNKT cell depletion by NKT14 is tissue specific and may be 
incomplete. The presence of iNKT cells that have downregulated their TCR is potentially 
problematic because iNKT cells can be activated independently of TCR signals, such as 
through IL-12 and IL-18 for example (10). Thus, they may still participate in the cytokine 
storm. Although, DJ mice and NKT14-injected mice showed similar reductions in TSS 
mortality compared to iNKT-sufficient controls (Fig 3.3), my findings highlight the need 
for a comprehensive evaluation of the NKT14 effectiveness throughout individual mouse 
tissues. 
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6.1.2 MDSCs rapidly accumulate in the liver during TSS 
In Chapter 4, I discovered a dramatic influx of myeloid cells into the liver of DR4tg mice 
shortly after SEB exposure (Fig. 4.1A). These cells resembled G-MDSCs in both cell 
surface phenotype (CD11b+Gr-1highLy-6C+) and morphology (Figs. 4.1B, 4.3 and 4.4). I 
classified these cells as bona fide MDSCs based on their ability to potently suppress 
SEB-induced T cell proliferation (Fig. 4.5A). Using several pharmacological inhibitors, I 
also showed that MDSC-mediated T cell suppression was mediated by ROS, as opposed 
to arginase or nitric oxide, confirming the identity of these cells as G-MDSCs (Fig. 
4.5B). Collectively, my results demonstrated that SAg exposure in DR4tg mice rapidly 
triggers the accumulation of G-MDSCs in the liver.  
During severe inflammation, MDSCs are known to amass in peripheral lymphoid organs, 
typically after several days (11). Contrastingly, I demonstrated the hepatic accumulation 
of MDSCs in just 2 hours after TSS onset. The rapidity of this response and a lack of 
Ki67 upregulation in the liver, in conjunction with decreased MDSC frequency in bone 
marrow (Fig. 4.6), is highly suggestive of direct MDSC recruitment from the bone 
marrow to the liver. The exact cellular and chemotactic factors that mediate this process 
are unknown. In mouse models of hepatocellular carcinoma, tumor derived GM-CSF and 
CXCL1 facilitate the recruitment of MDSCs to the liver (12). In addition, IL-17A derived 
from γδ T cells indirectly triggers MDSC migration to liver via inducing the secretion of 
CXCL5 by tumor cells (13). Importantly, I found that GM-CSF, CXCL1, IL-17A and 
CXCL5 were all rapidly produced within 2 hours of SAg exposure in DR4tg mice, as 
detailed in Chapter 3 (Fig. 3.4B). Interestingly, when injected with SEB, DJ mice did not 
show a reduction in hepatic MDSC accumulation (data not shown), despite the absence of 
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iNKT cells and a marked decrease in many inflammatory mediators in serum (Fig. 3.4B). 
The dramatic reduction of GM-CSF, CXCL1 and IL-17A in DJ relative to DR4tg mice 
suggests these factors may not play a dominant role in this response. Although CXCL5 
levels were also reduced in DJ mice, the difference was minor and deemed not 
statistically significant, which leaves open the possibility that CXCL5 may promote this 
process. Nevertheless, further inquiry into the mechanisms behind MDSC recruitment to 
the liver in TSS is required.    
Using a suppression assay, I established that MDSCs were potent suppressors of SAg-
mediated T cell proliferation in vitro. However, the capacity of MDSCs to mitigate 
hepatic tissue damage in vivo during TSS needs to be explored. To this end, I attempted 
to deplete MDSCs in DR4tg mice using an anti-Gr-1 mAb and the chemotherapy agent 
gemcitabine. Anti-Gr-1 antibodies are commonly used to deplete MDSCs in tumor 
bearing mice, although they are not necessarily selective in doing so (14). Previous 
studies also show that anti-Gr-1 antibodies have difficulty depleting MDSCs in the liver 
(15). Accordingly, mice treated with anti-Gr-1 antibody did not reduce MDSC 
recruitment to the liver in TSS (data not shown). Alternatively, the chemotherapy drug 
gemcitabine has also been shown to be effective in selectively depleting MDSCs in 
mouse models of cancer (16, 17). Treatment with gemcitabine prior to SAg exposure 
failed to prevent MDSCs recruitment to the liver (data not shown). Several other 
alternatives to gemcitabine can be used to selectively deplete MDSCs, such as 5-
fluorouracil (18), which may be effective in our mouse model of TSS and warrant further 
study. Qin et al. recently demonstrated a promising approach where the depletion of 
intratumoral MDSCs was achieved by a therapeutic ‘peptibody’ generated by fusing 
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MDSC-binding peptides with the Fc portion of a mouse IgG2b (19). It remains to be seen 
whether this method proves to be useful in depleting MDSCs in peripheral tissues or 
other disease contexts. An efficient and selective method for MDSC depletion in vivo 
would allow for a thorough investigation into the role of recruited MDSCs during TSS. 
In this chapter, I showed that ex-vivo generated human MDSCs were able to potently 
inhibit autologous T cell responses to SEB (Fig. 4.5D), indicating that human MDSCs 
possess the same SAg-suppressive capacity as in mice. However, MDSCs generated in 
this manner resemble M-MDSCs in both surface phenotype and morphology (20), as 
opposed to the G-MDSCs I detected in mice. Therefore, whether G-MDSCs expand and 
home to the liver in human TSS remains an unanswered but important question. A recent 
study in human sepsis found that as early as 12 hours after diagnosis, both M-MDSCs 
and G-MDSCs were present in high quantities in patients’ peripheral blood (21). Like 
TSS, the septic immune response begins with a cytokine storm (22), and thus the 
presence of early MDSCs in septic blood suggests that a similar process may occur in 
TSS patients as well.  
6.1.3 IL-17A is pathogenic in TSS 
In Chapter 5, I characterized the cellular source of rapid IL-17A production in both 
DR4tg mice and human PBMCs. Using IL-17A-GFP/DR4tg bone marrow chimeric mice, 
I identified CD4+ TEM cells in the intestinal epithelium as a major source of the rapid IL-
17A response to SEB (Fig. 5.1C-D). This phenotype was confirmed using D17 mice, 
which were generated by crossing DR4tg and IL-17A-GFP mice to homozygosity (Fig. 
5.2A-C). Furthermore, PBMCs from healthy human volunteers stimulated with SAgs 
also exhibited IL-17A production within hours, suggesting that rapid IL-17A responses in 
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TSS are translatable to humans (Fig. 5.3C). Similar to DR4tg mice, CD4+ TEM cells 
constituted the vast majority of IL-17A-producing cells among human PBMCs (Fig. 
5.4B-C). Notably, CD4+ TEM cells were also responsible for a large proportion of early 
IFNγ as well (Fig. 5.5C). Thus, my findings implicate CD4+ TEM cells as major players in 
the rapid production of inflammatory cytokines during TSS in both mice and humans.  
Importantly, I defined the role of rapidly produced IL-17A in response to SAgs as 
pathogenic in TSS. Since many downstream targets of IL-17A include cytokines known 
to participate in cytokine storm, I evaluated changes in inflammatory gene expression in 
SEB-stimulated human PBMCs after IL-17A signaling blockade. Several key 
inflammatory mediators of TSS including TNFα, IFNγ and IL-6 were downregulated as a 
result of incubation with anti-IL-17RA antibody (Fig. 5.6A), suggesting that IL-17A 
contributes to the cytokine storm and is therefore pathogenic in TSS. Accordingly, IL-
17A receptor blockade also abrogated the secondary effect of SAg-stimulated PBMCs on 
human dermal fibroblasts as judged by C/EBP delta (CEBPD) expression (Fig. 5.6B). In 
the DR4tg mouse model of TSS, in vivo neutralization of IL-17A significantly attenuated 
SEB-induced morbidity and mortality (Fig. 5.7A-B). Remarkably, mice receiving anti-
IL-17A antibody also demonstrated a stark reduction in intestinal and hepatic tissue 
damage compared to non-neutralized controls (Fig. 5.7C-D). Collectively, my findings 
reveal the previously unrecognized contribution of IL-17A to the initiation of the 
cytokine storm and the development of TSS immunopathology.  
The gene expression of many different cytokines, chemokines and inflammatory 
mediators in addition to those implicated in TSS pathogenesis were highly upregulated in 
human PBMCs 8 hours after SAg exposure. Strikingly, IL-22 was most highly 
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upregulated amongst all genes examined including IL-17A, IFNγ and IL-6 (Table 5.3), 
suggesting it may be produced in abundance after SAg stimulation. Similar to IL-17A, 
IL-22 is essential in immunity to several Gram-negative extracellular pathogens, yet in 
excess can be pathogenic in inflammatory disorders such as psoriasis and rheumatoid 
arthritis (23). Importantly, IL-22 acts synergistically with IL-17A to induce inflammation 
(24, 25) and may therefore be involved in the TSS cytokine storm. Future studies 
addressing the role of IL-22 and other highly upregulated genes in SAg-stimulated 
PBMCs may uncover novel mechanisms that drive or inhibit TSS pathogenesis.  
In this chapter, I provided the first report that rapid IL-17A responses induced by SEB 
exposure in mice are translatable to human PMBCs. However, the fundamental question 
is whether human patients show high levels of IL-17A during the cytokine storm in TSS. 
Although this question remains unanswered, there is accumulating evidence for the rapid 
production of IL-17A in the cytokine storm during sepsis. A recent study demonstrated 
that human neonates with sepsis exhibit IL-17A receptor signaling (26). In fact, IL-17RA 
emerged as a critical effector pathway upon gene expression analysis of whole blood 
from septic infants when compared to healthy controls. More conclusive, yet preliminary 
data was recently presented at the American Thoracic Society 2016 International 
Conference by Mikacenic et al., who measured IL-17A levels in septic patients within 24 
hours of diagnosis (27). A doubling of IL-17A concentration was associated with 
increased severity score, progression to septic shock and 28-day mortality. These studies 
demonstrate that IL-17A is rapidly produced during cytokine storm and is pathogenic in 
sepsis. Whether this is also the case with TSS requires further investigation. 
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6.2 Conclusions and Implications For Future Studies 
A recurrent theme throughout this thesis is that early immune responses to SAgs are 
critical for the development of TSS immunopathology. This is because the cytokine 
storm, which defines many symptoms of TSS, begins within hours of exposure to SAgs. 
Accordingly, I found that both DR4tg mice and human PBMCs rapidly produce a variety 
of inflammatory mediators in as little as 2 hours after stimulation with SAgs. The initial 
wave of the cytokine storm in both mice and humans was dominated by inflammatory 
cytokines such as TNFα, IFNγ, IL-2, IL-6 and IL-17A. Contrastingly, anti-inflammatory 
cytokines, like IL-10, appeared well after the inflammatory cytokine cascade reached 
excessive levels. These observations suggest that the early phase of the cytokine storm 
may be a critical period of systemic inflammation that culminates in tissue damage and 
eventually multi-organ failure. In support of this hypothesis, neutralizing IL-17A in 
DR4tg mice at the beginning of TSS onset attenuated hepatic and intestinal tissue damage 
in addition to mortality. Similarly, in a DR1tg mouse model of TSS, SAg-induced 
lethality was prevented only by pre-treatment of anti-TNFα antibody, whereas a 4-hour 
delay in antibody treatment after the onset of TSS was ineffective (28). Therefore, early 
immune responses to SAgs are likely responsible for initiating the inflammatory cascade 
that leads to organ damage and lethality in TSS. Interestingly, the rapid recruitment of 
MDSCs to the liver in DR4tg mice shortly after SEB exposure may represent an attempt 
by the host to mitigate hepatic pathology. Thus, future studies targeting this early 
timeframe should be fruitful in identifying novel mechanisms driving and/or attenuating 
TSS pathogenesis, or aid in the generation of therapies to reduce TSS severity.  
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Given that SAgs rapidly trigger the hyperactivation of the immune cells to cause disease, 
identifying the cellular processes that promote or inhibit the initial phases of the cytokine 
storm is critical to the understanding of TSS pathogenesis. In Chapter 3, I showed that 
iNKT cells were major contributors to the production of inflammatory mediators in TSS 
using DR4tg mice. In Chapter 4, I discovered a rapid influx of MDSCs into the liver in 
SAg-exposed DR4tg mice, which represents a novel mode of immunosuppression that 
may limit tissue damage in TSS. In Chapter 5, I demonstrated that CD4+ TEM cells in both 
DR4tg mice and human PBMCs were the main source of early IL-17A cytokine 
responses. Thus, my findings uncovered the previously unrecognized role of iNKT cells, 
MDSCs and TEM cells in the early stages of TSS. Future investigations targeting these 
cells and/or their downstream effector responses for potential therapeutics may prove 
useful in preventing TSS mortality.  
As the early cytokine storm is paramount to the pathogenesis of TSS, prospective 
therapies aimed at reducing disease severity are likely to be most effective early after 
exposure to SAgs. My findings suggest two novel approaches that target the early 
cytokine storm to reduce TSS severity. First, I demonstrated that skewing iNKT cell 
responses towards an anti-inflammatory phenotype using Th2-polarizing agonist OCH 
significantly attenuated both morbidity and mortality in a mouse model of TSS. 
Therefore, glycolipid agonists like OCH may be considered as potential therapeutics in 
TSS. Previous studies from this lab have similarly shown success with OCH in the 
prevention/treatment of inflammatory disorders in mouse models such as autoimmune 
arthritis (29), cardiac allograft rejection (30) and sepsis (31). Importantly, iNKT cell 
agonists exhibit significant promise in pre-clinical and clinical trials of cancer and viral 
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diseases (32). However, iNKT cell populations in humans are less abundant than in mice, 
at least in circulation, and whether their therapeutic manipulation has the same beneficial 
effect in this context needs to be confirmed. Another approach to the treatment of TSS 
would be to directly target inflammatory mediators in the cytokine storm. To this end, I 
demonstrated that neutralizing early IL-17A reduced the expression of many 
inflammatory mediators in SEB-stimulated human PBMCs and decreased tissue damage, 
morbidity and mortality in a mouse model of TSS. Therefore, targeting the multiple early 
inflammatory mediators of TSS, including IL-17A, may be effective to attenuate the 
inflammatory cascade and prevent tissue damage. However, a potential limitation to 
therapies aimed at mitigating rapid mediators of TSS is the need to identify patients early 
in the cytokine storm. As this thesis identifies novel contributors to TSS pathology, 
investigating the downstream mechanisms of these pathways is an important avenue for 
future research.  
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April 2016 
F.W. Luney Travel Award ($1000) April 2016 
London Health Research Day First Place Feature Platform 
Presentation ($700) 
March 2016 
Ontario Graduate Scholarship ($15000) May 2015 
CSI 2015 Travel Award ($500) May 2015 
American Association of Immunologists (AAI) 2015 Travel Award 
($500) 
May 2015 
F.W. Luney Travel Award ($1000) May 2015 
F.W. Luney Travel Award ($1000) March 2014 
PhD Candidacy Exam: Pass with Distinction March 2013 
Centre for Human Immunology Travel Award ($500) June 2012 
Federation of Clinical Immunology Societies (FOCIS) 2012 Travel 
Award ($500) 
June 2012 
F.W. Luney Travel Award ($1000) May 2012 
Western Graduate Research Scholarship (~$6000/year) Sept 2011-16     
McMaster University Senate Scholarship ($800) May 2010 
McMaster University Dean’s Honour List Sept 2008-11 
McMaster University Honour Award ($500) Sept 2006 
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ORAL PRESENTATIONS 
1. Szabo PA, Goswami A, Welch, I, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens trigger a rapid IL-17A response in memory T cells that is 
 pathogenic in toxic shock syndrome. London Health Research Day. London, ON, 
 Canada. March 2016.  
−Selected as one of 32 platform podium presentations out of 424 accepted 
abstracts 
−Awarded First Place Feature Platform Presentation Award 
2. Szabo PA, Goswami A, Welch, I, McCormick JK, Haeryfar SMM. IL-17A is 
 pathogenic in toxic shock syndrome. Lawson Health Research Institute Seminar 
 Series. London, ON, Canada. January 2016. 
3. Szabo PA, Goswami A, Welch, I, McCormick JK, Haeryfar SMM. IL-17A is rapidly 
 triggered by staphylococcal superantigens and is pathogenic in toxic shock 
 syndrome. Infection and Immunity Research Forum. London, ON, Canada. 
 December 2015.  
−Selected as one of 10 podium presentations out of 77 accepted abstracts 
4. Szabo PA, Goswami A, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens trigger rapid human IL-17A production by a novel population of 
 memory T cells. Canadian Society for Immunology. Winnipeg, MA, Canada. 
 June 2015.  
−Selected as one of 8 presentations in the Immune Mediated Diseases workshop  
5. Szabo PA, Goswami A, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens  trigger rapid human IL-17A production by a novel population of 
 memory T cells. American Association of Immunologists. New Orleans, LA, 
 USA. May 2015.  
−Selected as one of 8 presentations in the Cell Subsets, Cytokines and 
Inflammation block symposium.  
6. Szabo PA, McCormick JK, Haeryfar SMM. iNKT17 cells in toxic shock syndrome. 
 Canadian Society for Immunology. Quebec City, QC, Canada. March 2014. 
−Selected as one of 8 presentations in the Immune Mediated Diseases workshop 
PUBLISHED ABSTRACTS 
1. Szabo PA, Goswami A, Welch, I, McCormick JK, Haeryfar SMM. Rapid IL-17A 
 production  by memory T cells is critical for toxic shock syndrome 
 pathogenesis. Canadian Student  Health Research Forum: CIHR Nation 
 Student Research Poster Competition. Winnipeg, MA, Canada. June 2016. 
2. Cottrell J, Szabo PA, Zebian N, Lester J, Siroen D, Haeryfar SMM, Adams P, 
 Cruezenet C.  Variability in Dendritic Cell Immunological Responses to the 
 Secreted Helicobacter pylori Protein HcpE. Canadian National Medical 
 Student Research Symposium. Winnipeg, MA, Canada. June 2016. 
3. Szabo PA, Goswami A, Welch, I, McCormick JK, Haeryfar SMM. Rapid IL-17A 
 production by memory T cells is critical for toxic shock syndrome  pathogenesis. 
 Canadian Society for Immunology. Ottawa, ON, Canada. April 2016. 
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4. Cottrell J, Szabo PA, Zebian N, Lester J, Siroen D, Haeryfar SMM., Adams P, 
 Cruezenet C. Variability in Dendritic Cell Immunological Responses to the 
 Secreted Helicobacter pylori Protein HcpE. London Health Research Day. 
 London, ON, Canada. March 2016. 
5. Szabo PA, Goswami A, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens  trigger rapid human IL-17A production by a novel population of 
 memory T cells. Canadian Society for Immunology. Winnipeg, MA, Canada. 
 June 2015. 
6. Szabo PA, Goswami A, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens trigger rapid human IL-17A production by a novel population of 
 memory T cells. Joint  Microbiology/Immunology & Infectious Disease Retreat. 
 Grand Bend, ON, Canada. May  2015. 
7. Szabo PA, Goswami A, McCormick JK, Haeryfar SMM. Staphylococcal 
 superantigens trigger rapid human IL-17A production by a novel population of 
 memory T cells. American Association of Immunologists. New Orleans, LA, 
 USA. May 2015. 
8. Cottrell J, Lester J, Zebian N, Szabo PA, Siroen D, Haeryfar SMM, Adams P, 
 Cruezenet C. Effect of HcpE on maturation of dendritic cells and their cytokine 
 production. London Health Research Day. London, ON, Canada. March 2015. 
9. Cottrell J, Lester J, Zebian N, Szabo PA, Siroen D, Haeryfar SMM, Adams P, 
 Cruezenet C. Effect of immuno-modulatory proteins from Helicobacter pylori on 
 dendritic cells. Immunity and Infection Research Forum. London, ON, Canada. 
 November 2014. 
10. Woods M, Tong J, Tom S, Szabo PA, Cavanagh P, Dikeakos J, Haeryfar SMM, Barr 
 S. Interferon-induced HERC5 protein inhibits HIV-1 replication by two novel 
 mechanisms and is evolving under positive selection. The 20th International 
 AIDS Conference. Melbourne, Australia. July 2014. 
11. Szabo PA, McCormick JK, Haeryfar SMM. iNKT17 cells in toxic shock syndrome. 
 Canadian Society of Immunology. Quebec City, QC. March 2014. 
12. Goswami A, Szabo PA, Haeryfar SMM. Intrahepatic accumulation of 
 immunosuppressive myeloid cells in response to superantigen administration. 
 Canadian Society of Immunology. Quebec City, QC. March 2014. 
13. Szabo PA, McCormick JK, Haeryfar SMM. iNKT17 cells in toxic shock syndrome. 
 London Health Research Day. London, ON. March 2014. 
14. Goswami A, Szabo PA, Haeryfar SMM. Intrahepatic accumulation of 
 immunosuppressive myeloid cells in response to superantigen administration. 
 London Health Research Day. London, ON. March 2014. 
15. Goswami A, Szabo PA, Haeryfar SMM. Intrahepatic accumulation of 
 immunosuppressive myeloid cells in response to superantigen administration. 
 Infection and Immunity Research Forum. London, ON. November 2013. 
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16. Goswami A, Szabo PA, Haeryfar SMM. A staphylococcal superantigen mediates 
 CD11b+ Ly6C+ Ly6G+/- myeloid cell accumulation in the liver. Ontario Quebec 
 Undergraduate Immunology Conference. Toronto, ON. May 2013. 
17. Szabo PA, McCormick JK, Haeryfar SMM. Exploring the role of iNKT17 cells in 
 toxic shock syndrome. Infection and Immunity Research Forum. London, ON. 
 November  2012.  
18. Goswami A, Szabo PA, Haeryfar SMM. Hepatocytes bearing suppressor cell profiles 
 accumulate following superantigen exposure. Infection and Immunity Research 
 Forum. London, ON. November 2012. 
19. Szabo PA, McCormick JK, Haeryfar SMM. Exploring the role of iNKT17 cells in 
 toxic shock syndrome. Canadian Society of Immunology, St. John’s, NL. June 
 2012. 
20. Szabo PA, McCormick JK, Haeryfar SMM. Identification of iNKT17 cells in toxic 
 shock syndrome. Federation of Clinical Immunology Society Conference Trainee 
 Satellite Symposium, Vancouver, BC.  June 2012. 
TEACHING AND MENTORING 
• Future Professor Workshop Series (15 hours instruction), Teaching Support 
Centre, Western University, Jan 2017 
• Guest Lecturer (1 hr), MICROIMM 3820A: Microbiology and Immunology for 
Nursing Students, Western University, Oct 2016. 
• Teaching Mentorship Program Graduate, Teaching Support Centre, Western 
University, May 2016 
• Advanced Teaching Program Certificate (17.5 hours instruction), Teaching 
Support Centre, Western University, May 2016. 
• Guest Lecturer (1 hr), MICROIMM 3820A: Microbiology and Immunology for 
Nursing Students, Western University, Sept 2015. 
• Teaching Assistant, MICROIMM 3820A: Microbiology and Immunology for 
Nursing Students, Western University, Sept-Dec 2015. 
• Teaching Assistant, Medicine 5116 Infection & Immunity, Schulich School of 
Medicine, Oct-Dec 2012-2014. 
• 4th Year Microbiology and Immunology Undergraduate Thesis Mentor to Ankur 
Goswami, Haeryfar Laboratory, Sept 2012-Apr 2013. 
ADMINISTRATION 
Microbiology & Immunology Graduate Student Representative on the Appointments 
Committee, Western University, Sept 2013-2016. 
 
 
